



(19) **United States**  
 (12) **Patent Application Publication** (10) **Pub. No.: US 2003/0124529 A1**  
**Oxvig et al.** (43) **Pub. Date: Jul. 3, 2003**

---

(54) **PREGNANCY-ASSOCIATED PLASMA PROTEIN-A2 (PAPP-A2)**

(57) **ABSTRACT**

(75) Inventors: **Claus Oxvig**, Viby (DK); **Michael Toft Overgaard**, Aarhus C. (DK)

Correspondence Address:  
**BROWDY AND NEIMARK, P.L.L.C.**  
**624 Ninth Street, N.W.**  
**Washington, DC 20001 (US)**

(73) Assignee: **Como Biotech ApS**, Aarhus C. (DK)

(21) Appl. No.: **09/983,025**

(22) Filed: **Oct. 22, 2001**

**Related U.S. Application Data**

(60) Provisional application No. 60/241,840, filed on Oct. 20, 2000.

(30) **Foreign Application Priority Data**

Oct. 20, 2000 (DK)..... PA 2000 01571

**Publication Classification**

(51) **Int. Cl.<sup>7</sup>** ..... **C12Q 1/68**; C07H 21/04;  
 C12N 9/00; C12P 21/02; C12N 5/06;  
 C07K 14/475

(52) **U.S. Cl.** ..... **435/6**; 435/69.1; 435/183;  
 435/320.1; 435/325; 530/350;  
 536/23.2

The present invention provides nucleotide and amino acid sequences that identify and encode a new protein with homology to pregnancy-associated plasma protein-A (PAPP-A). We denote this protein PAPP-A2. The cDNA encoding PAPP-A2 was derived from human placenta. The present invention also provides for antisense molecules to the nucleotide sequences which encode PAPP-A2, expression vectors for the production of purified PAPP-A2, antibodies capable of binding specifically to PAPP-A2, hybridization probes or oligonucleotides for the detection of PAPP-A2-encoding nucleotide sequences, genetically engineered host cells for the expression of PAPP-A2, use of the protein to produce antibodies capable of binding specifically to the protein, methods for screening for pathologies in pregnant and non-pregnant patients that are based on detection of PAPP-A2 antigen in human body fluids or PAPP-A2-encoding nucleic acid molecules, use of the protein to screen for agents that alter the protease activity of PAPP-A2, use of the protein as a therapeutic target for such agents, and use of the protein as a therapeutic agent in relevant pathological states. Methods for screening for altered focal proliferation states in pregnant and/or non-pregnant patients, which include detecting levels of PAPP-A2, are also described. The present invention also provides the identification of a natural substrate of PAPP-A2, insulin-like growth factor binding protein (IGFBP)-5.

Figure 1.

ATGATGTGCTTAAAGATCCTAAGAATAAGCCTGGCGATTGTTGGCTGGGTGGGCACTCTGT M M C L K I L R I S L A I L A G W A L C	60 (20)
TCTGCCAACTCTGAGCTGGGCTGGACACGCAAGAAATCCTTGTTGAGAGGGAACACCTG S A N S E L G W T R K K S L V E R E H L	120 (40)
AATCAGGTGCTGTTGGAAGGAGAAGCTGTTGGCTGGGGCCAAAGTTCCAAGACCCAGA N Q V L L E G E R C W L G A K V R R P R	180 (60)
GCTTCTCCACAGCATCACCTCTTTGGAGTCTACCCAGCAGGGCTGGAACTACCTAAGG A S P Q H H L F G V Y P S R A G N Y L R	240 (80)
CCCTACCCCGTGGGGAGCAAGAAATCCATCATA CAGGACG CAGCAAAC CAGACACTGAA P Y P V G E Q E I H H T G R S K P D T E	300 (100)
GGAAATGCTGTGAGCCTTGTTCCCCAGACCTGACTGAAAATCCAGCAGGACTGAGGGGT G N A V S L V P P D L T E N P A G L R G	360 (120)
GCAGTTGAAGAGCCGGCTGCCCATGGGTAGGGGATAGTCTATTGGGCAATCTGAGCTG A V E E P A A P W V G D S P I G Q S E L	420 (140)
CTGGGAGATGATGACGCTTATCTCGCAATCAAAGATCCAAGGAGTCTTAGGTGAGGCC L G D D D A Y L G N Q R S K E S L G E A	480 (160)
GGGATTGAGAAAGGCTCAGCCATGGCTGCCACTACTACCACCGCCATTTTCACAACCCCTG G I Q K G S A M A A T T T T A I F T T L	540 (180)
AACGAACCCAAAC CAGAGACCCAAAGGAGGGGGCTGGGCCAAGTCCAGGCAGCCTCGCCAA N E P K P E T Q R R G W A K S R Q R R Q	600 (200)
GTGTGGAAGAGGCGGGCGGAAGATGGGCAGGGAGACTCCGGTATCTTTCACATTTCCAA V W K R R A E D G Q G D S G I S S H F Q	660 (220)
CCTTGGCCCAAGCATTCCCTTAAACACAGGGTCAAAAAGAGTCCACCGGAGGAAAGCAAC P W P K H S L K H R V K K S P P E E S N	720 (240)
CAAAATGTTGGAGAGGGCTCCTACCAGAGAAGCAGAGACCTTTAACTCCCAAGTAGGACTG Q N G G E G S Y R E A E T F N S Q V G L	780 (260)
CCCATCTTATACTTCTCTGGGAGGCGGGAGCGGCTGCTGCTGCCGTCCAGAAGTGTGGCT P I L Y F S G R R E R L L L R P E V L A	840 (280)
GAGATCCCCGGGAGGCGTTACAGTGGAAAGCCTGGGTTAAACCGGAGGGAGGACAGAAC E I C P R E A F T V E A W V K P E G G Q N	900 (300)
AACCCAGCCATCATCGCAGGTGTGTTTGATAACTGCTCCACACTGTCAGTGACAAGGC N P A I I A G V F D N C S H T V S D K G	960 (320)
TGGCCCTGGGGATCCGCTCAGGGAAGGACAAGGAAAAGCGGATGCTCGCTTCTTCTTC W A L G I R S G K D K G K R D A R F F F	1020 (340)
TCCCTCTGCACCAGCCGCTGAAGAAAGCCACCATCTTGATTAGCCACAGTCGCTACCAA S L C T D R V K K A T I L I S H S R Y Q	1080 (360)
CCAGGCACATGGACCCATGTGGCAGCCACTTACGATGGACGGACATGGCCCTGTATGTG P G T W T H V A A T Y D G R H M A L Y V	1140 (380)
GATGGCACTCAGGTGGCTAGCAGTCTAGACCAGTCTGGTCCCCTGAACAGCCCTTCATG D G T Q V A S S L D Q S G P L N S P F M	1200 (400)
GCATCTGCGCCTCTTTGCTCTGGGGGAGACAGCTCTGAGGATGGGCACTATTTCCGT A S C R S L L L G G D S S E D G H Y F R	1260 (420)
GGACACCTGGGCACACTGGTTTTCTGGTCGACCCCTGCCACAAGCCATTTTCAGCAC G H L G T L V F W S T A L P Q S H F Q H	1320 (440)
AGTTCTCAGCATTCAAGTGGGAGGAGGAAGCGACTGACTTGGTCTGACAGCGAGCTTT S S Q H S S G E E E A T D L V L T A S F	1380 (460)
GAGCCTGTGAACACAGAGTGGGTTCCCTTTAGAGATGAGAAGTACCCACGACTTGAGGTT E P V N T E W V P F R D E K Y P R L E V	1440 (480)
CTCCAGGGCTTTGAGCCAGAGCCTGAGATTCTGTCGCCTTTGACGCCCCACTCTGTGGG L Q G F E P E P E I L S P L Q P P L C G	1500 (500)
CAAACAGTCTGTGACAATGTGGAATTGATCTCCAGTACAATGGATACTGGCCCTTCGG Q T V C D N V E L I S Q Y N G Y W P L R	1560 (520)
GGAGAGAAGGTGATACGCTACCAGGTGGTGAACATCTGTGATGATGAGGGCCTAAACCCC G E K V I R Y Q V V N I C D D E G L N P	1620 (540)
ATTGTGAGTGAAGAGCAGATTCTGCTGACGACGAGGCACTGAATGAGGCCTTCAGCCGC I V S E E Q I R L Q H E A L N E A F S R	1680 (560)
TACAACATCAGCTGGCAGCTGAGCGTCCACCAGTCCACAATCCACCCTGCGACACCGG Y N I S W Q L S V H Q V H N S T L R H R	1740 (580)
GTTGTGCTGTGAACTGTGAGCCAGCAAGATTGGCAATGACCATTGTGACCCCGAGTGT V V L V N C E P S K I G N D H C D P E C	1800 (600)

Figure 1

GAGCACCCTACACAGGCTATGATGGGGTACTGCCGCTGCAGGGCCGCTGCTACTCC E H P L T G Y D G G D C R L Q G R C Y S	1860 (620)
TGGAACCGCAGGGATGGGCTCTGTACGTGGAGTGTAAACAACATGCTGAACGACTTTGAC W N R R D G L C H V E C N N M L N D F D	1920 (640)
GACGGAGACTGCTGCGACCCCCAGGTGGCTGATGTGCGCAAGACCTGCTTTGACCCTGAC D G D C C D P Q V A D V R K T C F D P D	1980 (660)
TCACCAAGAGGGCATAACATGAGTGTGAAGGAGCTGAAGGAGCCCTGCAGCTGAACAGT S P K R A Y M S V K E L K E A L Q L N S	2040 (680)
ACTCACTTCTCAACATCTACTTTGCCAGCTCAGTGCAGGAAAGACCTTGCAAGTGTGCGC T H F L N I Y F A S S V R E D L A G A A	2100 (700)
ACCTGGCCTTGGGACAAGGACGCTGTACTCACCTGGGTGGCATTGTCTCAGCCCAGCA T W P W D K D A V T H L G G I V L S P A	2160 (720)
TATTATGGGATGCTTGGCCACACCGACACCATGATCCATGAAGTGGGACATGTTCTGGGA Y Y G M P G H T D T M I H E V G H V L G	2220 (740)
CTCTACCATGTCTTTAAAGGAGTCACTGAAAGAGAATCCTGCAATGACCCCTGCAAGGAG L Y H V F K G V S E R E S C N D P C K E	2280 (760)
ACAGTGCCATCCATGAAACGGGAGACCTCTGTGCCGACACCGCCCCACTCCCAAGAGT T V P S M E T G D L C A D T A P T P K S	2340 (780)
GAGCTGTGCCGGGAACAGAGCCACTAGTGACACCTGTGGCTTCACTCGCTTCCCAGGG E L C R E P E P T S D T C G F T R F P G	2400 (800)
GCTCCGTTACCAACTACATGAGCTACACGGATGATAACTGCACTGACAACTTCACTCCT A P F T N Y M S Y T D D N C T D N F T P	2460 (820)
AACCAAGTGGCCGAATGCATTGCTATTGGACCTAGTCTATCAGCAGTGGACTGAAAGC N Q V A R M H C Y L D L V Y Q Q W T E S	2520 (840)
AGAAAGCCACCCCATCCCATTCACCTATGGTCATCGGACAGACCAACAAGTCCCTC R K P T P I P I P P M V I G Q T N K S L	2580 (860)
ACTATCCACTGGCTGCCTCCTATTAGTGGAGTTGTATATGACAGGGCCTCAGGCAGCTTG T I H W L P P I S G V V Y D R A S G S L	2640 (880)
TGTGGCCTTGCACTGAAGATGGGACCTTTCGTGATATGTGCACACAGCTTCTCCCGG C G A C T E D G T F R Q Y V H T A S S R	2700 (900)
CGGGTGTGTACTCCTCAGGTTATTGGACCCAGAGGAGGCTGTGGGGCCTCCTGATGTG R V C D S S G Y W T P E E A V G P P D V	2760 (920)
GATCAGCCCTGCGAGCAAGCTTACAGCCCTGGAGCCCTGAGGTCACCTGTACCACATG D Q P C E P S L Q A W S P E V H L Y H M	2820 (940)
AACATGACCGTCCCTGCCACAGAGGCTGTAGCTTGGAGCTGCTCTTCCAACACCCG N M T V P C P T E G C S L E L L F Q H P	2880 (960)
GTCCAAGCCGACACCCCTCACCTGTGGTCACTTCTTTCATGGAGTCCCTCGCAGGTC V Q A D T L T L W V T S F F M E S S Q V	2940 (980)
CTCTTTGACACAGAGATCTTGTGGAAAACAAGGAGTCACTGCACCTGGGCCCTTAGAC L F D T E I L L E N K E S V H L G P L D	3000 (1000)
ACTTCTGTGACATCCCACTCACCATCAAAGTGCAGTGGATGGGAGGTGTGGGGGTG T F C D I P L T I K L H V D G K V S G V	3060 (1020)
AAAGTCTACACCTTTGATGAGAGGATAGAGATTGATGCAGCACTCCTGACTTCTCAGCCC K V Y T F D E R I E I D A A L L T S Q P	3120 (1040)
CACAGTCCCTTGTGCTCTGGCTGCGGCTGTGAGGTACCAGGTTCTCCGGATCCCCCA H S P L C S G C R P V R Y Q V L R D P P	3180 (1060)
TTTGCCAGTGGTTTGGCCGTTGGTGGTGCACATTCTCACAGGAAGTTCACGGACGTGGAG F A S G L P V V V T H S H R K F T D V E	3240 (1080)
GTCACACCTGGACAGATGTATCAGTACCAAGTTCTAGCTGAAGCTGGAGGAGAAGTGGGA V T P G Q M Y Q Y Q V L A E A G G E L G	3300 (1100)
GAAGCTTCGCTCCTCTGAACCACATTCATGGAGCTCCTTATTGTGGAGATGGGAAGGTG E A S P P L N H I H G A P Y C G D G K V	3360 (1120)
TCAGAGAGACTGGGAGAAGAGTGTGATGATGGAGACCTTGTGAGCGGAGATGGCTGCTCC S E R L G E E C D D G D L V S G D G C S	3420 (1140)
AAGTGTGTGAGCTGGAGGAAGGTTTCAACTGTGTAGGAGAGCAAGCCTTTGCTACATG K V C E L E E G F N C V G E P S L C Y M	3480 (1160)
TATGAGGGAGATGGCATATGTGAACCTTTTGGAGAAAAACAGCATTGTAGACTGTGGC Y E G D I C E P F E R K T S I V D C G	3540 (1180)
ATCTACACTCCCAAGGATACTTGGATCAATGGGCTACCGGGCTTACTCCTCTCATGAA I Y T P K G Y L D Q W A T R A Y S S H E	3600 (1200)

Figure 1

GACAAGAAGTGTCTCTGTTTCCTTGGTAACTGGAGAACCTCATTCCCTAATTGACACA D K K K C P V S L V T G E P H S L I C T	3660 (1220)
TCATACCATCCAGATTACCCAACCACCGTCCCTAACTGGCTGGTTTCCTGTGTGGC S Y H P D L P N H R P L T G W F P C V A	3720 (1240)
AGTGAAATGAACTCAGGATGACAGGAGTGAACAGCCAGAAGGTAGCCTGAAGAAAGAG S E N E T Q D D R S E Q P E G S L K K E	3780 (1260)
GATGAGGTTTGGCTCAAAGTGTGTTTCAATAGACCAGGAGGCCAGAGCAATTTTATT D E V W L K V C F N R P G E A R A I F I	3840 (1280)
TTTTGACAACTGATGGCCTAGTTCCTGGAGAGCATCAGCAGCCGACAGTACTCTCTAC F L T T D G L V P G E H Q Q P T V T L Y	3900 (1300)
CTGACCGATGTCGGTGAAGCAACCACTCTCTTGAACCTATGGACTGTATGCCAGCAT L T D V R G S N H S L G T Y G L S C Q H	3960 (1320)
AATCCACTGATTATCAATGTGACCCATCACCAGAATGTCTTTCCACCATAACCACTCA N P L I I N V T H H Q N V L F H H T T S	4020 (1340)
GTGCTGCTGAATTTCTCATCCCCACGGTCCGGCATCTCAGCTGTGGCTCTAAGGACATCC V L L N F S S P R V G I S A V A L R T S	4080 (1360)
TCCCGCATGGTCTTTCGGCTCCAGTAACTGCATCTCAGAGSACGAGGGCCAGAATCAT S R I G L S A P S N C I S E D E G Q N H	4140 (1380)
CAGGGACAGAGCTGTATCCATCGGCCCTGTGGGAAGCAGGACAGCTGTCCGTATTGCTG Q G Q S C I H R P C G K Q D S C P S L L	4200 (1400)
CTTGATCATGTGATGTGGTGAACGTACTCTATAGGCCAGGTCTCATGAAGTGTGCT L D H A D V V N C T S I G P G L M K C A	4260 (1420)
ATCACTTGTCAAAGGGGATTTGCCCTTCAGGCCAGCAGTGGGAGTACATCAGGCCCATG I T C Q R G F A L Q A S S G Q Y I R P M	4320 (1440)
CAGAAGGAAATCTGCTCACATGTTCTTCTGGGCACTGGGACCAGAATGTGAGCTGCCTT Q K E I L L T C S S G H W D Q N V S C L	4380 (1460)
CCCGTGGACTGCGGTTCCTCCGACCCGTCTTGGTGAACATGCAAACTTCTCCTGCTCA P V D C G V P D P S L V N Y A N F S C S	4440 (1480)
GAGGGAACCAAATTTCTGAAACGCTGCTCAATCTCTTGTGTCCACCAGCCAAAGCTGCAA E G T K F L K R C S I S C V P P A K L Q	4500 (1500)
GGACTGAGCCCATGGCTGACATGCTTGAAGATGGTCTCTGGTCTCTCCCTGAAGTCTAC G L S P W L T C L E D G L W S L P E V Y	4560 (1520)
TGCAAGTTGGAGTGTGATGCTCCCTATTATTCTGAATGCCAACTTGCTCCTGCCTCAC C K L E C D A P P I I L N A N L L L P H	4620 (1540)
TGCCCTCCAGGACAACCACGAGTGGCCACCATCTGCAAAATGAATGCAAAACCAGGGTAC C L Q D N H D V G T I C K Y E C K P G Y	4680 (1560)
TATGTGGCAGAAAGTGCAGAGGGTAAAGTCAAGAACAGCTCCTGAAGATAAATGCCCTG Y V A E S A E G K V R N K L L K I Q C L	4740 (1580)
GAAGTGGAACTCTGGGAGCAAGGCAGCTGCATTCTGTGGTGTGTGAGCCACCCCTCCT E G G I W E Q G S C I P V V C E P P P P	4800 (1600)
GTGTTGAAGGCATGTATGATGTACCAATGGCTTCAGCCTGGACAGCCAGTGTGTGCTC V F E G M Y E C T N G F S L D S Q C V L	4860 (1620)
AACTGTAACCCAGGAACGTGAAAGCTTCCCATCCTCTGCCTAAAGAGGGCCTGTGGACC N C N Q E R E K L P I L C T K E G L W T	4920 (1640)
CAGGAGTTAAGTTGTGTGAGAATCTGCAAGGAGAATGCCACCACCCCTCAGAGCTG Q E F K L C E N L Q G E C P P P P S E L	4980 (1660)
AATCTGTGGAGTACAAATGTGAACAAGGATATGGGATTTGGTGCAGTGTGTTCCTTGG N S V E Y K C E Q G Y G I G A V C S P L	5040 (1680)
TGTGTAATCCCCCAGTGACCCCGTATGTACTGAGAAATACACTGCTGACTCTG C V I P P S D P V M L P E N I T A D T L	5100 (1700)
GAGCACTGGATGGAACCTGTCAAAGTCCAGAGCATTGTGTGCACTGGCCGGCGTCAATGG E H W M E P V K V Q S I V C T G R R Q W	5160 (1720)
CACCCAGACCCCGTCTTAGTCCACTGCATCCAGTCATGTGAGCCCTTCCAAGCAGATGGT H P D P V L V H C I Q S C E P F Q A D G	5220 (1740)
TGGTGTGACACTATCAACAACCGAGCCTACTGCCACTATGACGGGGAGACTGTGTCTCT W C D T I N N R A Y C H Y D G G D C C S	5280 (1760)
TCCCACTCTCCTCCAAGAAGGTCAATCCATTTGCTGCTGACTGTGACCTGGATGAGTGC S T L S S K K V I P F A A D C D L D E C	5340 (1780)
ACCTGCCGGGACCCAAAGGCAGAAGAAATCAGTAA T C R D P K A E E N Q *	5376 (1791)

Figure 2







Figure 4



# Figure 5





Figure 6



## Figure 7

ATGATGTGCT	TAAAGATCCT	AAGAATAAGC	CTGGCGATT	TGGCTGGGTG	GGCACTCTGT	60
TCGCAACT	CTGAGCTGGG	CTGGACACGC	AAGAAATCCT	TGTTGAGAG	GGAACACCTG	120
AATCAGGTGC	TGTTGGAAGG	AGAACGTTGT	TGGCTGGGGG	CCAAGGTTCC	AAGACCCAGA	180
GCTTCTCCAC	AGCATCACCT	CTTTGGAGTC	TACCCAGCA	GGGCTGGGAA	CTACCTAAGG	240
CCCTACCCCG	TGGGGGAGCA	AGAAATCCAT	CATACAGGAC	GCAGCAAACC	AGACACTGAA	300
GGAAATGCTG	TGAGCCTTGT	TCCCCAGAC	CTGACTGAAA	ATCCAGCAGG	ACTGAGGGGT	360
GCAGTTGAAG	AGCCGGCTGC	CCCATGGGTA	GGGGATAGTC	CTATTGGGCA	ATCTGAGCTG	420
CTGGGAGATG	ATGACGCTTA	TCTCGGCAAT	CAAAGATCCA	AGGAGTCTCT	AGGTGAGGCC	480
GGGATTGAGA	AAGGCTCAGC	CATGGCTGCC	ACTACTACCA	CCGCCATTTT	CACAACCTGT	540
AACGAACCCA	AACCAGAGAC	CCAAAGGAGG	GGCTGGGCCA	AGTCCAGGCA	GGCTCGCCAA	600
GTGTGGAAGA	GGCGGGCGGA	AGATGGGCAG	GGAGACTCCG	GTATCTCTTC	ACATTTCCAA	660
CCTTGGCCCA	AGCATTCCTT	TAAACACAGG	GTCAAAAAGA	GTCCACCCGA	GGAAAGCAAC	720
CAAAATGGTG	GAGAGGGCTC	CTACCAGAAA	GCAGAGACCT	TAACTCCCA	AGTAGGACTG	780
CCCATCTTAT	ACTTCTCTGG	GAGGCGGGAG	CGGCTGCTGC	TGCGTCCAGA	AGTGCTGGCT	840
GAGATTCCCC	GGGAGCGGTT	CACAGTGGAA	GCCTGGGTTA	AACCGGAGGG	AGGACAGAAC	900
AACCCGACCA	TCATCGCAGG	TGTGTTTGAT	AACTGCTCCC	ACACTGTCCG	TGACAAAGGC	960
TGGGCCCTGG	GGATCCGCTC	AGGGAAGGAC	AAGGGAAAGC	GGGATGCTCG	CTTCTTCTTC	1020
TCCCTCTGCA	CCGACCGCGT	GAAGAAAGCC	ACCATCTTGA	TAGCCACAG	TCGCTACCAA	1080
CCAGGCACAT	GGACCCATGT	GGCAGCCACT	TACGATGGAC	GGCACATGGC	CCTGTATGTG	1140
GATGCTGACT	AGGTGGCTAG	CAGTCTAGAC	CAGTCTGGTC	CCCTGAACAG	CCCTTCATG	1200
GCATCTTGCC	GCTCTTTGCT	CCTGGGGGGA	GACAGCTCTG	AGGATGGGCA	CTATTTCCGT	1260
GGACACCTGG	GCACACTGGT	TTTCTGGTCG	ACCGCCCTGC	CACAAAGCCA	TTTTCAAGC	1320
AGTTCTCAGC	ATTCAAGTGG	GGAGGAGGAA	GCGACTGACT	TGGTCTTGAC	AGCGAGCTTT	1380
GAGCCTGTGA	ACACAGAGTG	GGTTCCTTTT	AGAGATGAGA	AGTACCCACG	ACTTGAGGTT	1440
CTCCAGGGCT	TTGAGCCAGA	GCCTGAGATT	CTGTGCGCTT	TGCAGCCCC	ACTCTGTGGG	1500
CAAAACAGTCT	GTGACAATGT	GGAAATGATC	TCCAGTACA	ATGGATACTG	GGCCCTTCGG	1560
GGAGAGAAGG	TGATACGCTA	CCAGGTGGTG	AACATCTGTG	ATGATGAGGG	CCTAAACCCC	1620
ATTGTGAGTG	AGGAGCAGAT	TGCTCTGCA	CACGAGGCAC	TGAATGAGGC	CTTCAGCCG	1680
TACAACATCA	GCTGGCAGCT	GAGCGTCCAC	CAGGTCCACA	ATTCCACCCT	GGCACCCGG	1740
GTTGTGCTTG	TGAACTGTGA	GCCCAGCAAG	ATTGGCAATG	ACCATTGTGA	CCCCGAGTGT	1800
GAGCACCCAC	TCACAGGCTA	TGATGGGGGT	GACTGCCGCC	TGCAGGGCCG	CTGCTACTCC	1860
TGGAACCCGA	GGGATGGGCT	CTGTCACTGT	GAGTGTAAAC	ACATGCTGAA	CGACTTTGAC	1920
GACGGAGACT	GCTGCGACCC	CCAGGTGGCT	GATGTGCGCA	AGACCTGCTT	TGACCCTGAC	1980
TCACCCAAGA	GGGCATACAT	GAGTGTGAAG	GAGCTGAAGG	AGGCCCTGCA	GCTGAACAGT	2040
ACTCACTTCC	TCAACATCTA	CTTTGCCAGC	TCAGTGGGGG	AAGACCTTGC	AGGTGCTGCC	2100
ACCTGGCCCT	GGGACAAGGA	CGCTGTCACT	CACCTGGGTG	GCATTGTCCT	CAGCCACAGA	2160
TATTATGGGA	TGCCTGGCCA	CACCGACACC	ATGATCCATG	AACTGGGACA	TGTTCTGGGA	2220
CTCTACCATG	TCTTTAAAGG	AGTCAAGTAA	AGAGAATCCT	GCAATGACCC	CTGCAAGGAG	2280
ACAGTGCCAT	CCATGGAAC	GGGAGACCTC	TGTGCCGACA	CCGCCCCAC	TCCCAAGAGT	2340
GAGCTGTGCC	GGGAACCCGA	GCCCACTAGT	GACACCTGTG	GCTTCACTCG	CTTCCAGGG	2400
GCTCCGTTCA	CCAACTACAT	GAGCTACACG	GATGATAACT	GCACAGCAA	CTTCACTCCT	2460
AACCAAGTGG	CCCGAATGCA	TTGCTATTTG	GACCTAGTCT	ATCAGCAGTG	GACTGAAAGC	2520
AGAAAGCCCA	CCCCATCCC	CATTCACCTT	ATGGTCATCG	GACAGACCAA	CAAGTCCCTC	2580
ACTATCCACT	GGCTGCCTCC	TATTAGTGGG	GTTGTATATG	ACAGGGCCTC	AGGCAGCTTG	2640
TGTGGCGCTT	GCACTGAAGA	TGGGACCTTT	CGTCAATATG	TGCACACAGC	TCCCTCCCGG	2700
CGGTGTGTG	ACTCCTCAGG	TTATTGGACC	CCAGAGGAGG	CTGTGGGGCC	TCCTGATGTG	2760
GATCAGCCCT	GCGAGCCAAG	CTTACAGGCC	TGGAGCCCTG	AGGTCCACCT	GTACCACATG	2820
AACATGACGG	TCCCCTGCC	CACAGAAAGC	TGTAGCTTGG	AGTGTCTCTT	CCAACACCCG	2880
GTCCAAGCCG	ACACCCTCAC	CCTGTGGGTC	ACTTCCTTCT	TCATGGAGTC	CTCGCAGGTC	2940
CTCTTTGACA	CAGAGATCTT	GCTGGAATA	AAGGAGTCA	TGCACCTGGG	CCCCTTAGAC	3000
ACTTTCTGTG	ACATCCCCT	CACCATCAA	CTGCACGTGG	ATGGGAAGGT	GTCGGGGGTG	3060
AAAGTCTACA	CCTTTGATGA	GAGGATAGAG	ATTGATGCAG	CACTCCTGAC	TTCTCAGCCC	3120
CACAGTCCCT	TGTGCTCTGG	CTGCAGGCC	GTGAGGTACC	AGGTTCTCCG	CGATCCCCCA	3180
TTTGCCAGTG	GTTTGCCCGT	GGTGGTGACA	CATTCTCACA	GGAAATTCAC	GGAGCTGGAG	3240
GTCACACCTG	GACAGATGTA	TCAGTACCAA	GTTCTAGCTG	AAGCTGGAGG	AGAAGCTGGGA	3300
GAAGCTTCGC	CTCCTCTGAA	CCACATTCA	GGAGCTCCTT	ATTGTGGAGA	TGGGAAGGTT	3360
TCAGAGAGAC	TGGGAGAAGA	GTGTGATGAT	GGAGACCTTG	TGAGCGGAGA	TGGCTGCTCC	3420
AAGGTGTGTG	AGCTGGAGGA	AGGTTCAAC	TGTGTAGGAG	AGCCAAGCCT	TTGCTACATG	3480
TATGAGGGAG	ATGGCATAATG	TGAACCTTTT	GAGAGAAAA	CCAGCATTGT	AGACTGTGGC	3540
ATCTACACTC	CCAAAGGATA	CTTGGATCAA	TGGGCTACCC	GGGCTTACTC	CTCTCATGAA	3600
GACAAGAAGA	AGTGTCTGT	TTCCTTGTA	ACTGGAGAAC	CTCATTCCCT	AATTTGCACA	3660
TCATACCATC	CAGATTTACC	CAACCACCGT	CCCCTAAGTG	GCTGGTTTCC	CTGTGTGCCC	3720
AGTGAAAATG	AAACTCAGGA	TGACAGGAGT	GAACAGCCAG	AAGGTAGCCT	GAAGAAAGAG	3780
GATGAGGTTT	GGCTCAAAGT	GTGTTTCAAT	AGACCAGGAG	AGGCCAGAGC	AATTTTTTAT	3840
TTTTTGACAA	CTGATGGCCT	AGTTCCCGGA	GAGCATCAGC	AGCCGACAGT	GACTCTCTAC	3900
CTGACCGATG	TCCGTGGAG	CAACCACCTT	CTTGGAACTT	ATGGACTGTC	ATGCCAGCAT	3960
AATCCACTGA	TTATCAATGT	GACCCATCAC	CAGAATGTCC	TTTTCCACCA	TACCACCTCA	4020
GTGCTGCTGA	ATTTCTCAT	CCCACGGGTC	GGCATCTCAG	CTGTGCTCT	AAGGACATCC	4080
TCCCGCATTG	GTCCTTCCGC	TCCCAGTAAC	TGCATCTCAG	AGGACGAGGG	GCAGAATCAT	4140
CAGGGACAGA	GCTGTATCCA	TCCGCCCTGT	GGGAAGCAGG	ACAGCTGTCC	GTCATTGCTG	4200
CTTGATCATG	CTGATGTGGT	GAAGTGTACC	TCTATAGGCC	CAGGTCTCAT	GAAGTGTGCT	4260
ATCACTTGTG	AAAGGGGATT	TGCCCTTCAG	GCCAGCAGTG	GGCAGTACAT	CAGGCCCATG	4320

Figure 7

CAGAAGGAAA	TTCTGCTCAC	ATGTTCTTCT	GGGCACTGGG	ACCAGAATGT	GAGCTGCCTT	4380
CCCGTGGACT	GCCGTGTTCC	CGACCCGTCT	TTGGTGAAC	ATGCAAACTT	CTCCTGCCTA	4440
GAGGGAAACCA	AATTTCTGAA	ACGCTGCTCA	ATCTCTTGTG	TCCCACCAGC	CAAGCTGCAA	4500
GGACTGAGCC	CATGGCTGAC	ATGTCTTGAA	GATGGTCTCT	GGTCTCTCCC	TGAAGTCTAC	4560
TGCAAGTTGG	AGTGTGATGC	TCCCCATATT	ATTCTGAATG	CCAACCTTGT	CCTGCCTCAC	4620
AGCCTCCAGG	ACAACCACGA	CGTGGGCACC	ATCTGCAAA	ATGAATGCAA	ACCAGGGTAC	4680
TATGTGGCAG	AAAGTGCAGA	GGGTAAGTGC	AGGAACAAGC	TCCTGAAGAT	ACAATGCCTG	4740
GAAGGTGGAA	TCTGGGAGCA	AGGCAGCTGC	ATTCCCTGTG	TGTGTGAGCC	ACCCCTCCTT	4800
GTGTTTGAAG	GCATGTATGA	ATGTACCAAT	GGCTTCAGCC	TGGACAGCCA	GTGTGTGCTC	4860
AACTGTAAAC	AGGAACGTGA	AAAGCTTCCC	ATCCTCTGCA	CTAAAGAGGG	CCTGTGGGAC	4920
CAGGAGTTTA	AGTTGTGTGA	GAATCTGCAA	GGAGAATGCC	CACCACCCCC	CTCAGAGCTG	4980
AATTCTGTGG	AGTACAAATG	TGAACAAGGA	TATGGGATTG	GTGCAGTGTG	TTCCCCATTG	5040
TGTGTAATCC	CCCCAGTGA	CCCCGTGATG	CTACCTGAGA	ATATCACTGC	TGACACTCTG	5100
GAGACTGGGA	TGGAACCTGT	CAAAGTCCAG	AGCATTGTGT	GCCTGGCCCG	GCGTCAATGG	5160
CACCCAGACC	CCGTCTTAGT	CCACTGCATC	CAGTCATGTG	AGCCCTTCCA	AGCAGATGGT	5220
TGGTGTGACA	CTATCAACAA	CCGAGCCTAC	TGCCACTATG	ACGGGGGAGA	CTGCTGCTCT	5280
TCCACACTCT	CCTCCAAGAA	GGTCATTCCA	TTTGTGCTGT	ACTGTGACCT	GGATGATGTC	5340
ACCTGCCGGG	ACCCCAAGGC	AGAAGAAAAT	CAGTAACTGT	GGGAACAAGC	CCCTCCCTCC	5400
ACTGCCTCAG	AGGCAGTAAG	AAAGAGAGGC	CGACCCAGGA	GGAAACAAGG	GGTGAATGAA	5460
GAAGAACAAT	CATGAAATGG	AAGAAAGGAG	AAGAGCATGA	AGGATCTTAT	AAGAAATGCA	5520
AGAGGATATT	GATAGGTGTG	AACTAGTTCA	TCAAGTAGCC	CAAGTAGGAG	AGAATCATAG	5580
GCAAAAAGTTT	CTTTAAAGTG	GCAAGTTGATT	AACATGGAAG	GGGAAATATG	ATAGATATAT	5640
AAGGACCCCTC	CTCCCTCACT	TATATTCTAT	TAATCCTAT	CCTCAACTCT	TGCCCTGCTC	5700
TCCGCTCCAC	CCCTGCCAA	CTACTCAGTC	CCACCCAACT	TGTAAACCAA	TACCAAAATA	5760
CTAGAGGAGA	AGTTGGCAGG	GATACTGTTA	ATACCCATTT	TGAATGGATT	GCCATCTTTC	5820
AGAGCTTGTG	TGCTCTCAAC	TGGCTCTTTT	TCTTTTGTG	TAGTTTCCCT	TAAATAATGA	5880
AGTTAGTTAT	TAATCTTTA	TAAGTATTTA	AACATAATTA	TATAAATATA	TTATATATAT	5940
TATATTTTTT	GCTGTTTACT	AAGCTAAAAA	TTATTCAATG	TTCCACACAT	GCTGTGTGTA	6000
AGTTCACATT	CAAGATGAAT	GTGAGACTTT	TGAGGACAGA	AAGGCCAATT	ATTTCCCAT	6060
CTTTCTATGG	ATGCGGATTG	GCAGGTTGAA	TGGGAAGTAC	AGAAGGAGAG	AGAGTAATTA	6120
GATGGAATTC	TGGATGCTAG	CATGTAAGC	TAATCATCTT	TTTTTTTATG	ACCTGGGAGC	6180
TGGGCCCAT	TTATGACCAA	GGAGATGGGG	AGTTGGAATG	GTGGTACTAA	GAGGCATAGG	6240
AAGTTGAGTG	TGAATACCAT	TGGTGTGGG	TCCAGGAGAA	CTAGACTATG	GTCTTGAAT	6300
ATCTGTCCAC	AAAGAATATA	CTAACTTTTG	TCAACTTCTC	AGAACTCCCA	ACTGGAGTCG	6360
GTGAGACCTA	GGATTTTCTG	CACTTCCACA	CATGCCTGTT	CCAAGTGTGG	CTGTCAAGCA	6420
GTCAACAAGT	TTGTACTATG	GCCCAITCTC	TGATCACCAG	GATTACAGGA	ACTCACACAC	6480
TCCTCATAGT	TGGCCTGTAG	TCCTACTTCT	TGTTAGAAGT	CTCCAAGTCT	GGCCAGTCTC	6540
ATGACCAAGT	GTGATTTTTT	CTGGAGGAAA	AATTTTATGG	AAATGATATA	GGGAAAGGTT	6600
GGGAGGAGAT	GAAAGAACAG	GCAAGAGCTG	TCAGGGTTAA	ATCCAGGCCC	GGGCATGAGA	6660
ATGGAAGTGA	TCAGGGAGAC	TCCGTCCTTG	TTCCAAGTCT	CCAAAGAAGA	CCAAAGTGGG	6720
TCCCTTGAGC	AATGAAGAAT	CTGAGATAAA	TTCTCTTCAA	GTATCATGTA	CAAAATCTGT	6780
CAGCCAGAGA	TTTTGACTTG	AGCAAGCCAT	GGAAATGCAT	GGAGCAAGGG	TGACACTCTG	6840
TGGGGAGACA	GAAGAATTTT	AACTATTTAA	TGTCCATTTT	GTGTTTTTTA	CCCTTCTTTA	6900
TCCAATAGAT	GGAAATGCACA	TGAAATGACC	ATATTAAGCC	TCTCTCTATT	TACATCCCAG	6960
GCTCACTGGG	ATGTGATCTA	CTGCAGTTAC	ATTTTCTTGT	AACGGTTTCT	GGATTAGACC	7020
CTAGGGAAAG	TGAGTAAGGA	GCCAGTTTCT	GTTTAAACAT	CTAGTTTTAC	TCATTTTAGG	7080
AAGGCTGTGA	GTGAGGCTTG	TCTCCTTTAA	AGTTTCTTCT	CCAATGGAAA	CCAAGAACAG	7140
ACAAAATTTA	GAGCTCAGCT	GTGGTCTCTT	CTCATCTTCT	GCTCTTTTGC	TTTGACCACA	7200
GTTTTTCTAC	TCTTCCATC	AACACTAGAG	CAATGGCTGT	GCAAAATAGGA	ATAGGAAATA	7260
CTACCACAAT	GATAGAAATA	TTATCCACAC	TATCACGTAG	GGAAGAACAA	TATCTGAAA	7320
GAGAATAAAA	CACGAATAAG	GTGATGTACC	CACATTAATC	TGTGGGTTTG	TGGAATGAGG	7380
GTTGCAAAGT	TATTGGGAAA	AGGAAAGAGC	AGAGTTCACC	CATTCAAAAA	AAACCTTTTG	7440
TCTACTAATC	TCTAGTGTAA	AGAAAATGTA	GTTCAGATAC	CATTCAATGT	CTTGGGTCTG	7500
GCTTAGTGCC	CCCAAGAAGA	CAAACATATT	TATTCTTGGG	ATTCTGATAG	GCTTCAATAT	7560
GCAAAGGACA	ATGGAAAAGT	TTAGACACTC	TATTTTCAA	ATTTTATAAA	CTTGTTTTAT	7620
TGGGGAAAAT	GTCCAAATTT	CTAGACACAT	TCTAAGTTCT	GCCTTGAGGA	ATCCTACTTT	7680
GTCTGAGATT	GAGGCAGAGG	AATTGTTATC	CTGGGCATTA	CTCAGCTCAG	GAACATGGAG	7740
CCTGTGGTTC	ATGCCAGTGT	GTGTCTTCAT	GCAGTCTCTC	CACAAGAGCA	ACAGTAAGAA	7800
CATTTCTGTT	TTAAATTTCA	TTTTAAAATA	TTTTATATAT	TGCAATTCAC	CACTGCTCTG	7860
GGAAAGCAAA	AGGAAAGTCT	CTGTTGTGTG	TGAAGAGCCT	CTTAGGCTAT	AAGGCTTCCC	7920
AGCCATAGTC	AGCTATAGCT	ATTCAGAGAC	AGCAGGTTCT	TCCAGTCTTT	GTTCCCTGGGA	7980
CCTGATGTTT	TGAGCAACTC	AGGTCAGTGA	TAAAGTGGAA	GGACTAAGAC	ACTGTGGTCA	8040
CAGATCCCAG	CAACATCAAC	TCACACTCAA	TCCATGTGGT	GGTCCACATT	CTGCTACTCT	8100
TATCCACCACA	TGTGGTCATT	GAGAGCCTTT	CTCAGAGACT	CTTCTGTGTG	TTTGATTGTG	8160
CCCAGGTGGC	CCAGGGCTAG	CTGGCTCTAA	CAACTAGCAT	GACAGCCTCC	AATCAGAAAG	8220
GCAGGTAAGG	GGACAGGGTG	AGGAGAATGG	GCAGATACTG	ACAGAAATTA	AAGTAAGGGG	8280
ATTGTGAAG	TAAAGAGCTC	TTCCTGATTC	TCATCTTCTC	TTTTTCTAT	TACAAGGCAT	8340
TGAATCTGGC	ACTTCTGTTA	TTCTTTGTGA	TCACTATTGA	GTGCATTAGT	TACACCCAA	8400
GGGGATGGCT	TGATTGGGAA	TGTAGTGA	GGAGCTGATC	TACTGTATTG	TAATGTAAAA	8460
CAGCTACAGC	CAGTTATTTT	GTAAGATTAT	AAGTTGTTC	TTAAAAATC	AGCACACAAA	8520
ATATGAA						8527



## PREGNANCY-ASSOCIATED PLASMA PROTEIN-A2 (PAPP-A2)

### FIELD OF THE INVENTION

[0001] The present invention relates to a novel polypeptide with homology to pregnancy-associated plasma protein-A (PAPP-A). The novel polypeptide according to the invention is denoted PAPP-A2. The invention further relates to novel polynucleotides comprising a nucleic acid sequence encoding such a polypeptide, or a fragment thereof.

[0002] The invention further relates to methods for using the novel polynucleotides, including fragments thereof as defined herein below, and methods for using the novel polypeptides capable of being produced from such polynucleotides.

[0003] The invention also relates to expression and purification of recombinant PAPP-A2, and to production of polyclonal and monoclonal antibodies against PAPP-A2, and to the purification of native PAPP-A2 from human tissues or body fluids.

[0004] In further aspects the invention relates to uses of PAPP-A2 as a marker for pathological states, and as a therapeutic target for drugs that modify the proteolytic activity of PAPP-A in pregnant as well as non-pregnant individuals.

### BACKGROUND OF THE INVENTION

[0005] Pregnancy-Associated Plasma Protein-A (PAPP-A)

[0006] PAPP-A was first isolated in 1974 from pregnancy serum along with other proteins believed to be of placental origin (Lin et al., 1974, *Am J Obstet Gynecol* 118, 223-36). The concentration in serum reaches about 50 mg/liter at the end of pregnancy (Folkamen et al., 1981, *Am J Obstet Gynecol* 139, 9104; Oxvig et al., 1995, *J Biol Chem* 270, 13645-51). PAPP-A was originally characterized as a high molecular weight homotetramer (Bischof, 1979, *Arch Gynecol* 227, 315-25; Lin et al., 1974, *Am J Obstet Gynecol* 118, 223-36; Sinosich, 1990, *Electrophoresis* 11, 70-), but it has now been demonstrated that PAPP-A primarily exists in pregnancy serum and plasma as a covalent, heterotetrameric 2:2 complex with the proform of eosinophil major basic protein (proMBP), PAPP-A/proMBP (Oxvig et al., 1993, *J Biol Chem* 268, 12243-6). Only about 1% of PAPP-A in pregnancy serum and plasma is present as a homodimer, as recently demonstrated (Overgaard et al., 2000, *J Biol Chem*). The existence of the PAPP-A/proMBP complex was revealed, in part, by the isolation of a PAPP-A and a proMBP peptide, linked together by a disulfide bond, from a digest of purified PAPP-A/proMBP (Oxvig et al., 1993, *J Biol Chem* 268, 12243-6).

[0007] The subunits of the PAPP-A/proMBP complex can be irreversibly separated by reduction of disulfide bonds and denaturation (Oxvig et al., 1993, *J Biol Chem* 268, 12243-6). In reducing SDS-PAGE, the PAPP-A subunit has an apparent molecular weight of 200 kDa (Oxvig et al., 1994, *Biochim Biophys Acta* 1201, 415-23), and its 1547-residue sequence is known from cloned cDNA (Kristensen et al., 1994, *Biochemistry* 33, 1592-8). PAPP-A is synthesized as a pre-pro-protein (preproPAPP-A), including a 80-residue pre-pro-piece (Haaning et al., 1996, *Eur J Biochem* 237, 159-63). No proteins with global homology to PAPP-A has

been reported in the literature, but PAPP-A contains sequence motifs, including an elongated zinc binding motif (HEXXHXXGXXH) at position 482-492 (numbering according to Kristensen et al., 1994, *Biochemistry* 33, 1592-8). This motif and a structurally important methionine residue, also thought to reside in PAPP-A at position 556 are strictly conserved within the metzincins, a superfamily of zinc peptidases: astacins, adamalysins (or repropolysins), seralysins and matrixins (matrix metalloproteinases or MMP's) (Bode et al., 1993, *FEBS Lett* 331, 134-40; Stocker et al., 1995, *Protein Sci* 4, 823-40).

[0008] The proMBP subunit has a calculated peptide mass of 23 kDa (Barker et al., 1988, *J Exp Med* 168, 1493-8; McGrogan et al., 1988, *J Exp Med* 168, 2295-308). In SDS-PAGE, however, proMBP migrates as a smear of 5-90 kDa that is not visible in Coomassie-stained gels (Oxvig et al., 1993, *J Biol Chem* 268, 12243-6), probably due to its strong and unusual glycosylation (Oxvig et al. 1994, *Biochim Biophys Acta* 1201, 415-23). PAPP-A and proMBP are both produced in the placenta during pregnancy, but mainly in different cell types as shown by in situ hybridization (Bonno et al., 1994, *Lab Invest* 71, 560-6). Analyses by RT-PCR revealed that both PAPP-A and proMBP mRNA are present in several reproductive and nonreproductive tissues, although the levels are lower than in the placenta (Overgaard et al., 1999, *Biol Reprod* 61, 1083-9).

[0009] Clinical Use of PAPP-A

[0010] Clinically, depressed serum levels of PAPP-A are increasingly being used as a predictor of Down's syndrome pregnancies (Brambati et al., 1993, *Br J Obstet Gynaecol* 100, 324-6; Haddow et al., 1998, *N Engl J Med* 338, 955-61; Wald et al., 1992, *Bmi* 305, 28; Wald et al., 1999, *N Engl J Med* 341, 461-7), and it has been shown that PAPP-A serum levels are also depressed in other fetal abnormalities (Biagiotti et al., 1998, *Prenat Diagn* 18, 907-13; Spencer et al., 2000, *Prenat Diagn* 20, 411-6; Westergaard et al., 1983, *Prenat Diagn* 3, 225-32).

[0011] Further, the synthesis of PAPP-A in smooth muscle cells of the coronary artery following angioplasty is increased (Bayes-Genis et al., 2000, *Arterioscler Thromb Vaso Biol*, in press) which is currently being evaluated for potential clinical value. Data show that measurements of proMBP in pregnancy serum also have a diagnostic value (Christiansen et al., 1999, *Prenat Diagn* 19, 905-10).

[0012] Proteolytic Activity of PAPP-A: Cleavage of IGFBP-4

[0013] Only recently, the putative metalloproteinase activity of PAPP-A has been experimentally confirmed (Lawrence et al., 1999, *Proc Natl Acad Sci USA* 96, 3149-53). PAPP-A was partially purified from human fibroblast-conditioned medium (HFCM) and shown to be responsible for the proteolytic activity of HFCM against insulin-like growth factor binding protein (IGFBP)-4. IGFBP's, of which six have been described, are important modulators of IGF-I and -II activity (Fowlkes, 1997, *Trends Endocrinol Metab* 8, 299-306; Rajaram et al., 1997, *Endocr Rev* 18, 801-31).

[0014] IGF-I and -II are essential polypeptides with potent anabolic and mitogenic actions both in vivo and in vitro. IGF bound to IGFBP-4 cannot interact with its receptor, but

bioactive IGF is released once the binding protein is cleaved. Interestingly, cleavage IGFBP-4 by PAPP-A strictly requires the presence of IGF (Conover et al., 1993, *J Clin Invest* 91, 1129-37; Lawrence et al., 1999, *Pro Natl Acad USA* 96, 3149-53). PAPP-A secretion has also been demonstrated from osteoblasts and marrow stromal cells (Lawrence et al., 1999, *Proc Natl Acad Sci USA* 96, 3149-53), from granulosa cells (Conover et al., 1999, *J Clin Endocrinol Metab* 84, 4742-5), and from vascular smooth muscle cells (Bayes-Genis et al., 2000, *Arterioscler Thromb Vasc Biol. in press*), all of which have known IGF-dependent IGFBP-4 proteinase activity.

[0015] IGFBP-5

[0016] Like IGFBP-4, IGFBP-5 cleavage has been widely reported to occur by unidentified proteinases in a number of tissues and conditioned media (Hwa et al., 1999, *Endocr Rev* 20, 761-87).

#### SUMMARY OF THE INVENTION

[0017] Pregnancy-Associated Plasma Protein-A2

[0018] The novel nucleic acid according to the invention has been isolated from human placenta and characterized by means of sequencing analysis. The novel nucleotide sequence encodes a new polypeptide, PAPP-A2.

[0019] The amino acid sequence of PAPP-A2 is composed of a 233-residue pre-pro-piece and a 1558-residue mature portion. The mature portion of PAPP-A2 is homologous with the mature portion of PAPP-A (approx. 45% identity), but the prepro-pieces do not show any similarity between the two proteins. Like PAPP-A, PAPP-A2 contains conserved amino acid stretches that classify it as a putative metallo-proteinase of the metzincin superfamily.

[0020] PAPP-A2 has been expressed in a mammalian expression system, and it has been demonstrated that PAPP-A2 is an active enzyme. Further, it has been shown that PAPP-A2 cleaves IGFBP-5, Insulin Like Growth Factor Binding Protein S. In comparison, the cleavage of IGFBP-4 by PAPP-A has previously been demonstrated.

[0021] A complementary DNA (cDNA) which encodes the full length form of PAPP-A2 is identified, sequenced and isolated. The cDNA or portions of the cDNA is cloned into expression vectors for expression in a recombinant host. The cDNA is useful to produce recombinant full-length PAPP-A2 or fragments of PAPP-A2. The cDNA and the recombinant PAPP-A2 protein derived therefrom are useful in the production of anti-bodies, diagnostic kits, laboratory reagents and assays.

[0022] The cDNA and the recombinant PAPP-A2 protein may also be used to identify compounds that affect PAPP-A2 function. PAPP-A2 antisense oligonucleotides or antisense mimetics may be clinically useful for reducing the expression of PAPP-A2 protein and thereby antagonizing the effects of PAPP-A. Similarly, the PAPP-A2 coding sequence can be used for gene therapy to introduce PAPP-A2 into target cells thereby enhancing the effects of PAPP-A2.

[0023] The invention furthermore pertains to PAPP-A2 for use as a therapeutic target for the reduction or elimination of IGFBP-5 proteolytic activity in a cell.

[0024] It is furthermore an objective of the present invention to provide methods for use of PAPP-A2 for diagnostic purposes.

[0025] Other features and advantages of the invention will be apparent from the following drawings and description hereof, from the following detailed description, and from the claims.

#### DEFINITIONS

[0026] As used herein, PAPP-A2 refers to an isolated PAPP-A2 polypeptide having the amino acid sequence listed in FIG. 1 (SEQ ID NO:2), or a variant thereof as defined herein. The PAPP-A2 according to the invention, or a variant thereof, may be produced by recombinant DNA technology, or the PAPP-A2 may be naturally occurring.

[0027] A PAPP-A2 encoding nucleotide sequence refers to an isolated nucleic acid having the sequence listed in FIG. 1 (SEQ ID NO:1), or a variant thereof as defined herein.

[0028] "Active" refers to those forms of PAPP-A2 which retain the biological and/or immunological activities of any naturally occurring PAPP-A2.

[0029] "Naturally occurring PAPP-A2" refers to PAPP-A2 produced by human cells that have not been genetically engineered and specifically contemplates various PAPP-A2s arising from post-translational modifications of the polypeptide including but not limited to acetylation, carboxylation, glycosylation, phosphorylation, lipidation, acylation, or complex formation, covalent or noncovalent, with other polypeptides.

[0030] An "isolated polypeptide" is a protein, or a variant or fragment thereof, which constitutes 90% or more of the protein contents of a given preparation as evaluated by standard methods known in the art of protein chemistry.

[0031] "Derivative" refers to polypeptides derived from naturally occurring PAPP-A2 by chemical modifications such as ubiquitination, labeling (e.g., with radionuclides, various enzymes, etc.), pegylation (derivatization with polyethylene glycol), or by insertion (or substitution by chemical synthesis) of amino acids (amino acids) such as ornithine, which do not normally occur in human proteins.

[0032] "Recombinant variant" refers to any polypeptide differing from naturally occurring PAPP-A2 by amino acid insertions, deletions, and substitutions, created using recombinant DNA techniques. Guidance in determining which amino acid residues may be replaced, added or deleted without abolishing activities of interest, such as proteolytic activity or cell adhesion, may be found e.g. by comparing parts of the sequence of PAPP-A2 with structurally similar proteins (e.g. other metzincin family proteinases), with locally homologous proteins of known disulfide structure, or by secondary structure predictions.

[0033] Preferably, amino acid "substitutions" are the result of replacing one amino acid with another amino acid having similar structural and/or chemical properties, such as, but not limited to, the replacement of a leucine with an isoleucine or valine, replacement of an aspartate with a glutamate, or replacement with a threonine with a serine, i.e., conservative amino acid replacements. Further examples and definitions falling within the meaning of the term "substitutions" as applied herein are provided in the detailed description of the invention herein below.

[0034] Amino acid "insertions" or "deletions" are typically in the range of from about 1 amino acid to about

50 amino acids, such as from about 1 amino acid to about 20 amino acids, for example from about 1 amino acid to about 20 amino acids, such as from about 1 amino acid to about 10 amino acids. The variation allowed may be experimentally determined by systematically making insertions, deletions, or substitutions of amino acids in a PAPP-A2 molecule using recombinant DNA techniques and assaying the resulting recombinant variants for activity.

[0035] Where desired, a "signal or leader sequence" can direct the polypeptide (full length PAPP-A2, or portions of the PAPP-A2 polypeptide) through the membrane of a cell. Such a sequence may be naturally present on the polypeptides of the present invention or provided from heterologous protein sources by recombinant DNA techniques.

[0036] A polypeptide "fragment", "portion", or "segment" is a stretch of amino acid residues of at least about 5 amino acids, often at least about 7 amino acids, typically at least about 9 to 13 amino acids, such as at least about 17 or more amino acids in various embodiments. It may also be a longer stretch of residues up to intact PAPP-A2 in length. To be active, any PAPP-A2 polypeptide or PAPP-A2 polypeptide fragment must have sufficient length to display biologic and/or immunologic activity on their own, or when conjugated to a carrier protein such as keyhole limpet hemocyanin.

[0037] An "oligonucleotide" or polynucleotide "fragment", "portion", or "segment" is a stretch of the PAPP-A2 encoding sequence which is useful in the expression of PAPP-A2 polypeptide fragments. It may also be a stretch of nucleotide residues capable of being used in a polymerase chain reaction (PCR) or a hybridization procedure, typically for amplifying or revealing related parts of mRNA or DNA molecules. In particular, one or both oligonucleotide probes will comprise sequence that is identical or complementary to a portion of PAPP-A2 where there is little or no identity or complementarity with any known or prior art molecule. For this purpose, such oligonucleotide probes will generally comprise between about 10 nucleotides and 50 nucleotides, and preferably between about 15 nucleotides and about 30 nucleotides.

[0038] "Animal" as used herein may be defined to include human, domestic or agricultural (cats, dogs, cows, sheep, etc) or test species (mouse, rat, rabbit, etc).

[0039] "Recombinant" may also refer to a polynucleotide which encodes PAPP-A2 and is prepared using recombinant DNA techniques. The DNAs which encode PAPP-A2 may also include allelic or recombinant variants and mutants thereof.

[0040] "Nucleic acid probes" are prepared based on the cDNA sequences which encode PAPP-A2 provided by the present invention. Nucleic acid probes comprise portions of the sequence having fewer nucleotides than about 6 kb, usually fewer than about 1 kb. After appropriate testing to eliminate false positives, these probes may be used to determine whether mRNAs encoding PAPP-A2 are present in a cell or tissue or to isolate similar nucleic acid sequences from chromosomal DNA extracted from such cells or tissues as described in (Walsh et al., 1992, *PCR Methods Appl* 1, 241-50). Probes may be derived from naturally occurring or recombinant single- or double-stranded nucleic acids or be chemically synthesized. They may be labeled by nick trans-

lation, Klenow fill-in reaction, PCR or other methods well known in the art. Probes of the present invention, their preparation and/or labeling are elaborated in (Sambrook et al., 1989); or (Ausubel et al., 1989).

[0041] Alternatively, recombinant variants encoding these PAPP-A2 or similar polypeptides may be synthesized or selected by making use of the "redundancy" in the genetic code. Various codon substitutions, such as the silent changes which produce various restriction sites, may be introduced to optimize cloning into a plasmid or viral vector or expression in a particular prokaryotic or eukaryotic system. Mutations may also be introduced to modify the properties of the polypeptide, including but not limited to activity, interchain affinities, or polypeptide degradation or turnover rate. One example involves inserting a stop codon into the nucleotide sequence to limit the size of PAPP-A2 so as to provide a molecule of smaller molecular weight.

[0042] "Expression vectors" are defined herein as DNA sequences that are required for the transcription of cloned copies of genes and the translation of their mRNAs in an appropriate host. Such vectors can be used to express eukaryotic genes in a variety of hosts such as bacteria, yeast, bluegreen algae, plant cells, insect cells and animal cells.

[0043] The term "antibody" as used herein includes both polyclonal and monoclonal antibodies, as well as fragments thereof, such as, Fv, Fab and F(ab)<sub>2</sub> fragments that are capable of binding antigen or hapten. It includes conventional murine monoclonal antibodies as well as human antibodies, and humanized forms of non-human antibodies, and it also includes 'antibodies' isolated from phage antibody libraries.

[0044] "Ribozymes" are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA. The mechanism of ribozyme action involves sequence specific hybridization of the ribozyme molecule to complementary target RNA, followed by an endonucleolytic cleavage. Within the scope of the invention are engineered hammerhead motif ribozyme molecules that specifically and efficiently catalyze endonucleolytic cleavage of PAPP-A2 RNA sequences. Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites which include the following sequences, GUA, GUU and GUC. Once identified, short RNA sequences of between fifteen (15) and twenty (20) ribonucleotides corresponding to the region of the target gene containing the cleavage site may be evaluated for predicted structural features such as secondary structure that may render the oligonucleotide sequence unsuitable. The suitability of candidate targets may also be evaluated by testing their accessibility to hybridization with complementary oligonucleotides, using ribonuclease protection assays.

#### DETAILED DESCRIPTION OF THE INVENTION

[0045] Isolation of a Nucleotide Sequence Encoding PAPP-A2

[0046] The present invention in one aspect relates to a novel cDNA sequence encoding a protein with global homology to pregnancy-associated plasma protein-A (PAPP-A). This protein has been denoted PAPP-A2. The complete nucleotide sequence of PAPP-A2 has been

obtained from mRNA isolated from human placenta (Example 1). The complete nucleotide sequence (SEQ ID NO:1) and translated amino acid sequence (SEQ ID NO:2) of PAPP-A2 are both shown in **FIG. 1**.

**[0047]** Homology of PAPP-A2 with PAPP-A is evident upon alignment of the two amino acid sequences as shown in **FIG. 3**. PAPP-A2 and PAPP-A share approximately 45% of their amino acid residues. Sequence motifs known to be important for the function of PAPP-A (Kristensen et al., 1994, *Biochemistry* 33, 1592-8; Lawrence et al., 1999, *Proc Natl Acad Sci USA* 96,3149-53; Overgaard et al. 2000, *J Biol Chem*) are also found in PAPP-A2. Principally, PAPP-A2 contains an elongated zinc binding motif (HEXX-HXXGXXH, amino acids shown by one letter code) at position 733-743 (**FIG. 2**) This motif and a structurally important methionine residue, are strictly conserved within the metzincins, a superfamily of zinc peptidases (Bode et al., 1993, *FEBS Lett* 331, 13440; Stocker et al., 1995, *Protein Sci.* 4, 823-40).

**[0048]** Like PAPP-A, PAPP-A2 is synthesized as a prepro-protein. PreproPAPP-A2 has 1791 amino acids (**FIG. 1**). There is no homology between the prepro-portions of PAPP-A and PAPP-A2. Further, the prepro-portions of the two proteins differ significantly in length. The PAPP-A2 prepro-peptide has 233 residues (**FIG. 3**); the PAPP-A prepro-peptide has 80 residues (Heaning et al., 1996, *Eur J Biochem* 237, 159-63).

**[0049]** Uses of the Nucleotide Sequence Encoding PAPP-A2

**[0050]** The nucleotide sequence encoding PAPP-A2 (or its complement) have numerous applications in techniques known to those skilled in the art of molecular biology. These techniques include use as hybridization probes, use in the construction of oligomers for PCR, use in the recombinant production of PAPP-A2 or fragments hereof, and use in generation of anti-sense DNA or RNA, their chemical analogs (e.g. PNA or LNA) and the like. Uses of nucleotides encoding PAPP-A2 disclosed herein are exemplary of known techniques and are not intended to limit their use in any technique known to a person of ordinary skill in the art. Furthermore, the nucleotide sequences disclosed herein may be used in molecular biology techniques that have not yet been developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, e.g., the triplet genetic code, specific base pair interactions, etc.

**[0051]** It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of PAPP-A2-encoding nucleotide sequences, some bearing minimal homology to the nucleotide sequence of any known and naturally occurring gene may be produced. The invention has specifically contemplated each and every possible variation of nucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the nucleotide sequence of naturally occurring PAPP-A2, and all such variations are to be considered as being specifically disclosed.

**[0052]** Although the nucleotide sequences which encode PAPP-A2 and/or its variants are preferably capable of hybridizing to the nucleotide sequence of the naturally

occurring PAPP-A2 under stringent conditions, it may be advantageous to produce nucleotide sequences encoding PAPP-A2 or its derivatives possessing a substantially different codon usage. Codons can be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic expression host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding PAPP-A2 and/or its derivatives Without altering the encoded amino acid sequence include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

**[0053]** Nucleotide sequences encoding PAPP-A2 may be joined to a variety of other nucleotide sequences by means of well established recombinant DNA techniques (Sambrook et al., 1989). Useful nucleotide sequences for joining to PAPP-A2 include an assortment of cloning vectors, e.g., plasmids, cosmids, lambda phage derivatives, phagemids, and the like, that are well known in the art. Vectors of interest include expression vectors, replication vectors, probe generation vectors, sequencing vectors, and the like. In general, vectors of interest may contain an origin of replication functional in at least one organism, convenient restriction endonuclease sensitive sites, and selectable markers for the host cell.

**[0054]** Another aspect of the subject invention is to provide for PAPP-A2-specific nucleic acid hybridization probes capable of hybridizing with naturally occurring nucleotide sequences encoding PAPP-A2. Such probes may also be used for the detection of similar PAPP-A2 encoding sequences and should preferably contain at least 50% of the nucleotides from the conserved region or active site. The hybridization probes of the subject invention may be derived from the nucleotide sequences of the SEQ ID NO:1 or from genomic sequences including promoters, enhancer elements and/or possible introns of the respective naturally occurring PAPP-A2. Hybridization probes may be labeled by a variety of reporter groups, including radionuclides such as <sup>32</sup>P or <sup>35</sup>S, or enzymatic labels such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

**[0055]** PCR as described (U.S. Pat. Nos. 4,683,195; and 4,966,188) provides additional uses for oligonucleotides based upon the nucleotide sequence which encodes PAPP-A2. Such probes used in PCR may be of recombinant origin, may be chemically synthesized, or a mixture of both and comprise a discrete nucleotide sequence for diagnostic use or a degenerate pool of possible sequences for identification of closely related genomic sequences.

**[0056]** Other means of producing specific hybridization probes for PAPP-A2 DNAs include the cloning of nucleic acid sequences encoding PAPP-A2 or PAPP-A2 derivatives into vectors for the production of mRNA probes. Such vectors are known in the art and are commercially available and may be used to synthesize RNA probes in vitro by means of the addition of the appropriate RNA polymerase as T7 or SPS RNA polymerase and the appropriate radioactively labeled nucleotides.

**[0057]** It is possible to produce a DNA sequence, or portions thereof, encoding PAPP-A2 and their derivatives entirely by synthetic chemistry, after which the gene can be

inserted into any of the many available DNA Vectors using reagents, vectors and cells that are known in the art at the time of the filing of this application. Moreover, synthetic chemistry may be used to introduce mutations into the PAPP-A2 sequences or any portion thereof.

**[0058]** The nucleotide sequence can be used in an assay to detect disease associated with abnormal levels of expression of PAPP-A2. The nucleotide sequence can be labeled by methods known in the art and added to a fluid or tissue sample from a patient under hybridizing conditions. After an incubation period, the sample is washed with a compatible fluid which optionally contains a dye (or other label requiring a developer) if the nucleotide has been labeled with an enzyme. After the compatible fluid is rinsed off, the dye is quantitated and compared with a standard. Alternatively, levels of PAPP-A2 mRNA can be measured by micro array techniques using immobilized probes. Expression in samples can also be evaluated by (semi-quantitative) RT-PCR. Expression in samples can alternatively be evaluated by techniques based on hybridization. For example, in situ hybridization can be used to detect PAPP-A2 mRNA. This technique has the advantage that it locates the cells that synthesize the mRNA, but also is less sensitive than RT-PCR.

**[0059]** Included in the scope of the invention are oligoribonucleotide sequences, that include antisense RNA and DNA molecules and ribozymes that function to inhibit translation of PAPP-A2. Antisense techniques are known in the art and may be applied herein. Both antisense RNA and DNA molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of RNA molecules. These include techniques for chemically synthesizing oligodeoxyribonucleotides well known in the art such as for example solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding the antisense RNA molecule. Such DNA sequences may be incorporated into a wide variety of vectors which incorporate suitable RNA polymerase promoters such as the T7 or SP6 polymerase promoters. Alternatively, antisense cDNA constructs that synthesize antisense RNA constitutively or inducibly, depending on the promoter used, can be introduced stably into cell lines.

**[0060]** The invention also relates to unknown PAPP-A2 genes isolated from other species and alleles of the PAPP-A4 gene, in which PAPP-A2 orthologues or homologues exist. A bacteriophage cDNA library may be screened, under conditions of reduced stringency, using a radioactively labeled fragment of the human PAPP-A2 clone described herein. Alternatively the human PAPP-A2 sequence can be used to design degenerate or fully degenerate oligonucleotide probes which can be used as PCR probes or to screen bacteriophage cDNA libraries. The PCR product may be sub-cloned and sequenced to insure that the amplified sequences represent the PAPP-A2 sequences. The PCR fragment may be used to isolate a full length PAPP-A2 clone by radioactively labeling the amplified fragment and screening a bacteriophage cDNA library. Alternatively, the labeled fragment may be used to screen a genomic library. For a review of cloning strategies which may be used, see e.g., (Ausubel et al., 1989; Sambrook et al., 1989).

#### **[0061]** Expression of Recombinant PAPP-A2

**[0062]** In order to express a biologically active proteinase, the nucleotide sequence coding for the protein, or a functional equivalent, can be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for the transcription and translation of the inserted coding sequence. For example, recombinant protein can be used for immunization to obtain antibodies, as a laboratory reagent, and in diagnostic kits.

**[0063]** More specifically, methods which are well known to those skilled in the art can be used to construct expression vectors containing the PAPP-A2 sequence and appropriate transcriptional/translational control signals. These methods include in vitro recombinant DNA techniques, synthetic techniques and in-Vivo recombination/genetic recombination. See e.g., the techniques described in (Ausubel et al., 1989; Sambrook et al., 1989).

**[0064]** Further, expression vectors containing fragments of the PAPP-A2 encoding sequence may also be constructed. In particular, this may be relevant for the use of portions of the PAPP-A2 polypeptide as an antigen for immunization. In addition, the coding sequence of PAPP-A2 or fragments hereof may be cloned in frame with a coding nucleotide sequence present in the vector to result in a fusion protein or a 'tagged' PAPP-A2 protein. For example, such a fusion protein may be composed of PAPP-A2 and GST, and such tag may be a c-myc tag (for detection) and/or a histidine tag (for purification).

**[0065]** A variety of host-expression vector systems may be utilized to express the PAPP-A2 coding sequence or fragments hereof. These include but are not limited to microorganisms such as bacteria transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing the PAPP-A2 coding sequence; yeast transformed with recombinant yeast expression vectors containing the PAPP-A2 coding sequence; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing the PAPP-A2 coding sequence; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing the PAPP-A2 coding sequence; or animal cell systems infected with recombinant virus expression vectors (e.g., adenovirus, vaccinia virus, human tumor cells) including cell lines engineered to contain multiple copies of the PAPP-A2 DNA either stably amplified (CHO/dhfr) or unstably amplified in double-minute chromosomes (e.g., murine cell lines).

**[0066]** The expression elements of these systems vary in their strength and specificities. Depending on the host/vector system utilized, any of a number of suitable transcription and translation elements, including constitutive and inducible promoters, may be used in the expression vector. For example, when cloning in bacterial systems, inducible promoters such as pL of bacteriophage lambda, play, ptrp, ptac (ptrp-lac hybrid promoter) and the like may be used; when cloning in insect cell systems, promoters such as the baculovirus polyhedron promoter may be used; when cloning in plant cell systems, promoters derived from the genome of plant cells (e.g., heat shock promoters; the promoter for the small subunit of RUBISCO; the promoter for the chlorophyll a/b binding protein) or from plant viruses (e.g., the 35S

RNA promoter of CaMV; the coat protein promoter of TMV) may be used; When cloning in mammalian cell systems, promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the CMV promoter, the adenovirus late promoter, the vaccinia Virus 7.5K promoter) may be used; when generating cell lines that contain multiple copies of the PAPP-A2 DNA SV40-, BPV- and EBV-based vectors may be used with an appropriate selectable marker.

**[0067]** The expression vector may be introduced into host cells via any one of a number of techniques including but not limited to transformation, transfection, infection, protoplast fusion, and electroporation. The expression vector-containing cells are clonally propagated and individually analyzed to determine whether they produce PAPP-A2 protein. Identification of PAPP-A2 expressing host cell clones may be done by several means, including but not limited to immunological reactivity with anti-PAPP-A2 antibodies, and the presence of host cell-associated PAPP-A2 activity.

**[0068]** In bacterial systems, a number of expression vectors may be advantageously selected depending upon the use intended for the PAPP-A2 expressed. For example, when large quantities of PAPP-A2 are to be produced, vectors which direct the expression of high levels of fusion protein products that are readily purified may be desirable. Such vectors include but are not limited to the *E. coli* expression vector pUR278 (Ruther and Muller-Hill, 1983, *Embo J* 2, 1791-4), in which the PAPP-A2 coding sequence may be ligated into the vector in frame with the lac Z coding region so that a hybrid AS-lac Z protein is produced. pGEX vectors may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathioneagarose beads followed by elution in the presence of free glutathione. The pGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the coned polypeptide of interest can be released from the GST moiety. In yeast, a number of vectors containing constitutive or inducible promoters may be used. For a review, see (Ausubel et al., 1989; Sitter et al., 1987, *Methods Enzymol* 153, 516-44; Rosenfeld, 1999. *Methods Enzymol* 306, 154-69).

**[0069]** In cases where plant expression vectors are used, the expression of the PAPP-A2 coding sequence may be driven by any of a number of promoters. For example, viral promoters such as the 35S RNA and 19S RNA promoters of CaMV may be used (Gmunder and Kohli, 1989, *Mol Gen Genet* 220, 95-101); alternatively, plant promoters such as the small subunit of RUBISCO (Broglie et al., 1984, *Science* 224, 838-43).

**[0070]** An alternative expression system which could be used to express PAPP-A2 is an insect system. In one such system, Baculovirus is used as a vector to express foreign genes. The virus then grows in the insect cells. The PAPP-2 coding sequence may be cloned into non-essential regions (for example the polyhedron gene) of the virus and placed under control of a Baculovirus promoter. These recombinant viruses are then used to infect insect cells in which the inserted gene is expressed. For example, see (Smith et al., 1983, *Mol Cell Biol* 3, 2156-66).

**[0071]** A variety of mammalian expression vectors may be used to express recombinant PAPP-A2 in mammalian cells.

Commercially-available mammalian expression vectors which may be suitable for recombinant PAPP-A2 expression, include but are not limited to, pMC1neo (Stratagene), pXT1 (Stratagene), pSGS (Stratagene), EBO-pSV2-neo (ATCC 37593), pBPV-1 (8-2) (ATCC 37110), pcDNA3.1 and its derivatives (Stratagene), Cell lines derived from mammalian species which may be suitable and which are commercially available, include but are not limited to, CV-1, COS-1, COS-7, CHO-K1, 3T3, NIH3T3, HeLa, C127I, BS-C-1, MRC-5, and 293. Further, in mammalian host cells, a number of viral based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, the PAPP-A2 coding sequence may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus genome by in vitro or in vivo recombination. Insertion in a non-essential region of the viral genome (e.g., region EP or ES) will result in a recombinant virus that is viable and capable of expressing PAPP-A2 in infected hosts. See for example (Logan and Shenk, 1984, *Proc Natl Acad Sci USA* 81, 3655-9). Alternatively, the vaccinia 7.5K promoter may be used. See for example (Mackett et al., 1982, *Proc Natl Acad Sci USA* 79, 7415-9).

**[0072]** For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express PAPP-A2 may be engineered. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with PAPP-A2 DNA controlled by appropriate expression control elements (e.g., promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc), and a selectable marker. Following the introduction of foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into call lines.

**[0073]** Some applications of the recombinant PAPP-A2 may require the protein to be in purified or partially purified form. Recombinantly expressed PAPP-A2 or fragments of the PAPP-A2 polypeptide can be isolated by liquid chromatography. Various methods of protein purification well known in the art include those described in for example (Scopes, 1987). Alternatively, recombinant PAPP-A2 fusion proteins or 'tagged' PAPP-A2 may be purified by affinity chromatography. Further, antibodies raised against PAPP-A2 may be used for purification by immunoaffinity chromatography.

**[0074]** Recombinant variant of PAPP-A2 may be produced by site directed mutagenesis. In some applications of PAPP-A2 such variants may be preferred due to for example increased protein stability, or changes in activity.

**[0075]** Production and Uses of Antibodies Against PAPP-A2

**[0076]** The recombinant protein may be used to generate antibodies. Monospecific antibodies to PAPP-A2 can be purified from mammalian antisera containing antibodies reactive against PAPP-A2 or can be prepared as monoclonal antibodies reactive with PAPP-A2 using standard techniques.

[0077] Monospecific antibody as used herein is defined as a single antibody species or multiple antibody species with homogenous binding characteristics for PAPP-A2. Homogenous binding as used herein refers to the ability of the antibody species to bind to a specific antigen or epitope, such as those associated with the PAPP-A2, as described above. PAPP-A2 specific antibodies are raised by immunizing animals such as mice, rats, guinea pigs, rabbits, goats, horses and the like, with rabbits or mice being preferred, with an appropriate concentration of PAPP-A2 either with or without an immune adjuvant. For example, antibodies specific against PAPP-A2 can be used for the purification of native and recombinant PAPP-A2, as a laboratory reagent, and in antibody based diagnostic kits.

[0078] Monoclonal antibodies (mAb) reactive With PAPP-A2 can be prepared by conventional methods, such as by immunizing inbred mice with PAPP-A2. The mice are immunized with about 0.1 mg to about 10 mg, preferably about 1 mg, of PAPP-A2 in about 0.5 ml buffer or saline incorporated in an equal volume of an acceptable adjuvant Freund's complete adjuvant is preferred. The mice receive an initial immunization on day 0 and are rested for about 3 to about 30 weeks. Immunized mice are given one or more booster immunizations of about 0.1 to about 10 mg of PAPP-A2 in a buffer solution such as phosphate buffered saline (PBS) by the intravenous (IV) route, Lymphocytes from antibody-positive mice are obtained by removing spleens from immunized mice by standard procedures known in the art. Hybridoma cells are produced by mixing the splenic lymphocytes with an appropriate fusion partner under conditions which will allow the formation of stable hybridomas. Fused hybridoma cells are selected by growth in hypoxanthine, thymidine and aminopterin supplemented Dulbecco's Modified Eagles Medium (DMEM) by procedures known in the art. Supernatant fluids are collected from growth positive wells on about days 14, 18, and 21 and are screened for antibody production by an immunoassay such as solid phase immunoradioassay (SPIRA) using PAPP-A2 as the antigen. The culture fluids are also tested in the Ouchterlony precipitation assay to determine the isotype of the mAb. Hybridoma cells from antibody positive wells are then cloned. For details, see (Peters and Baumgarten, 1992).

[0079] In Vitro production of anti-PAPP-A2 is carried out by growing the hybridoma in DMEM containing about 2% fetal calf serum to obtain sufficient quantities of the specific mAb. The mAb are purified by techniques known in the art.

[0080] Antibody titers of ascites or hybridoma culture fluids are determined by various serological or immunological assays which include, but are not limited to, precipitation, passive agglutination, enzyme-linked immunosorbent antibody (ELISA) technique (Crowther, 1995).

[0081] The "monoclonal antibodies" may also be isolated from phase antibody libraries using the techniques described in (Clackson et al., 1991, *Nature* 352, 624-8; Marks et al., 1991, *J Mol Biol* 222, 581-97), for example, identified phage antibodies can be produced by expression in bacteria.

[0082] Methods such as those described above may be used to produce monospecific antibodies specific for PAPP-A2 polypeptide fragments or full-length nascent PAPP-A2 polypeptide.

[0083] PAPP-A2 antibody affinity columns can be made by adding the antibodies to a gel support, such as Affigel-10

(Biorad), a gel support which is pre-activated with N-hydroxysuccinimide esters such that the antibodies form covalent linkages with the agarose gel bead support. The antibodies are then coupled to the gel via amide bonds with the spacer arm. The remaining activated esters are then quenched with 1M ethanamine HCl (pH 8). The column is washed with water followed by 0.23 M glycine HCl (pH 2.6) to remove any non-conjugated antibody or extraneous protein. The column is then equilibrated in phosphate buffered saline (pH 7.3) and the cell culture supernatants or cell extracts containing PAPP-A2 or PAPP-A2 fragments are slowly passed through the column. The column is then washed, and the protein is eluted. The purified PAPP-A2 protein is then dialyzed against phosphate buffered saline.

[0084] Native PAPP-A2 from sources such as human plasma or serum, tissue extracts, or media from nontransfected cell lines (that endogenously secrete PAPP-A2) may also be purified by use of an antibody affinity column.

[0085] Using polyclonal or monoclonal antibodies against PAPP-A2 a number of assays may be constructed for measurement of PAPP-A2 antigen in body fluids or tissue and cell extract. Kits based on antibodies may be used for diagnostic purposes. The assays include, but are not limited to, precipitation, passive agglutination, enzyme-linked immunosorbent assay (ELISA) techniques, and radioimmunoassay (RIA) techniques.

[0086] For example, in one such ELISA, a sandwich assay can be constructed where antigen present in a sample is caught by immobilized polyclonal anti(PAPP-A2). Detection is then performed by the use of one or more monoclonal PAPP-A2 antibodies and peroxidase conjugated anti(murine IgG). In another assay, antigen present in a sample is caught by immobilized polyclonal anti(PAPP-A2), and detected using biotinylated polyclonal anti(PAPP-A2). For further examples and details, see (Crowther, 1995) Assays can be calibrated using purified PAPP-A2 to construct a standard curve by serial dilution. The concentration of PAPP-A2 in solution in a purified form can be accurately measured by amino acid analysis (Sottrup-Jensen, 1993, *Biochem Mol Biol Int* 30, 789-94).

[0087] Polyclonal antibodies may be used to inhibit the biological activity of PAPP-A2. Specifically, in analogy with the inhibition of the IGFBP-4 proteolytic activity of PAPP-A by polyclonal PAPP-A antibodies (Lawrence et al., 1999, *Proc Natl Acad Sci USA* 96, 3149-53), anti(PAPP-A2) may be used to inhibit the proteolytic activity of PAPP-A2. Certain monoclonal antibodies may also be inhibitory towards the activity of PAPP-A2. Such monoclonal antibodies are likely to recognize an epitope in close proximity to the active site of PAPP-A2, but the inhibitory activity may also be based on binding to epitopes other than those close to the active site. Inhibitory monoclonal antibodies can be obtained by immunization with PAPP-A2, PAPP-A2 fragments, with peptides derived from PAPP-A2.

[0088] Inhibitory (monoclonal) antibodies may have therapeutic value in conditions of pathologies in which it may be desirable to decrease the activity of PAPP-A2.

[0089] Activity of PAPP-A2

[0090] Like PAPP-A, PAPP-A2 contains conserved amino acid stretches that classify it as a putative metalloproteinase of the metzincin superfamily (Stocker et al., 1995, *Protein*

*Sci* 4, 823-40) It has been experimentally verified that PAPP-A2 does exhibit proteolytic activity by demonstrating its cleavage of insulin-like growth factor binding protein (IGFBP)-5 (Example 6.7).

[0091] In general, proteolytic activity of PAPP-A2 against potential protein substrates may be evaluated by the incubation of purified or partially purified PAPP-A2 with the potential substrate under a variety of experimental conditions (such as for example temperature, buffer composition, ionic strength, and pH). Enzymatic activity of PAPP-A2 against the protein in question can be evaluated by SDS-PAGE (in which degradation or release of well defined proteolytic fragment(s) will be evident), or by high-pressure liquid chromatographic detection of released peptide(s). By means of such procedures, other substrate targets of PAPP-A2 may be identified. Incubation with a variant of PAPP-A2 where, for example, a residue in the active site has been substituted to obtain an inactive enzyme, serves as a proper negative control.

[0092] Random peptide libraries consisting of all possible combinations of amino acids attached to a solid phase support may be used to identify peptides that can be cleaved by PAPP-A2. Identification of such peptides may be accomplished by screening a peptide library with recombinant soluble PAPP-A2. Methods for expression and purification of the enzyme are described above and may be used to express recombinant full length PAPP-A2 or fragments, analogs, or derivatives thereof depending on the functional domains of interest. For further details, see (Meldal, 1998, *Methods Mol Biol* 87, 65-74; Meldal, 1998, *Methods Mol Biol* 87, 51-7). Alternatively, peptide substrates may be derived from identified protein substrates of PAPP-A2.

[0093] Alternatively, phage display of peptide libraries may be used to identify peptides that can be cleaved by PAPP-A2 (Matthews and Wells, 1993, *Science* 260, 1113-7).

[0094] Peptides that function as PAPP-A2 substrates may function in assays for the detection of PAPP-A2 proteolytic activity in body fluids or tissue and cell extracts. Substrate peptides may be derivatized to function in an assay based on quenched-fluorescence (Meldal, 1998, *Methods Mol Biol* 87, 65-74). Kits based on such, or other, techniques may be used for diagnostic purposes in pathologies where measurement of PAPP-A2 activity is relevant.

[0095] Identification of Agents that Modify the Activity of PAPP-A2

[0096] An assay for the detection of PAPP-A2 proteolytic activity, as described above, provides a method for the identification of molecules that modify the activity of PAPP-A2. Such molecules may be, for example, peptides, derivatized peptides, hydroxamic acid derivatized peptides, small organic molecules, or antibodies.

[0097] The screening of peptide libraries can be used to discover pharmaceutical agents that act to modulate and/or inhibit the biological activity of PAPP-A2. Methods for expression and purification of the enzyme are described above and may be used to express recombinant full length PAPP-A2 or fragments, analogs, or derivatives thereof depending on the functional domains of interest. Random peptide libraries consisting of all possible combinations of amino acids attached to a solid phase support may be used to identify peptides that are able to modulate and/or inhibit

PAPP-A2 activity by binding to the active site or other sites of PAPP-A2. For example, see (Meldal, 1998, *Methods Mol Biol* 87, 75-82).

[0098] Similarly, combinatorial chemistry may be used to identify low molecular weight organic molecules that affect the activity of PAPP-A2.

[0099] Measurement of Complexes of PAPP-A or PAPP-A2

[0100] PAPP-A primarily exists in pregnancy serum as a disulfide bound 2:2 complex with the proform of eosinophil major basic protein (proMBP), PAPP-A/proMBP. In addition to the PAPP-A/proMBP complex, proMBP exists in the circulation as a disulfide bound 2:2 complex with angiotensin (ANG), proMBP/ANG, and a fraction of this complex is further complexed to a fragment of complement component C3dg (PROMBP/ANG/C3dg) (Oxvig, 1996; Christensen, 2000).

[0101] The level of complexes comprising PAPP-A and/or PAPP-A2 and/or proMBP in body fluids of an individual may be indicative of predisposition to a clinical condition or indicative of the presence of a clinical condition. Accordingly, the present invention in one embodiment is directed towards a method of diagnosing a clinical condition or diagnosing predisposition to said clinical condition. In an individual comprising the steps of

[0102] a) providing a body sample from said individual; and

[0103] b) measuring the level of a complex selected from the group consisting of PAPP-A/proMBP, PAPP-A2/proMBP, PAPP-A/PAPP-A2, PAPP-A/PAPP-A2/proMBP, proMBP/ANG and proMBP/ANG/C3dg in said body fluid sample; and

[0104] c) diagnosing the clinical condition or diagnosing predisposition to the clinical condition, wherein the level of the complex above or below a predetermined value is indicative of the clinical condition or predisposition to the clinical condition.

[0105] Furthermore, the levels of complexes comprising PAPP-A and/or PAPP-A2 and/or proMBP in body fluids of a mammalian mother may be indicative of predisposition to a clinical condition or indicative of the presence of a clinical condition in a fetus of said mother. Hence, the present invention provides methods of diagnosing a clinical condition or diagnosing predisposition to said clinical condition in a mammalian fetus comprising the steps of

[0106] a) providing a body fluid sample from the mother of said fetus; and

[0107] b) measuring the level of a complex selected from the group consisting of PAPP-A/proMSP, PAPP-A2/proMBP, PAPP-A/PAPP-A2, PAPP-A/PAPP-A2/proMBP, proMSP/ANG and proMSP/ANG/C3dg in said body fluid sample; and

[0108] c) diagnosing the clinical condition or diagnosing predisposition to the clinical condition, wherein the level of the complex above or below a predetermined value is indicative of the clinical condition or predisposition to the clinical condition.

[0109] In particular, according to the present method the level of one or more of the following complexes may be determined:

[0110] PAPP-A/proMBP

[0111] PAPP-A2 and proMBP (PAPP-A2/proMBP)

[0112] PAPP-A2 and PAPP-A (PAPP-A/PAPP-A2)

[0113] PAPP-A/PAPP-A2 with proMBP (PAPP-A/PAPP-A/proMBP)

[0114] proMBP/ANG

[0115] prOMBp/ANG/C3dg

[0116] The level of complexes comprising PAPP-A and/or PAPP-A2 and/or proMBP in a body fluid sample may be determined by any conventional method known to the person skilled in the art for example, be level can be measured by a method comprising the use of immunospecific reagents specifically interacting with one or more components of the complex desirable to measure, such as immunospecific reagents specifically interacting with PAPP-A, PAPP-2, proMSP, ANG or C3gd. Immunospecific reagents may for example be monoclonal antibodies, polyclonal antibodies and/or antigen binding fragments thereof, specific towards the individual components of the complex.

[0117] Such methods include but are not limited to sandwich ELISA, wherein an immunospecific reagent specifically recognising one component of the complex is employed as catching antibody and another immunospecific reagent specifically recognising another component if the complex is employed as detection antibody. The detection antibody is preferably either directly or indirectly detectable, for example the detection antibody may be directly coupled to a detectable label or the detection antibody may be capable of interacting with another agent which is coupled to a detectable label.

[0118] A detectable label may for example be a fluorescent label, a chromatophore, a radioactive label, a heavy metal or an enzyme.

[0119] For example, the level of PAPP-A/proMBP complexes in a body fluid sample may be determined by sandwich ELISA using a PAPP-A specific monoclonal or polyclonal antibody for catching and a proMBP specific monoclonal or polyclonal antibody for detection or the level of proMBP/ANG in a body fluid sample may be determined by sandwich ELISA using a proMBP specific monoclonal or polyclonal antibody for catching and a ANG specific monoclonal or polyclonal antibody for detection.

[0120] The clinical condition may be any clinical condition which may be diagnosed by the level of complexes comprising PAPP-A and/or PAPP-A2 and/or proMBP or wherein predisposition may be diagnosed by the level of complexes comprising PAPP-A and/or PAPP-A2 and/or proMBP. The clinical condition may for example be selected from the group comprising Down's syndrome, preeclampsia and acute coronary syndrome, including unstable angina and myocardial infarction.

[0121] The body fluid sample may be any useful body fluid sample, such as a blood sample including a serum sample, a urine sample, a saliva sample or an amniotic fluid sample.

[0122] In particular, the level of PAPP-A/proMBP may be determined when the clinical condition is selected from the group consisting of Down's syndrome and acute coronary syndrome including unstable angina and myocardial infarction.

[0123] In one embodiment of the present invention diagnosing Down's syndrome or diagnosing predisposition to Down's syndrome, comprises determining the level of PAPP-A/proMBP, wherein the level of PAPP-A/proMBP below a predetermined value is indicative of the Down's syndrome or predisposition to Down's syndrome.

[0124] In another embodiment of the present invention diagnosing acute coronary syndrome, including unstable angina and myocardial infarction or diagnosing predisposition to acute coronary syndrome, including unstable angina and myocardial infarction, comprises determining the level of PAPP-A/proMBP, wherein the level of PAPP-A/proMBP above a predetermined value is indicative of the acute coronary syndrome, including unstable angina and myocardial infarction or predisposition to acute coronary syndrome, including unstable angina and myocardial infarction.

[0125] In yet another embodiment the level of proMBP/ANG may be determined to diagnose predisposition to Down's syndrome or to diagnose Down's syndrome. All the above mentioned methods of diagnosis may also be performed in combination with one or more other methods of diagnosis. In addition, more than one different diagnosis according to the present invention may be performed, for example it is possible to measure the level of more than one complex or to measure the level of one complex in different body samples.

[0126] Use of PAPP-A2 to Generate Natural Proteolytic Fragments

[0127] PAPP-A2 may be used to generate natural fragments of proteins that are specifically cleaved by PAPP-A2. As in the case of IGFBP-5 (see Examples 6.7 and 0.9), such fragments may have biological effects different from intact IGFBP-5. Fragments can be purified by standard chromatography after cleavage with purified PAPP-A2 (see Example 6.9)

[0128] Design of Fragments of PAPP-A2 for Expression

[0129] Because all cysteine residues found in mature PAPP-A are also found in mature PAPP-A2 (see FIG. 3), the pattern of disulfide bonds can be assumed to be the same for PAPP-A2 for those common cysteine residues. Therefore, knowledge of the disulfide structure of the PAPP-A subunit (see FIG. 8) can be used to rationally design fragments of PAPP-A2 in which pairing of all cysteine residues is possible. Putative domain boundaries of PAPP-A2 can be defined based on the disulfide structure shown in FIG. 8. Those domains can be expressed separately or in combination. In the event that a domain contains a cysteine residue known to form an inter-chain disulfide bridge to another PAPP-A subunit or to proMBP (see FIG. 8), it may be required that this cysteine is mutated to for example a serine or an alanine residue

[0130] Thus, possible boundary regions are between Cys-A03 and Cys-499, between Cys-828 and Cys-881, between Cys-1048 and Cys-1115, between Cys-1390 and Cys 1396, between Cys-1459 and Cys-1464, between Cys-1621 and

Cys-1525, between Cys-1590 and Cys-1595, between Cys-1646 and Cys-1653, and between Cys-1729 and Cys-1733 (numbering of preproPAPP-A2, as in **FIGS. 1 and 3**).

**[0131]** Pharmaceutical Compositions

**[0132]** Identification of PAPP-A2 as the IGFBP-5 protease provides methods for affecting growth and differentiation in vivo by using PAPP-A2 as a therapeutic target. Inhibitors of PAPP-A2 is believed to decrease the amount of bioavailable IGF-I and IGF-II. For example, inhibition of PAPP-A2 activity can be useful in disorders such as restenosis, atherosclerosis, and fibrosis. Activators, or agents that increase the activity of PAPP-A2 is believed to increase the amount of bioavailable IGF-I and IGF-II.

**[0133]** Agents that alter PAPP-A2 activity or that alter adherence of PAPP-A2 to cell surfaces can be incorporated into pharmaceutical compositions. Such agents may be incorporated together with agents that alter PAPP-A activity or that alter adherence of PAPP-A to cell surfaces. A combination of PAPP-A2 specific agents and PAPP-A specific agents may be more effective than traditional agents directed against PAPP-A. There is also provided a method of treatment comprising the step of administering to an individual in need thereof a combination of PAPP-A2 specific agents and PAPP-A specific agents in pharmaceutically effective amounts.

**[0134]** As an example, an antibody such as anti-PAPP-A2 polyclonal or monoclonal, can be formulated into a pharmaceutical composition by admixture with pharmaceutically acceptable non-toxic excipients or carriers. Such compounds and compositions may be prepared for parenteral administration, particularly in the form of liquid solutions or suspensions in aqueous physiological buffer solutions; for oral administration, particularly in the form of tablets or capsules; or for intranasal administration, particularly in the form of powders, nasal drops, or aerosols. Compositions for other routes of administration may be prepared as desired using standard methods.

**[0135]** Formulations for parenteral administration may contain as common excipients (i.e., pharmaceutically acceptable carriers) sterile water or saline, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, hydrogenated naphthalenes, and the like. In particular, biocompatible, biodegradable lactide polymer, lactide/glycolide copolymer, or polyoxyethylene-polyoxypropylene copolymers are examples of excipients for controlling the release of a compound of the invention in vivo. Other suitable parenteral delivery systems include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes. Formulations for inhalation administration may contain excipients such as lactose, if desired. Inhalation formulations may be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or they may be oily solutions for administration in the form of nasal drops. If desired, the compounds can be formulated as gels to be applied intranasally. Formulations for parenteral administration may also include glycocholate for buccal administration.

**[0136]** Medical Devices

**[0137]** The invention also features a medical device for placement in a patient (e.g., an implant) that includes an agent that inhibits or activates PAPP-A2 protease activity.

Suitable agents are readily identified using the methods described herein. The device can be impregnated with the agent or can be coated with the agent. Non-limiting examples of inhibitors include an antibody such as anti-PAPP-A2 polyclonal or monoclonal, or a metalloprotease inhibitor such as 1,10-phenanthroline.

**[0138]** IGFBP-5 protease activity of PAPP-A2 is potentially inhibited by 1,10-phenanthroline, but is not inhibited by tissue inhibitors of matrix metalloproteases (TIMP'S). Other inhibitors include small molecules such as derivatives of hydroxamic acid. Anti-PAPP-A2 polyclonal IgG may also inhibit IGF-dependent- or IGF-independent-IGFBP-5 specific PAPP-A2 protease activity in HFCM in a dose-dependent manner.

**[0139]** In addition, polypeptides (i.e., any chain of amino acids, regardless of length or post-translational modification), including modified polypeptides, can function as inhibitors. Any inhibitor of the IGFBP-5 protease activity of PAPP-A2 can be used for coating or impregnating a medical device according to the invention. Modified polypeptides include amino acid substitutions, deletions, or insertions in the amino acid sequence as compared with a corresponding wild-type sequence, as well as chemical modifications. Although protease-resistant IGFBP-5 is not an inhibitor per se of the IGFBP-5 protease activity of PAPP-A2, similar results are expected when it is used for coating or impregnating a medical device.

**[0140]** As an example, coating or impregnating the medical device with a PAPP-A2 inhibitor, optionally in combination with a PAPP-A inhibitor, can help prevent the development of restenosis following balloon angioplasty, or can prevent a further increase in size of an atherosclerotic plaque. Coronary angioplasty with stent placement is currently the leading therapeutic approach for coronary atherosclerosis. An important goal of angioplasty of coronary artery disease is to prevent both acute and chronic complications. Modern procedures are quite successful in eliminating immediate problems. Unfortunately, restenosis still occurs in 20-30% of stented patients. No known pharmacological intervention is available to prevent the restenosis.

**[0141]** Without being bound by a particular mechanism, it is thought that an increase in IGFBP-5 protease expression by coronary smooth muscle cells precedes neointimal formation in response to angioplasty in humans.

**[0142]** For example, enhanced PAPP-A2 activity can be useful for wound healing, fractures, osteoporosis, or ovulation. Osteoporosis or other conditions of bone loss may benefit from increased bone formation and decreased bone resorption. Agents that enhance PAPP-A2 activity can be, for example, a modified IGF, i.e., an IGF analog.

**[0143]** Analogs include IGF polypeptides containing amino acid insertions, deletions or substitutions, as well as chemical modifications. Amino acid substitutions can include conservative and non-conservative amino acid substitutions. Conservative amino acid substitutions replace an amino acid with an amino acid of the same class, whereas non-conservative amino acid substitutions replace an amino acid with an amino acid of a different class. Non-conservative substitutions result in a change in the hydrophobicity of the polypeptide or in the bulk of a residue side chain. In addition, non-conservative substitutions can make a substan-

tial change in the charge of the polypeptide, Such as reducing electropositive charges or introducing electronegative charges. Examples of non-conservative substitutions include a basic amino acid for a non-polar amino acid, or a polar amino acid for an acidic amino acid. Amino acid insertions, deletions and substitutions can be made using random mutagenesis, situdirected mutagenesis, or other recombinant techniques known In the art.

[0144] The medical device can be, for example, bone plates or bone screws that are used to stabilize bones, or a stent, which typically is used within the body to restore or maintain the patency of a body lumen. Blood vessels, for example, can become obstructed due to an atherosclerotic plaque that restricts the passage of blood, A stent typically has a tubular structure defining an inner channel that accommodates flow within the body lumen. The outer walls of the stent engage the inner walls of the body lumen. Positioning of a stent within an affected area can help prevent further occlusion of the body lumen and permit continued flow. A stent typically is deployed by percutaneous insertion of a catheter or guide wire that carries the stent. The stent ordinarily has an expandable structure. Upon delivery to the desired site, the stent can be expanded with a balloon mounted on the catheter Alternatively, the &ten may have a biased or elastic structure that is held within a sheath or other restraint in a compressed state. The stent expands voluntarily when the restraint is removed. In either case, the walls of the stent expand to engage the inner wall of the body lumen, and generally fix the stent in a desired position.

#### STATEMENTS OF INVENTION

[0145] In a first aspect the present invention relates to a purified polynucleotide selected from the group consisting of

[0146] i) a polynucleotide comprising nucleotides 1 to 5376 of SEQ ID NO:1, corresponding to the coding sequence of PAPP-A2, as deposited with DSMZ under accession number DSM 13783; and

[0147] ii) a polynucleotide encoding a polypeptide having the amino acid sequence as shown in SEQ ID NO:2; and

[0148] iii) a polynucleotide encoding a fragment of a polypeptide encoded by polynucleotides (i) or (ii), wherein said fragment

[0149] a) has a proteolytic activity specific for Insulin Like Growth Factor Binding Protein 5 (IGFEP-5), or a derivative thereof, or any other substrate; and/or

[0150] b) is recognised by an antibody, or a binding fragment thereof which is capable of recognising a polypeptide having the amino acid sequence as shown in SEQ ID NO.2: and/or

[0151] c) competes with a polypeptide having the amino acid sequence as shown in SEQ ID NO:2 for binding to a cell surface receptor having an affinity for said polypeptide; and

[0152] iv) a polynucleotide, the complementary strand of which hybridizes, under stringent conditions, with a polynucleotide as defined in any of (I), (ii) and (iii), said polynucleotide encoding a

polypeptide having the amino acid sequence as shown in SEQ ID NO:2, or a fragment thereof, wherein said fragment

[0153] a) has a proteolytic activity specific at least for Insulin Like Growth Factor Binding Protein 5 (IGFBP-5); and/or

[0154] b) is recognised by an antibody or a binding fragment thereof, which is capable of racognising a polypeptide having the amino acid sequence as shown in SEC ID NO:2; and/or

[0155] c) competes with a polypeptide having the amino acid sequence as shown in SEQ ID NO:2 for binding to a cell surface receptor having 2.5 an affinity for said polypeptide; and

[0156] v) a polynucleotide comprising a nucleotide sequence which is degenerate to the nucleotide sequence of a polynucleotide as defined in any of (iii) and (iv), and the complementary strand of such a polynucleotide.

[0157] A polynuclatide as used herein shall denote any naturally occurring polynucleotide having any naurally occurring backbone structure, as Well as nucleotides known in the art as LNA (locked nucleic acid) and PNA (peptide nucleic acid).

[0158] In preferred embodiments the purified polynucleotide comprises the coding sequence of PAPP-A2, nucleotides 1 to 5376, as shown in SEQ ID NO:1, or a nucleotide sequence encoding the amino acid sequence as shown in SEQ ID NO:2 In another preferred embodiment the polynucleotide comprises a nucleotide sequence encoding a fragment of the polypeptide having the amino acid sequence as shown in SEQ ID NO:2 , wherein said fragment

[0159] a) has a proteolytic activity specific for Insulin Like Growth Factor Binding Protein 5 (IGFBP-5), or 2 derivative thereof, or any other substrate; and/or

[0160] b) is recognized by an antibody, or a binding fragment thereof, which is capable of recognising a polypeptide having the amino acid sequence as shown in SEQ ID NO:2; and/or

[0161] c) competes with a polypeptide having the amino acid sequence as shown in SEQ NO:2 for binding to a cell surface receptor having an affinity for said polypeptide

[0162] There is also provided a polynucleotide, the complementary strand of which hybridizes, under stringent conditions, with a polynucleotide according to the invention.

[0163] Stringent conditions as used herein shall denote stringency as normally applied in oonnection with Southern blotting and hybridization as described e.g. by Southern E. M., 1975, J. Mol. Biol. 98:503-517. For such purposes R is routine practise to include steps of prehybridization and hybridization. Such steps are normally performed using solutions containing 6xSSPE, 5% Denhardt's, 0.5% SDS, 50% formamide, 100 µg/ml denaturated salmon testis DNA (incubation for 16 hrs at 42° C.). followed by washings with 2xSSC and 0.5% SDS (at room temperature and at 37° C.), and a washing with 0.1xSSC and 0.5% SDS (incubation at 68° C. for 30 min), as described by Sambrook et al., 1989,

in "Molecular Cloning/A Laboratory Manual", Cold Spring Harbor), which is incorporated herein by reference.

**[0164]** The DNA sequences are used in a variety of ways. They may be used as probes for identifying homologs of uHase (e.g., homologs of huHase). Mammalian homologs have substantial sequence similarity to one another, i.e. at least 75%, usually at least 90%, more usually at least 95% sequence identity. Sequence similarity is calculated based on a reference sequence, which may be a subset of a larger sequence, such as a conserved motif, coding region, flanking region, etc. A reference sequence will usually be at least about 18 nt long, more usually at least about 30 nt long, and may extend to the complete sequence that is being compared. Algorithms for sequence analysis are known in the art, such as BLAST, described in Altschul et al. 1990 J Mol Biol 215:403-10.

**[0165]** Nucleic acids having sequence similarity are detected by hybridization under low stringency conditions, for example, at 50.degree. C. and 10.times.SSC (0.9 M saline/0.109 M sodium citrate) and remain bound when subjected to washing at 55.degree. C in 1.times.SSC. Sequence identity may be determined by hybridization under high stringency conditions, for example, at 50.degree. C. or higher and 0.1-times.SSC (9 mM saline/0.9 mM sodium citrate). By using probes, particularly labeled probes of DNA sequences, one can isolate homologous or related genes. The source of homologous genes may be any species, e.g. Primate species, particularly human; rodents, such as rats and mice, canines, felines, bovine, opines, equine, yeast, Drosophila, Caenorhabditis, etc.

**[0166]** In a further embodiment there is provided a polynucleotide comprising a nucleotide sequence which is degenerate to a polynucleotide capable of hybridising to SEQ ID NO:1, or a fragment thereof.

**[0167]** Degeneracy as used herein is defined in terms of the activity or functionality associated with the polypeptide expressed from said degenerate polynucleotide, said polynucleotide is either i) comprising a proteolytic activity specific at least for Insulin Like Growth Factor Binding Protein 6 (IGFBP-6); and/or ii) recognised by an antibody, or a binding fragment thereof, which is capable of recognising a polypeptide having the amino acid sequence as shown in SEQ ID NO:2; and/or iii) competing with a polypeptide having the amino acid sequence as shown in SEQ ID NO:2 for binding to a cell surface receptor having an affinity for said polypeptide.

**[0168]** In a further embodiment there is provided a polynucleotide comprising the complementary strand of a polynucleotide according to the invention.

**[0169]** The polynucleotide according to the invention may be operably linked to a further polynucleotide comprising nucleic acid residues corresponding to the 3' untranslated region of PAPP-A2, or a fragment thereof. As used herein the 3' untranslated region comprises nucleic acid residues 5377 to 8527 of SEQ ID NO:1.

**[0170]** There is also provided a recombinant DNA molecule in the form of an expression vector comprising an expression signal operably linked to a polynucleotide according to the invention.

**[0171]** In a further embodiment there is provided a host organism transfected or transformed with the polynucleotide

according to the invention, or the vector according to the invention. The host organism is preferably a mammalian organism such as e.g. a mammalian cell line. However, a microbial eukaryote such as yeast or fungi may also be used, as may a microbial prokaryote such as *Bacillus* or *E. coli*. The person skilled in the art will know how to select expression signals, including leader sequences and/or signal peptides suitable for expression in a given cell. The person skilled in the art will also know how to determine the level of expression in a given cell by using standard molecular biology techniques.

**[0172]** In a further aspect the invention relates to an isolated polypeptide comprising or essentially consisting of the amino acid sequence of SEQ ID NO:2, or a fragment thereof, wherein said fragment

**[0173]** a) has a proteolytic activity specific at least for Insulin Like Growth Factor Binding Protein 5 (IGFBP-5); and/or

**[0174]** b) is recognised by an antibody, or a binding fragment thereof, which is capable of recognising a polypeptide having the amino acid sequence as shown in SEQ ID NO:2; and/or

**[0175]** c) competes with a polypeptide having the amino acid sequence as shown in SEQ ID NO:2 for binding to a cell surface receptor with an affinity for said polypeptide.

**[0176]** In one preferred embodiment of the invention there is also provided variants of SEQ ID NO:2, and variants of fragments thereof. Variants are determined on the basis of their degree of identity or their homology with a predetermined amino acid sequence, said predetermined amino acid sequence being SEQ ID NO:2, or, when the variant is a fragment, a fragment of SEQ ID NO:2.

**[0177]** Accordingly, variants preferably have at least 75% sequence identity, for example at least 80% sequence identity, such as at least 85% sequence identity, for example at least 90% sequence identity, such as at least 91% sequence identity, for example at least 91% sequence identity, such as at least 92% sequence identity, for example at least 93% sequence identity, such as at least 94% sequence identity, for example at least 95% sequence identity, such as at least 96% sequence identity, for example at least 97% sequence identity, such as at least 98% sequence identity, for example 99% sequence identity with the predetermined sequence.

**[0178]** Variants are also determined based on a predetermined number of conservative amino acid substitutions as defined herein below. Conservative amino acid substitution as used herein relates to the substitution of one amino acid (within a predetermined group of amino acids) for another amino acid (within the same group), wherein the amino acids exhibit similar or substantially similar characteristics.

**[0179]** Within the meaning of the term "conservative amino acid substitution" as applied herein, one amino acid may be substituted for another within the groups of amino acids indicated herein below:

**[0180]** i) Amino acids having polar side chains (Asp, Glu, Lys, Arg, His, Asn, Gln, Ser, Thr, Tyr, and Cys.)

**[0181]** ii) Amino acids having non-polar side chains (Gly, Ala, Val, Leu, Ile, Phe, Trp, Pro, and Met)

[0182] iii) Amino acids having aliphatic side chains (Gly, Ala, Val, Leu, Ile)

[0183] iv) Amino acids having cyclic side chains (Pho, Tyrn, Trp, His, Pro)

[0184] v) Amino acids having aromatic side chains (Phe, Tyr, Trp)

[0185] vi) Amino acids having acidic side chains (Asp, Glu)

[0186] vii) Amino acids having basic side chains (Lys, Arg, His)

[0187] viii) Amino acids having amide side chains (Asn, Gin)

[0188] ix) Amino acids having hydroxy side chains (Ser, Thr)

[0189] x) Amino acids having sulphur-containing side chains (Cys, Met),

[0190] xi) Neutral, weakly hydrophobic amino acids (Pro, Ala, Gly, Ser, Thr)

[0191] xii) Hydrophilic, acidic amino acids (Gin, Asn, Glu, Asp), and

[0192] xiii) Hydrophobic amino acids (Leu, Ile, Val)

[0193] Accordingly, a variant or a fragment thereof according to the invention may comprise, within the same variant of the sequence or fragments thereof, or among different variants of the sequence or fragments thereof, at least one substitution, such as a plurality of substitutions introduced independently of one another.

[0194] It is clear from the above outline that the same variant or fragment thereof may comprise more than one conservative amino acid substitution from more than one group of conservative amino acids as defined herein above.

[0195] The addition or deletion of an amino acid may be an addition or deletion of from 2 to 10 amino acids, such as from 10 to 20 amino acids, for example from 20 to 30 amino acids, such as from 40 to 50 amino acids. However, additions or deletions of more than 50 amino acids, such as additions from 10 to 100 amino acids, addition of 100 to 150 amino acids, addition of 150-250 amino acids, are also comprised within the present invention.

[0196] The polypeptide fragments according to the present invention, including any functional equivalents thereof, may in one embodiment comprise less than 250 amino acid residues, such as less than 240 amino acid residues, for example less than 225 amino acid residues, such as less than 200 amino acid residues, for example less than 180 amino acid residues, such as less than 160 amino acid residues, for example less than 150 amino acid residues, such as less than 140 amino acid residues, for example less than 130 amino acid residues, such as less than 120 amino acid residues, for example less than 110 amino acid residues, such as less than 100 amino acid residues, for example less than 90 amino acid residues, such as less than 85 amino acid residues, for example less than 80 amino acid residues, such as less than 75 amino acid residues, for example less than 70 amino acid residues, such as less than 65 amino acid residues, for

example less than 60 amino acid residues, such as less than 55 amino acid residues, for example less than 50 amino acid residues.

[0197] "Functional equivalency" as used in the present invention is according to one preferred embodiment established by means of reference to the corresponding functionality of a predetermined fragment of the sequence. More specifically, functional equivalency is to be understood as the ability of a polypeptide fragment to exert IGFBP-5 specific protease activity and/or to be recognised by an antibody capable of recognising PAPP-A2 and/or to compete with PAPP-A2 for binding to a receptor having affinity for PAPP-A2.

[0198] Functional equivalents or variants of PAPP-A2 will be understood to exhibit amino acid sequences gradually differing from the preferred predetermined PAPP-A2 sequence, as the number and scope of insertions, deletions and substitutions including conservative substitutions increases. This difference is measured as a reduction in homology between the preferred predetermined sequence and the fragment or functional equivalent.

[0199] All fragments or functional equivalents of SEQ ID NO:2 are included within the scope of this invention, regardless of the degree of homology that they show to a preferred predetermined sequence of PAPP-A2 as reported herein. The reason for this is that some regions of PAPP-A are most likely readily mutable, or capable of being completely deleted, without any significant effect on the binding activity of the resulting fragment.

[0200] A functional variant obtained by substitution may well exhibit some form or degree of native PAPP-A2 activity, and yet be less homologous, if residues containing functionally similar amino acid side chains are substituted. Functionally similar in this respect refers to dominant characteristics of the side chains such as hydrophobic, basic, neutral or acidic, or the presence or absence of steric bulk. Accordingly, in one embodiment of the invention, the degree of identity is not a principal measure of a fragment being a variant or functional equivalent of a preferred predetermined fragment according to the present invention.

[0201] The homology between amino acid sequences may be calculated using well known algorithms such as BLOSUM 30, BLOSUM 40, BLOSUM 45, BLOSUM 50, BLOSUM 55, BLOSUM 60, BLOSUM 62, BLOSUM 65, BLOSUM 70, BLOSUM 75, BLOSUM 80, BLOSUM 85, or BLOSUM 90.

[0202] Fragments sharing at least some homology with fragments of SEQ ID NO:2 are to be considered as falling within the scope of the present invention when they are at least about 90 percent homologous, for example at least 92 percent homologous, such as at least 94 percent homologous, for example at least 95 percent homologous, such as at least 96 percent homologous, for example at least 97 percent homologous, such as at least 98 percent homologous, for example at least 99 percent homologous. With said fragments of SEQ ID NO:2. According to one embodiment of the invention the homology percentages refer to identity percentages.

[0203] Additional factors that may be taken into consideration when determining functional equivalence according to the meaning used herein are I) the ability of antisera to

detect a PAPP-A2 fragment according to the present invention, or ii) the ability of the functionally equivalent PAPP-A2 fragment to compete with PAPP-A2 in a binding assay. One method of determining a sequence of immunogenically active amino acids within a known amino acid sequence has been described by Geysen in U.S. Pat. No. 5,595,915 and is incorporated herein by reference.

**[0204]** A further suitably adaptable method for determining structure and function relationships of peptide fragments is described by U.S. Pat. No. 6,013,478, which is herein incorporated by reference. Also, methods of assaying the binding of an amino acid sequence to a receptor moiety are known to the skilled artisan.

**[0205]** Conservative substitutions may be introduced in any position of a preferred predetermined fragment of SEQ ID NO:2, and it may also be desirable to introduce non-conservative substitutions in any one or more positions.

**[0206]** A non-conservative substitution leading to the formation of a functionally equivalent fragment of PAPP-A2 would for example i) differ substantially in polarity, for example a residue with a non-polar side chain (Ala, Leu, Pro, Trp, Val, Ile, Leu, Phe or Met) substituted for a residue with a polar side chain such as Gly, Ser, Thr, Cys, Tyr, Asn, or Gin or a charged amino acid such as Asp, Olu, Arg, or Lys, or substituting a charged or a polar residue for a non-polar one: and/or ii) differ substantially in its effect on polypeptide backbone orientation such as substitution of or for Pro or Gly by another residue: and/or iii) differ substantially in electric charge, for example substitution of a negatively charged residue such as Glu or Asp for a positively charged residue such as Lys, His or Arg (and vice versa); and/or iv) differ substantially in steric bulk, for example substitution of a bulky residue such as His, Trp, Phe or Tyr for one having a minor side chain, e.g. Ala, Gly or Ser (and vice versa).

**[0207]** Variants obtained by substitution of amino acids may in one preferred embodiment be made based upon the hydrophobicity and hydrophilicity values and the relative similarity of the amino acid side-chain substituents, including charge, size, and the like. Exemplary amino acid substitutions which take various of the foregoing characteristics into consideration are well known to those of skill in the art and include; arginine and lysine; glutamate and aspartate; serine and threonine; glutamine and asparagine; and valine, leucine and isoleucine.

**[0208]** In addition to the variants described herein, sterically similar variants may be formulated to mimic the key portions of the variant structure and that such compounds may also be used in the same manner as the variants of the invention. This may be achieved by techniques of modelling and chemical designing known to those of skill in the art. It will be understood that all such sterically similar constructs fall within the scope of the present invention.

**[0209]** In a further embodiment the present invention relates to functional comprising substituted amino acids having hydrophilic or hydrophobic indices that are within  $\pm 2.5$ , for example within  $\pm 2.3$ , such as within  $\pm 2.1$ , for example within  $\pm 2.0$ , such as within  $\pm 1.8$ , for example within  $\pm 1.1$ , such as within  $\pm 1.5$ , for example within  $\pm 1.4$ , such as within  $\pm 1.3$  for example within  $\pm 1.2$ , such as within  $\pm 1.1$ , for example within  $\pm 1.0$ , such as within  $\pm 0.9$ , for example within  $\pm 0.8$ , such as within

$\pm 0.7$ , for example within  $\pm 0.6$ , such as within  $\pm 0.5$ , for example within  $\pm 0.4$ , such as within  $\pm 0.3$ , for example within  $\pm 0.25$ , such as Within  $\pm 0.2$  of the value of the amino acid it has substituted.

**[0210]** The importance of the hydrophilic and hydrophobic amino acid indices in conferring interactive biologic function on a protein is well understood in the art (Kyte & Doolittle, 1982 and Hopp, U.S. Pat. No. 4,554,101, each incorporated herein by reference).

**[0211]** The amino acid hydrophobic index values as used herein are: isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine/cystine (+2.5); methionine (+1.9); alanine (+1.8); glycine (-0.4); threonine (-0.7); serine (-0.8); tryptophan (-0.9); tyrosine (-1.3); proline (-1.6); histidine (-3.2); glutamate (-3.6); glutamine (-3.5); aspartate (-3.5); asparagine (-3.5); lysine (-3.9); and arginine (4.5) (Kyte & Doolittle, 1982).

**[0212]** The amino acid hydrophilicity values are: arginine (+3.0); lysine (+3.0); aspartate (+3.0+0.1); glutamate (+3.0+0.1); serine (+0.3); asparagine (+0.2); glutamine (+0.2); glycine (0); threonine (-0.4); proline (-0.5+0.1); alanine (-0.5); histidine (-0.5); cystine (-1.0); methionine (-1.3); valine (-1.5); leucine (-1.8); isoleucine (-1.8); tyrosine (-2.3); phenylalanine (-2.5); tryptophan (-3,4) (U.S. Pat. No. 4,554,101).

**[0213]** In addition to the peptidyl compounds described herein, sterically similar compounds may be formulated to mimic the key portions of the peptide structure and that such compounds may also be used in the same manner as the peptides of the invention. This may be achieved by techniques of modelling and chemical designing known to those of skill in the art. For example, esterification and other alkylations may be employed to modify the amino terminus of, e.g., a di-arginine peptide backbone, to mimic a tetra peptide structure. It will be understood that all such sterically similar constructs fall within the scope of the present invention.

**[0214]** Peptides with N-terminal alkylations and C-terminal esterifications are also encompassed within the present invention. Functional equivalents also comprise glycosylated and covalent or aggregative conjugates formed with the same or other PAPP-A2 fragments and/or PAPP-A2 molecules, including dimers or unrelated chemical moieties. Such functional equivalents are prepared by linkage of functionalities to groups which are found in fragment including at any one or both of the N- and C-terminal, by means known in the art.

**[0215]** Functional equivalents may thus comprise fragments conjugated to aliphatic or acyl esters or amides of the carboxyl terminus, alkylamines or residues containing carboxy side chains, e.g., conjugates to alkylamines at aspartic acid residues: O-acyl derivatives of hydroxyl group-containing residues and N-acyl derivatives of the amino terminal amino acid or amino-group containing residues, e.g. conjugates with fMet-Lou-Phe or immunogenic proteins. Derivatives of the acyl groups are selected from the group of alkyl-moieties (including C3 to C10 normal alkyl), thereby forming alkanoyl species, and carbocyclic or heterocyclic compounds, thereby forming aroyl species. The reactive groups preferably are difunctional compounds known per se for use in cross-linking proteins to insoluble matrices through reactive side groups.

[0216] Covalent or aggregative functional equivalents and derivatives thereof are useful as reagents in immunoassays or for affinity purification procedures. For example, a fragment of PAPP-A2 according to the present invention may be insolubilized by covalent bonding to cyanogen bromide-activated Sepharose by methods known per se or adsorbed to polyolefin surfaces, either with or without glutaraldehyde cross-linking, for use in an assay or purification of anti-PAPP-A2 antibodies or cell surface receptors. Fragments may also be labelled with a detectable group, e.g., radiolabelled by the chloramine T procedure, covalently bound to rare earth chelates or conjugated to another fluorescent moiety for use in e.g. diagnostic assays.

[0217] Mutagenesis of a preferred predetermined fragment of PAPP-A2 can be conducted by making amino acid insertions, usually on the order of about from 1 to 10 amino acid residues, preferably from about 1 to 5 amino acid residues, or deletions of from about from 1 to 10 residues; such as from about 2 to 5 residues.

[0218] In one embodiment the fragment of PAPP-A2 is synthesised by automated synthesis. Any of the commercially available solid-phase techniques may be employed, such as the Merrifield solid phase synthesis method, in which amino acids are sequentially added to a growing amino acid chain. (See Merrifield, J. Am. Chem. Soc. 85:2149-2146, 1963).

[0219] Equipment for automated synthesis of polypeptides is commercially available from suppliers such as Applied Biosystems, Inc. of Foster City, Calif., and may generally be operated according to the manufacturer's instructions. Solid phase synthesis will enable the incorporation of desirable amino acid substitutions into any fragment of PAPP-A2 according to the present invention. It will be understood that substitutions, deletions, insertions or any subcombination thereof may be combined to arrive at a final sequence of a functional equivalent. Insertions shall be understood to include amino-terminal and/or carboxyl-terminal fusions, e.g. with a hydrophobic or immunogenic protein or a carrier such as any polypeptide or scaffold structure capable of serving as a carrier.

[0220] Oligomers including dimers including homodimers and heterodimers of fragments of PAPP-A2 according to the invention are also provided and fall under the scope of the invention. PAPP-A2 functional equivalents and variants can be produced as homodimers or heterodimers with other amino acid sequences or with native PAPP-A2 sequences. Heterodimers include dimers containing immunoreactive PAPP-A fragments as well as PAPP-A2 fragments that need not have or exert any biological activity.

[0221] PAPP-A2 fragments according to the invention may be synthesised both in vitro and in vivo. Method for in vitro synthesis are well known, and methods being suitable or suitably adaptable to the synthesis in vivo of PAPP-A2 are also described in the prior art. When synthesized in vivo, a host cell is transformed with vectors containing DNA encoding PAPP-A2 or a fragment thereof. A vector is defined as replicable nucleic acid construct. Vectors are used to mediate expression of PAPP-A2. An expression vector is a replicable DNA construct in which a nucleic acid sequence encoding the predetermined PAPP-A2 fragment, or any functional equivalent thereof that can be expressed in vivo, is operably linked to suitable control sequences capable of effecting the

expression of the fragment or equivalent in a suitable host. Such control sequences are well known in the art.

[0222] Cultures of cells derived from multicellular organisms represent preferred host cells. In principle, any higher eukaryotic cell culture is workable, whether from vertebrate or invertebrate culture. Examples of useful host cell lines are VERO and HeLa cells, Chinese hamster ovary (CHO) cell lines, and WI38, BHK, COS-7, 293 and MDCK cell lines. Preferred host cells are eukaryotic cells known to synthesize endogenous PAPP-A2. Cultures of such host cells may be isolated and used as a source of the fragment, or used in therapeutic methods of treatment, including therapeutic methods aimed at promoting or inhibiting a growth state, or diagnostic methods carried out on the human or animal body.

[0223] In particular embodiments the present invention relates to a polypeptide fragment according to the invention, wherein the PAPP-A2 fragment comprises or essentially consists of amino acid residues 234 to 1791 corresponding to the mature part of PAPP-A2, including any processing variants thereof.

[0224] Processing variants are variants resulting from alternative processing events, possibly processing events catalysed by any protease including, but not limited to, a signal peptidase and a furin. One putative cleavage site is located after position 233 is described herein below in detail. Another putative cleavage site is located after the motif RQRP (position 196-199 in the amino acid sequence of PAPP-A2). Processing variants shall be understood to comprise variants arising from processing in vivo when PAPP-A2 is expressed in human or animal tissue, sera or body fluids.

[0225] Mature PAPP-A2 amino acid sequences essentially consisting of the mature sequence designated in SEQ ID NO:2 (amino acid residues 234 to 1791) shall be understood in one embodiment to comprise this part of the sequence lacking between 1 to about 10 N-terminal amino acids or C-terminal amino acids, preferably 1 to 10 N-terminal amino acids, such as 2 to 8 N-terminal acids, for example 3 to 6 N-terminal amino acids.

[0226] Also included in the definition of essentially consisting of as used herein shall be the mature sequence designated in SEQ ID NO:2 (amino acid residues 234 to 1791) having in addition thereto an additional 1 to about 10 N-terminal amino acids or C-terminal amino acids, preferably 1 to 10 N-terminal amino acids, such as 2 to 8 N-terminal acids, for example 3 to 6 N-terminal amino acids. This definition of essentially consisting of shall also apply in other aspects and is not restricted to being used in connection with a particular part of PAPP-A2. The definition shall also apply to other processes PAPP-A2 polypeptides including polypeptides arising from alternative processing in tissue, sera or body fluids other than the ones from where the processed PAPP-A2 has originally been isolated.

[0227] Additionally preferred fragments comprise or essentially consists of amino acid residues 1 to 233 corresponding to the prepro part of PAPP-A2, of amino acid residues 23 to 233 corresponding to the pro part of PAPP-A2, of amino acid residues 1 to 22 corresponding to the signal peptide or leader sequence of PAPP-A2, and to such sequences operably linked to the mature part of PAPP-A2 corresponding to amino acid residues 234 to 1791 of SEQ ID NO:2.

[0228] There is also provided recombinant PAPP-A2 polypeptide, or a fragment thereof, wherein preferably the polypeptide is free of human proteins, or other proteins natively associated with said polypeptide.

[0229] In a further aspect there is provided a composition comprising i) a polynucleotide according to the invention, and for ii) a vector according to the invention, and/or iii) a host organism according to the invention, and/or iv) a polypeptide according to the so invention, in combination with a physiologically acceptable carrier.

[0230] In yet another aspect there is provided a pharmaceutical composition comprising i) a polynucleotide according to the invention, and/or ii) a vector according to the invention, and/or iii) a host organism according to the invention, and/or iv) a polypeptide according to the invention, in combination with a pharmaceutically acceptable carrier.

[0231] The invention further pertains to a method for producing an antibody with specificity for a PAPP-A2 polypeptide according to the invention, or a fragment thereof, said method comprising the steps of

[0232] i) providing a host organism,

[0233] ii) immunizing the host organism with the polypeptide according to claim 10, and

[0234] iii) obtaining said antibody.

[0235] There is also provided monoclonal antibodies and polyclonal antibodies having specific binding affinity for a PAPP-A2 polypeptide according to the invention, or a fragment thereof. The antibody is preferably a monoclonal.

[0236] In a further aspect there is provided a method for producing a PAPP-A2 polypeptide according to the invention, said method comprising the steps of

[0237] i) providing a suitable host organism, preferably a mammalian cell,

[0238] ii) transfecting or transforming the host organism provided in step i) with a polynucleotide according to the invention, or a vector according to the invention,

[0239] iii) culturing the host organism obtained in step ii) under conditions suitable for expression of the polypeptide encoded by the polynucleotide or the vector; and optionally

[0240] iv) isolating from the host organism the polypeptide resulting from recombinant expression by the host organism.

[0241] In a still further aspect of the invention there is provided a method for inhibiting and/or reducing the expression of PAPP-A2 in a cell by means of anti-sense technology, said method comprising the steps of

[0242] i) providing an anti-sense polynucleotide according to the invention,

[0243] ii) transfecting or transforming a cell capable of expressing PAPP-A2 with said anti-sense polynucleotide provided in step i),

[0244] iii) culturing the cell obtained in step ii) under conditions suitable for hybridization of the poly-

nucleotide provided in step i) to a complementary polynucleotide in said cell involved in the expression of PAPP-A2, and

[0245] iv) inhibiting and/or reducing the expression of PAPP-A2 in said cell.

[0246] The antisense polynucleotide and the complementary polynucleotide may be coexpressed from distinct polynucleotide molecules or they may be expressed from the same molecule. As an alternative to hybridization, the method may include the use of reverse transcriptase PCR technology (rt PCT technology).

[0247] In yet another aspect of the invention there is provided a method for detecting PAPP-A2, or measuring the level of PAPP-A2, in a biological sample obtained from an individual, said method comprising the steps of

[0248] i) obtaining a biological sample from said individual,

[0249] ii) detecting PAPP-A2 in said sample by detecting

[0250] a) a PAPP-AA polypeptide, or a fragment thereof, and/or

[0251] b) a polynucleotide in the form of mRNA originating from PAPP-A2 expression, and/or

[0252] c) PAPP-A2 specific protease activity, preferably IGFBP-5 protease activity, or proteolytic activity directed against a derivative of IGFBP-5.

[0253] The method may comprise the further step of comparing the PAPP-A2 or the level of PAPP-A2 detected in step ii) with a predetermined value selected from the group consisting of

[0254] a) a predetermined amount and/or concentration of PAPP-A2; and/or

[0255] b) a predetermined amount and/or concentration of PAPP-A2 mRNA; and/or

[0256] c) a predetermined PAPP-A2 specific protease activity.

[0257] The predetermined value in one embodiment will be indicative of a normal physiological condition of said individual.

[0258] The biological sample is preferably selected from the group consisting of blood, urine, pleural fluid, oral washings, tissue biopsies, and follicular fluid.

[0259] When the level of PAPP-A2 is measured as an amount of PAPP-A2 protein, the PAPP-A2 protein is preferably measured by immunochemical analysis wherein PAPP-A2 protein is detected by at least one monoclonal antibody. PAPP-A2 protein may also be detected in a complex comprising at least one additional component, preferably a polypeptide such as, but not limited to, pro-MBP (pro-Major-Basic Protein). PAPP-A2 may also be detected as a PAPP-A2 monomer or as a PAPP-A2 dimer.

[0260] Further aspects of the invention relates to a method of diagnosing a clinical condition in an individual, said method comprising the steps of

[0261] i) performing a method for detecting PAPP-A2 or measuring the level of PAPP-A2, and

[0262] ii) diagnosing the clinical condition.

[0263] The clinical condition is preferably a fetal abnormality such as, but not limited to, a fetal abnormality selected from the group consisting of Trisomy 21, Trisomy 18, Trisomy 13, and Open Spina Bifida.

[0264] Addition fetal abnormalities capable of being diagnosed according to the invention is ectopic pregnancy, open spina bifida, neural tube defects, ventral wall defects, Edwards Syndrome, Patau's Syndrome, Turner Syndrome, Monosomy X or Klinefelter's Syndrome.

[0265] In another aspect the clinical condition is an altered growth state selected from the group consisting of a growth promoting state and a growth inhibiting state, including, but not limited to restenosis, atherosclerosis, wound healing, fibrosis, myocardial infarction, osteoporoses, rheumatoid arthritis, multiple myeloma, or cancer.

[0266] In a yet further aspect of the invention there is provided a method for detecting expression of a polynucleotide according to the invention in a biological sample, said method comprising the steps of

[0267] i) providing a biological sample putatively containing a polynucleotide according to the invention and ii) contacting the biological sample with a polynucleotide comprising a strand that is i) complementary to the polynucleotide according to the invention and ii) capable of hybridizing thereto, and

[0268] iii) allowing hybridization to occur, and

[0269] iv) detecting the hybridization complex obtained in step iii),

[0270] wherein the presence of the hybridization complex is indicative of the expression in the biological sample of the polynucleotide according to the invention, or a fragment thereof.

[0271] In a still her aspect of the invention there is provided a method for identifying an agent inhibiting the protease activity of PAPP-A2, said method comprising the steps of

[0272] i) incubating a) the polypeptide according to the invention, or a fragment thereof, and b) a predetermined substrate for said polypeptide or fragment, and c) a, putative inhibitory agent, and

[0273] ii) determining if proteolysis of said substrate is inhibited.

[0274] The substrate preferably comprises a polypeptide that may be an internally quenched fluorescent peptide. One preferred substrate comprises or essentially consists of IGFBP-5, or a fragment thereof.

[0275] The invention also pertains to an inhibitory agent obtainable according to such a method for identifying an agent inhibiting the protease activity of PAPP-A2.

[0276] There is also provided the use of such provided inhibitory agents in the manufacture of a medicament for treating a clinical condition in an individual in need of such treatment.

[0277] In a still further aspect the invention pertains to a method for identifying an agent capable of enhancing the protease activity of PAPP-A2, said method comprising the steps of

[0278] i) incubating a) the polypeptide according to the invention, or a fragment thereof, and b) a pre-

determined substrate for said polypeptide, and c) a putative enhancer agent, and

[0279] ii) determining if proteolysis of said Substrate is enhanced.

[0280] The substrate preferably comprises a polypeptide including an internally quenched fluorescent peptide. IGFBP-5, or a fragment thereof, is particularly preferred as a substrate.

[0281] There is also provided an enhancing agent obtainable according to the method for identifying an agent capable of enhancing the protease activity of PAPP-A2, and the invention also pertains to the use of such enhancing agents in the manufacture of a medicament for treating a clinical condition in an individual in need of such treatment.

[0282] In yet another aspect there is provided a method of treatment by therapy of an individual, said method comprising the step of administering to said individual i) a pharmaceutical composition according to the invention, and/or ii) the inhibitory agent according to the invention, and/or the enhancing agent according to the invention.

[0283] In a still further aspect there is provided a method for purification of PAPP-A2 or complexes of PAPP-A2 with other proteins, said method comprising the steps of

[0284] i) providing a polyclonal or monoclonal antibody with specific binding affinity for a polypeptide according to the invention, or a fragment thereof, and

[0285] ii) purifying PAPP-A2, or a fragment thereof, by means of affinity chromatography.

[0286] It is understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

#### BRIEF DESCRIPTION OF THE DRAWINGS

[0287] **FIG. 1** shows the cDNA sequence (in 5'→3' orientation) corresponding to the mRNA that encodes preproPAPP-A2. Only the coding part of the sequence and the terminal stop codon (\*) is shown and is numbered 1-5376. The translated polypeptide sequence of preproPAPP-A2 is also shown. The signal peptide cleavage site was predicted using SignalP V2.0 to be after the alanine residue encoded by nt. 64-66 ((Nielsen et al. 1997, *Protein Eng* 10, 1-6). WWW prediction server is located at <http://genome.cbs.dtu.dk/>). The signal peptide of preproPAPP-A2 (nt. 1-66, 22 residues) is shown in bold. The nucleotide sequence of this figure represents nt. 1 to 5376 of SEQ ID NO:1. The protein sequence of this figure is illustrated as SEQ ID NO:2.

[0288] **FIG. 2** is a schematic drawing of the relationship between PAPP-A (Kristensen et al., 1994, *Biochemistry* 33, 1592-8), and sequence stretches contained within two genomic clones with homology to the N-terminal end (hom-N, coding portion of accession number AL031734) and the C-terminal end (hom-C, coding portion of accession number AL031290) of PAPP-As when translated into amino acid sequence. This figure also illustrates the method by which a cDNA sequence with homology to the midregion of PAPP-A

was obtained. Horn-N, hom-C, and the midregion together encodes the complete sequence of a novel protein, PAPP-A2, which is a homolog of PAPP-A. The midregion was obtained by PCR using specifically primed (primer RT-N-mid), reversed transcribed human placental mRNA as the template, and primers PR-mid5 and PR-mid3 for the PCR (Table 1). To obtain a cDNA construct encoding the full-length PAPP-A2, DNA clones corresponding to the genomic clones hom-N and hom-C were also obtained using cDNA synthesized with specifically primed placental mRNA as the template (primers not shown, see Table 1). This required identification of a signal peptide stretch (in hom-N) and a stop codon (at the 3' end of hom-C), as detailed in the main text. All primers used are shown in Table 1. Note: The relative positions of the sequences depicted here are in accordance with the experiments performed, but the figure is not accurately drawn to scale.

[0289] FIG. 3 shows the amino acid sequence of preproPAPP-A2 (SEQ ID NO:2) aligned with preproPAPP-A. The deduced amino acid sequence of preproPAPP-A2 (PA2) was aligned with the sequence of preproPAPP-A (PA) ((Haaning et al., 1996, *Eur J Biochem* 237, 1693), AAC50543) using CLUSTAL W (Thompson et al., 1994, *Nucleic Acids Res* 22, 4673-80). Because the prepro-portion of PAPP-A did not show significant identity with the corresponding region of PAPP-A2, the alignment was manually adjusted to emphasize difference in length of propeptides. Arrows indicate the N-termini of the mature proteins as found earlier for PAPP-A (Kristensen et al., 1994, *Biochemistry* 33, 1592-8) (Glu-81), and here for PAPP-A2 (Ser-234). Putative signal peptides, strongly predicted using SignalP V2.0 (Nielsen et al. 1997, *Protein Eng* 10, 1-6) are shown with lower case letters. The pro-portion of PAPP-A2 contains one other candidate initiation codon corresponding to Met-168, but no signal peptide was predicted following this residue using SignalP. The sequence motifs of PAPP-A (Kristensen et al., 1994, *Biochemistry* 33, 1592-8) are also found in PAPP-A2; The catalytic zinc binding motif and residues of the putative Met-turn are underlined and bolded in both sequences. Lin-notch motifs (LNR1-3) and short consensus repeats (SCR-1-5) are boxed. Cysteine residues are shaded. All cysteines of mature PAPP-A are also found in PAPP-A2. In addition, the secreted form of PAPP-A2 has four cysteine residues (Cys-343, Cys-533, Cys-618, and Cys-1268) with no counterpart in PAPP-A.

[0290] FIG. 4 shows PAPP-A2 by Western blotting and Coomassie staining. Medium from transfected 293T cells was Western blotted using monoclonal anti-c-myc. Lane 1, cells transfected with empty vector; lane 2, cells transfected with cDNA encoding wild-type PAPP-A2 C-terminally tagged with the c-myc peptide (pPA2-mH), non-reduced; lane 3, cells transfected with or cDNA encoding PAPP-A2 with an inactivating E734Q mutation (pPA2-KO-mH), non-reduced; lane 4, as lane 2, but reduced. Recombinant PAPP-A2 was purified by nickel affinity chromatography from serum free medium of cells transfected with pPA2-KO-mH, to eliminate possible autocatalysis (lane 5, reduced).

[0291] FIG. 5 shows the activity of PAPP-A2 against IGFBP-1-6. Medium from 293T cells transfected with empty vector (-), or cDNA encoding PAPP-A2 (pPA2) (+) was incubated with each of the six IGFBPs (BP1-BP6), and the activity was assessed by ligand blotting using radiolabeled IGF-II. Complete cleavage of IGFBP-5 is evident

from the absence of a signal in the EP5+ lane. Partial degradation of IGFBP-3 is also evident.

[0292] FIG. 6 shows proteolytic activity of PAPP-A2 against IGFBP-5. Medium from 293T cells transfected with empty vector (lane 1), cDNA encoding PAPP-A2 with an inactivating E734Q mutation (pPA2-KO) (lane 2), or cDNA encoding wild-type PAPP-A2 (pPA2) (lanes 3-6) was incubated with C-terminally c-myc tagged rIGFBP-5. Proteolytic activity was assessed by Western blotting using anti-c-myc. 'i' denotes intact rIGFBP-5; 'c' denotes the detectable C-terminal c-myc tagged cleavage product. In the absence of inhibitors, wild-type PAPP-A2 degraded all rIGFBP-5 (lane 3). The PAPP-A2 activity was abolished by 10 mM phenantroline (lane 4) and 5 mM EDTA (lane 5), but not affected by 100  $\mu$ M 3,4-DCI (lane 6). Coomassie-stained SDS-PAGE of purified rIGFBP-5 is shown before (lane 7) and after (lane 8) digestion with purified PAPP-A2. A Western blot of the same digest, using anti-c-myc, is also shown (lane 9). Sequence analysis revealed that PAPP-A2 cleaves IGFBP-5 at one site, between Ser-142 and Lys-143.

[0293] FIG. 7 shows the cDNA sequence of the PAPP-A2 mRNA coding region directly followed by the sequence of the 3'UTR. The sequence of the 3'UTR was obtained as detailed in Example 6.3. The first 5376 nucleotides of this sequence (nt. 1-5376) represents the coding sequence as illustrated in FIG. 1 and SEQ ID NO:1 (nt 1-5376). Nucleotides 5377-8527 of this sequence corresponds to the 3' UTR of the PAPP-A2 mRNA as illustrated in SEQ ID NO:3 (nt. 5377-8527).

[0294] FIG. 8 shows the disulfide structure of the PAPP-A subunit in the PAPP-A/proMBP complex (upper bar). Cysteine containing peptides originating from the PAPP-A/proMBP complex were isolated by degrading PAPP-A/proMBP complex with proteinases and cyanogen bromide followed by standard HPLC. Peptides were identified by amino acid analysis, N-terminal sequence analysis, and by mass spectrometry (Overgaard, M. T., Oxvig, C., unpublished). Disulfide bonds are shown by thin lines. Two cysteine residues form inter-chain disulfide bridges to proMBP, and one forms an inter-chain bridge to PAPP-A causing it to be a dimer (as indicated). Asterisks mark a cysteine residue to which no partner has been found. The cysteine residues present in mature PAPP-A is also present in mature PAPP-A2 (see FIG. 3). It is reasonable to assume that the disulfide pairing of PAPP-A2 is the same. Thus, this information is valuable in determination of boundary regions for expression of isolated domains (fragments) of PAPP-A2. The gene structure of PAPP-A is also shown (lower bar). Exon/intron boundaries are based on comparison of PAPP-A cDNA (AN X68280) with genomic sequences (ANs AB020878, AL353141, and AL137024). The central bar shows putative domains of PAPP-A based on information of the upper and lower bars.

## EXAMPLES

[0295] 6.1. Identification of a Nucleotide Sequence Encoding PAPP-A2

[0296] Accession number (ANs) given in this text refer to sequences deposited in GenBank or other biological sequence databases. ANs are used interchangeably with the protein or nucleotide sequences deposited under the given AN.

[0297] Searching public nucleotide databases for DNA sequences with homology to PAPP-A ((Kristensen et al., 1994, *Biochemistry* 33, 1592-8), AN CAA48341) when translated into polypeptide sequence revealed two genomic clones with the ANs AL031734 and AL031290. Both originate from the human chromosome 1 (1q24). The search was performed against the "nr" collection of databases using the program tblastn at <http://www.ncbi.nlm.nih.gov/BLAST/> with default settings. In this example, PAPP-A is numbered

To obtain the midregion (FIG. 2), cDNA was synthesized using human placental mRNA as a template and a primer, RT-N-mid, derived from AL031290 (Table 1, FIG. 2). This cDNA was used as a template in a PCR to obtain a cDNA corresponding to the midregion of the hypothesized PAPP-A2. PCR primers were PR-mid5 and PR-mid3 (Table 1, FIG. 2). The coding sequence of the midregion obtained corresponds to residues 665-1572 of FIG. 3 (SEQ ID NO:1), a total of 908 amino acids.

TABLE 1

Locations of primers used for reverse transcription or PCR. The primers are listed in the order of their use.			
NAME	SOURCE <sup>a</sup>	Nt. NUMRERS <sup>b</sup>	SEQUENCE <sup>c</sup>
RT-N-mid:	AL031290	10262-10281, (4770-4789)	GCTCACACACCACAGGAATG*
PR-mid5:	AL031734	141874-141894, (1947-1967)	GGCTGATGTGCGCAAGACCTG
PR-mid3:	AL031290	10208-10229, (4716-4737)	GCATTGTATCTTCAGGAGCTTG*
PR-N5:	AL031734	102606-102628, (-)	GAAGTTGACTTCTGGTCTGTAG
PR-N3:	"	—, (2380-2400)	CCCTGGGAAGCGAGTGAAGCC*
RT-C:	AL031290	62982-63006. (-)	GCAITTTCTATAAGATCCTTCATGC*
PR-C5:	—	—, (4180-4201)	GACAGCTGTCCGTCATTGCTGC
PR-C3:	AL031290	62876-82897, (-)	CTTACTGCCTCTGAGGCAGTGG*

<sup>a</sup>Accession numbers of the relevant genomic clones are given. Primers PR-N3 and PR-C5 were located in the sequence connecting hom-N and hom-C, and are therefore not represented in the databases.

<sup>b</sup>Nucleotide numbers refer to the numbering of the sequences as reported in the file with the relevant accession number. In parentheses are given the corresponding numbers of SEQ ID NO:1 (FIG. 1), except for primers PR-N5, RT-C and PR-C3, not within this sequence.

<sup>c</sup>Sequences are actual primer sequences (orientation 5'-to-3'). Sequences marked with an asterisk are complementary to the database sequences or the sequence given in FIG. 1.

with the N-terminal Glu as residue 1, as in (Kristensen et al., 1994, *Biochemistry* 33, 1592-8). In the deposited sequence record (AN X68280) this Glu is residue 5.

[0298] The sequence reported in AL031734 contains 168835 base pairs. Two noncontiguous sequence stretches (nt. 103432-103566, and 140846-141919) of the total sequence together aligned with residues 1659, and 59-413 of the PAPP-A polypeptide sequence when translated. The sequence reported in AL031290 contains 121780 base pairs. Four noncontiguous sequence stretches (nt 10209-10358, 11752-11901, 20631-20463, and 60636-60652) of the total sequence together aligned with residues 1313-1362, 1376-1425, 1457-1479, and 1470-1506 of the PAPP-A polypeptide sequence when translated. The sequence stretches between the coding regions of both of the genomic sequences represent noncoding genomic PNA (introns) or coding regions that do not align.

[0299] Based on these findings, we hypothesized the existence of a novel protein, PAPP-A2, with homology to PAPP-A. It was then established the complete coding sequence of the regions of PAPP-A2 that were partially covered by the two genomic sequences reported in AL031734 and AL031290. We denote those contiguous sequences hom-N and hom-C, respectively (FIG. 2). But first, we established the existence of a coding cDNA sequence that also showed homology to PAPP-A, and that connected the sequence of hom-N and hom-C (FIG. 2). All essential primers used are described in Table 1. The entire cDNA sequence encoding the 1791-residue preproPAPP-A2 is shown in FIG. 1. Standard cloning techniques were used, and all DNA constructs were analyzed by sequencing. The methodology used is described below. The name PAPP-A2 is used for the protein encoded by this DNA sequence.

[0300] Cloning of a contiguous coding cDNA stretch corresponding to the midregion between hom-N and hom-C:

[0301] Cloning of a contiguous coding cDNA stretch corresponding to the N-terminal end of PAPP-A2 (hom-N): Manuel inspection of the genomic sequence AL031734 revealed that the open reading frame of the sequence stretch corresponding to PAPP-A residues 16-59 continued further in the 5' direction: Nt. 102646-103566 encodes a polypeptide sequence of 307 residues that starts with a methionine residue. Based on this finding, the cDNA used to obtain the midregion (placental mRNA primed with RT-N-mid, as detailed above) was used as a template in a PCR to obtain the contiguous cDNA of hom-N. PCR primers were: PR-N5 and PR-N3 (Table 1, FIG. 2).

[0302] Cloning of a contiguous coding cDNA stretch corresponding to the C-terminal end of PAPP-A2 (hom-C): Searching available databases (using the program blastn at <http://www.ncbi.nlm.nih.gov/BLAST/> with default settings) for human EST sequences matching the genomic sequence of AL031290 revealed an EST sequence overlapping with some of the coding regions of AL031290 already defined by the stretch nt 60536-60652 (cf. above). Nt. 62790-62995 of AL031290 also matched the sequence of the human EST sequence AA368081 originating from placenta. When translated into polypeptide sequence, this EST sequence showed homology to the C-terminal end of PAPP-A. Further, a stop codon was present within the coding sequence corresponding to amino acid 1537 of PAPP-A. That is, PAPP-A2 does not extend C-terminally beyond PAPP-A when the two sequences are aligned. Based on this, cDNA was synthesized using human placental mRNA as a template and a primer originating from AL031290 (Table 1). This cDNA was used as a template in a PCR to obtain the contiguous cDNA of hom-C using PCR primers PR-CS and PR-C3 (Table 1, FIG. 2).

[0303] All PCRs were carried out with Pfu polymerase (Stratagene). The three overlapping PAPP-A2 cDNA fragments (hom-N, the novel midregion, and hom-C) were all

cloned into the vector pCR-Bluntli-TOPO (Invitrogen). Several clones were sequenced in both orientations. The constructs are referred to as p2N, p2Mid, and p2C, respectively. The entire nucleotide sequence encoding PAPP-A2 is shown in FIG. 1 (and SEQ ID NO:1).

**[0304]** 6.2. Analyses of the Nucleotide and Amino Acid Sequence of PAPP-A2

**[0305]** Of the 1547 residues of mature PAPP-A, 708 residues (45.8%) are identical in preproPAPP-A2. There is no significant degree of identity between the prepro portion of PAPP-A and the remaining (N-terminal) portion of PAPP-A2 (FIG. 3). In this example, PAPP-A is numbered according to ((Haaning et al. 1996. *Eur J Biochem* 237, 159-63), AAC50543).

**[0306]** The sequence motifs recognized in PAPP-A (Kristensen et al., 1994, *Biochemistry* 33, 1692-8) are also present PAPP-A2: An elongated zinc binding consensus sequence, three lin-notch repeats (LNR1-3), and five short consensus repeats (SCR1-5) (FIG. 3). Further, all 82 cysteine residues of PAPP-A are conserved between the two proteins, and an additional 4 cysteines are present in the PAPP-A2 polypeptide sequence.

**[0307]** 6.3. Identification of Human EST Sequences Originating from the PAPP-A2 mRNA

**[0308]** A cluster of EST sequences matching the genomic sequence of AL031290 were identified around nt 64000-6000 of AL031290, starting approximately 1.2 kb from the end of the PAPP-A2 encoding sequence. The existence of mRNA connecting the coding region of PAPP-A2 and this cluster was verified in a PCR using primers from AL031290 (5'-GGAAAGAGCAGAGTTCACCCAT-3', nt. 64900-64879 of AL031290) and the PAPP-A2 encoding sequence (5'-CCGTCTTAGTCCACTGCATCC-3', nt. 20499-20519 of AL03290, nt 5171-5191 of AF311940), and oligodT primed placental cDNA as a template (Overgaard et al., 1999, *Biol Reprod* 61, 1083-9). As expected, the size of the resulting product was 2.2 kb, further demonstrating the existence of a PAPP-A2 mRNA with a 3'UTR of about 3 kb. The distribution among tissues is shown in Table 2.

TABLE 2

Expression of PAPP-A2 mRNA in human tissues evaluated by available EST sequences <sup>a</sup> .	
Tissue of origin	Number of ESTs found
Human placenta	38
Pregnant uterus	21
Fetal liver/spleen	11
Kidney	5
Retina/Fetal retina	3
Corneal stroma	2
Fetal heart	2
Gessler Wilms tumor	2
Other tissues <sup>b</sup>	14

<sup>a</sup>Using the blast algorithm (Altechul et al., 1997, *NucleicAcidsRes* 25, 3389-402), a total of 98 human EST sequences were identified that matched the 3'UTR of the PAPP-A2 mRNA sequence. The distribution among tissues is based on the annotations of individual database entries (not listed).

<sup>b</sup>EST sequences originated from pools of tissue, or from tissue represented by only one EST sequence.

**[0309]** 6.4. Expression in Mammalian Cells of Recombinant PAPP-A2 and Variants of PAPP-A2

**[0310]** The following plasmid constructs were made:

**[0311]** a) pPA2: The cDNA sequence of pre-pro-PAPP-A2 encoding amino acids 1-1791 in expression vector pcDNA3.1+.

**[0312]** b) pPA2-KO: As pPA2, but Glu-734 of the above site of PAPP-A2 substituted with a Gln residue (E734Q).

**[0313]** c) pPA2-mH: The expression vector pcDNA3.1/MyC-His(-)A containing the cDNA sequence of pre-pro-PAPP-A2 encoding amino acids 1-1791, not followed by a stop codon, but rather a c-myc and a His tag.

**[0314]** d) pPA2-KO-mH: As pPA2-mH, but with the E734Q substitution of pPA2-KO.

**[0315]** The three overlapping PAPP-A2 cDNA fragments (hom-N, the midregion, and hom-C) were used for the construction of a single contiguous cDNA sequence encoding PAPP-A2. The overlapping fragments were all contained in the vector pCR-Bluntli-TOPO (Invitrogen) and referred to as p2N, p2Mid, and p2C, as detailed above (example 6.1). Clones of p2N and p2C were selected that had the proper orientation of the cDNA insert.

**[0316]** Construction of pPA2: The NotI-BamHI fragment was excised from p2C and cloned into pBluescriptIISK+ (Stratagene) to obtain p2CBlue. The NotI-SpeI fragment was excised from p2N, and the SpeI-BclI fragment was excised from p2Mid. Those two fragments were ligated into the NotI/BclI sites of p2CBlue in one reaction to obtain p2NMidCBlue, containing the entire PAPP-A2 cDNA. The NotI-ApaI fragment of pBluescriptIISK+ was excised and ligated into the NotI/ApaI sites of the mammalian expression vector pcDNA3.1+ (Invitrogen) to obtain a modified version of this vector, pcDNA-NA. The full length cDNA was then excised from p2NMidCBlue with NotI and XhoI and cloned into pcDNA-NA to obtain pPA2. All restriction sites used are in the multi cloning sites of the vectors, except for SpeI and BclI, both located in each of the two overlapping regions of the coding PAPP-A2 sequence stretches of p2N, p2Mid, and p2C (nt. 2365 and nt. 4203, respectively, of FIG. 3).

**[0317]** Construction of pPA2-KO: The construct pPA2-KO is a variant of the pPA2-expression construct in which residue Glu-734 of the active site of PAPP-A2 was substituted with a Gln residue. Thus, the mutant is E734Q. The pPA2-KO construct was made by site directed mutagenesis using the method of overlap extension PCR (Ho et al., 1989, *Gene* 77, 61-9) with pPA2 as the template. In brief, outer primers were 5'-CGCTCAGGGAAGGACAAGGG-3' (5' end primer, nt 976-995 of SEQ ID NO:1) and 5'-CTAGAAGGCACAGTCGAGGC-3' (3S end primer, nt. 1040-1021, sequence of vector pcDNA3.1+). Overlapping internal primers were 5'-TGTCCCACTTGATGGATCATGGT-GTCGGTGTGG-3' (nt 2210-2178 of SEQ ID NO:1, nt, 2200 not C, but G resulting in E734Q) and 5'-CCATCAAGTGGGACATGTTCTGGGAC-3' (nt. 2196-2221 of SEQ ID NO:1, nt-2200 not G, but C resulting in E734Q). The resulting mutated fragment was digested with Xba and XhoI and swapped into pPA2 to generate pPA2-KO. All

PCRs were carried out with Pfu DNA polymerase (Stratagene), and all constructs were verified by sequence analysis.

[0318] Construction of pPA2-mH; Two primers (5'-GAGGGCCTGTGGACCCAGGAG-3', nt. 49064926 of SEQ ID NO:1, and 5'-GACGTAAAGCTTCTGATTCTTCTGCCTTGG-3', nt. 5373-5354 of SEQ ID NO:1, preceded by a HindIII site, AAGCTT, and nt. GACGTA to facilitate cleavage of the PCR product) were used in a PCR with pPA2 as the template to generate a nucleotide fragment encoding the C-terminal 156 residues of PAPP-A2. With the stop codon replaced by a HindIII site for in-frame ligation to expression vector. In brief, the PCR product was digested with EcoRI and HindIII and cloned into the EcoRI/HindIII sites of the vector pcDNA3.1/Myc-His(-)A to generate pPA2C-mH. The NotI-XbaI fragment (encoding the N-terminal portion of PAPP-A2), and the XbaI-EcoRI fragment (encoding the remaining central portion of PAPP-A2) were excised from pPA2 and ligated in one reaction into the NotI/EcoRI sites of pPA2C-mH. The resulting construct, pPA2-mH, encoded PAPP-A2 followed by residues KLGP, the myc epitope (EQKLISEEDL), residues NSAVD, and six H-residues (amino acids are given as one letter code). A stop codon follows immediately after the six histidine residues.

[0319] Construction of pPA2-KO-mH: A variant of pPA2-mH was constructed with residue Glu-734 substituted into a Gln residue; The NotI-KpnI fragment of pPA2-KO was excised and swapped into the NotI-KpnI sites of pPA2-mH, to generate pPA2-KO-mH.

[0320] Expression in mammalian cells: All construct (pPA2, pPA2-KO, pPA2-mH, and pPA2-KO-mH) as well as empty expression vectors (pcDNA3.1+ and pcDNA3.1/Myc-His(-)A) were transiently transfected into mammalian cells for expression of recombinant PAPP-A2 protein. Briefly, human embryonic kidney 293T cells (293tsA1609neo) (DuBridge et al., 1987, *Mol Cell Biol* 7, 379-87) were maintained in high glucose DMEM medium supplemented with 10% fetal bovine serum, 2 mM glutamine, nonessential amino acids, and gentamicin (Life Technologies). Cells were plated onto 6 cm tissue culture dishes, and were transfected 18 h later by calcium phosphate coprecipitation (Pear et al., 1993, *Proc Natl Acad Sci USA* 90, 8392-6) using 10 µg of plasmid DNA prepared by QIAprep Spin Kit (Qiagen). After a further 48 h the supernatants were harvested, and replaced by serum-free medium (293 SFM II, Life Technologies) for another 48 h. The serum-free medium was harvested and cleared by centrifugation.

[0321] Analysis by Western blotting of recombinant protein resulting from transfection with the constructs pPA2-mH and pPA2-KO-mH, demonstrated that PAPP-A2 is secreted as a protein of 220 kDa (See FIG. 2). Reduction of disulfide bonds did not cause a visible change in band migration. Thus, in contrast to PAPP-A, PAPP-A2 is secreted as a monomer.

[0322] 6.5. Purification by Affinity Chromatography of Tagged PAPP-A2

[0323] A metal chelate affinity column (2 ml, Pharmacia) was charged with nickel ions and loaded with serum-free medium (50 ml) from cells transiently transfected with pPA2-KO-mH (see example 6.4). After washing in PBS

containing 1M NaCl, bound protein was eluted with 10 mM EDTA in PBS in fractions of 0.5 ml. PAPP-A2 containing fractions were located by SDS-PAGE (FIG. 4, lane 5). This protein was not seen from medium of cells transfected with empty vector (mock transfectants) and treated in a parallel manner.

[0324] 6.6. N-Terminal Sequence Analysis of PAPP-A2

[0325] C-terminally tagged PAPP-A2 purified from medium of cells transfected with construct pPA2-KO-mH (see examples 6.4 and 6.5) was reduced and run on a 10-20% SDS gel, and further blotted onto PVDF membrane (ProBlott, Applied Biosystems). Bands of 4 lanes were excised and subjected to N-terminal sequence analysis on an Applied Biosystems 477A sequencer equipped with an on-line HPLC (Sottrup-Jensen, 1995, *Anal Biochem* 225, 187-8). The N-terminal sequence observed at a level of approximately 20 pmol was: Ser-ProPro-Glu-Glu-Ser-Asn (SPPEESN), resulting from cleavage before Ser-234 of the PAPP-A2 polypeptide after R(230)VKK.

[0326] This confirms the prediction, that PAPP-A2, like PAPP-A, is synthesized as a prepro protein. The absence of an arginine residue in the P1 position, indicates that the proprotein processing enzyme responsible for this cleavage is not furin, but likely another proprotein convertase (Nakayama, 1997, *Biochem J* 327, 625-35). Cleavage of proPAPP-A2 might have been predicted after R(196)QRR, which archetypically marks furin cleavage (Nakayama, 1997, *Biochem J* 327, 625-35). We cannot exclude that cleavage occurred at this site, and that the observed N-terminus results from further processing.

[0327] 6.7. Cleavage of Insulin-Like Growth Factor Binding Protein (IGFBP)-5

[0328] Ligand blotting (Conover et al., 1993, *J Clin Invest* 91, 1129-37) with radiolabeled IGF-II (Bachem) was used to assay for activity against IGFBP-1 (from HepG2 conditioned medium), rIGFBP-2 (GroPep), rIGFBP-3 (gift of D. Powell), rIGFBP-4 (Austral), rIGFBP-5 (gift of D. Andres), and rIGFBP-6 (Austral). Of the six binding proteins, IGFBP-5 showed complete cleavage (FIG. 5). IGFBP-3 was partially degraded (FIG. 6). This cleavage was independent of the presence of IGF. Experiments were carried out with media from cells transfected with pPA2 or empty vector.

[0329] For further analysis, recombinant IGFBP-5 was produced in mammalian cells. In brief, human placental oligo-dT primed cDNA (Overgaard et al., 1999, *Biol Reprod* 61, 1083-9) was used as a template to amplify cDNA encoding human IGFBP-5 (Accession number M65062) Specific primers containing an XhoI site (5'-TCCGCTC-GAGATGGTTrTTGCTCACC GCGGT-3') and a HindII site (8'-CGATAAGCTTCTCAACOTTGCTGCTGTCG-5') were used, and the resulting-PCR product was digested and cloned into the XhoI/HindIII sites of pcDNA3.1/Myc-His(-)A (Invitrogen). The construct encoded the full-length pro-IGFBP-5, immediately followed by residues KLGP, the myc epitope (EQKLISEEDL), residues NSAVD, and six H-residues (amino acids are given as one letter code). The construct was verified by sequence analysis. Plasmid DNA for transfection was prepared by QIAprep Spin Kit (Qiagen). Cell culture and expression of recombinant IGFBP-5 was performed as described above in Example 6.4.

[0330] Cleavage analysis was performed by Western blotting (FIG. 6). Briefly, recombinant IGFBP-5 as contained in

5 microL cell culture medium was incubated with culture supernatants (10 microL) from cells transfected With pPA2, pPA2-KO, or empty expression expression vectors (see example 6.4) Phosphate buffered saline was added to a final volume of 60 microL. After incubation at 37 degrees Celsius for 12 hours, 15 microL of the reaction mixture was separated by reducing 16% SDS-PAGE, blotted onto a PVDF membrane, and the G-terminal cleavage product was detected with monoclonal anti-c-myc (clone 9E19, ATTC) using peroxidase-conjugated secondary antibodies (P260, DAKO), and enhanced chemiluminescence (ECL, Amersham).

**[0331]** 6.8. Inhibition of the Activity of PAPP-A2

**[0332]** Various agents were analyzed for their ability to inhibit the proteolytic activity of PAPP-A2 against IGFBP-5. The experimental conditions were essentially as do scribed in Example 6.7, except the agents to be tested were added (**FIG. 6**). Agents found to have no effect on the proteolytic activity of PAPP-A2 further included PMSF and aprotinin.

**[0333]** 6.9. Identification of the Cleavage Site in IGFBP-5

**[0334]** For cleavage site determination, purified rIGFBP-5 (**FIG. 6**, lane 7) was digested with purified PAPP-A2 and analyzed by SDS-PAGE (**FIG. 6**, lane 8). Edman degradation of blotted material showed that both distinct, visible degradation products (**FIG. 6**, lane 8) contained the N-terminal sequence K(144)FVGG (IGFBP-6 is numbered with the N-terminal Leu of the mature protein as residue 1). The two bands both represent intact C-terminal cleavage fragments, because they also contain the C-terminal c-myc tag (**FIG. 6**, lane 9); they are likely to be differently glycosylated, in accordance with the heterogeneity of purified rIGFBP-5 (**FIG. 6**, lane 7). Both bands contained a second sequence at lower level (45%). L(1)GXFVH, corresponding to the N-terminal sequence of IGFBP-5. The absence of Ser. expected in the third cycle, was taken as evidence for carbohydrate substitution of Ser-3. O-linked glycan on the N-terminal cleavage fragment is likely to cause it to smear around the two distinct, C-terminal fragments. Sequence analysis on the reaction mixture (>100 pmol) without SDS-PAGE separation showed only the same two IGFBP-5 sequences in equimolar amounts. Thus, PAPP-A2 cleaves IGFBP-5 at one site, between Ser-143 and Lys-144.

**[0335]** 6.10. Tissues where PAPP-A2 may cause proteolysis of IGFBP-5 Proteolytic activity against IGFBP-5 has been widely reported from several sources, e.g. pregnancy serum (Claussen et al., 1994, *Endocrinology* 134, 1964-6), seminal plasma (Lee et al., 1994, *J Clin Endocrinol Metab* 79, 1367-72), culture media from smooth muscle cells (Imai et al., 1997, *J Olin Invest* 100, 2596-605), granulosa cells (Resnick et al., 1998, *Endocrinology* 139, 1249-57), osteosarcoma cells (Conover and Kiefer, 1993, *J Clin Endocrinol Metab* 76, 1153-9), and also from osteoblasts (Thraillkill et al., 1995, *Endocrinology* 136, 3527-33), and fibroblasts (Busby et al., 2000, *J Biol Chem*). In general, the proteinase responsible for cleavage of IGFBP-5 has remained unidentified.

**[0336]** The recent identification of PAPP-A as the IGFBP4 proteinase in fibroblasts and osteoblasts (Lawrence et al., 1999, *Proc Natl Acad Sci USA* 96, 3149-53), ovarian follicular fluid (Conover et al., 1999, *J Clin Endocrinol Metab* 84, 4742-5), pregnancy serum (Overgaard et al., 2000, *J Biol*

*Chem*), and vascular smooth muscle cells (Bayes-Genis, A., Schwartz, R. S., Ashai, K., Lewis, D. A., Overgaard, M. T., Christiansen, M., Oxvig, C., Holmes, D. R., Jr., and Conover, C. A. *Arterioscler. Thromb. Vasc. Biol.*, in press) firmly establishes PAPP-A and IGFBP-4 as an important functional pair in several systems. No other substrate as has been found for PAPP-A, and no other proteinase has been shown to cleave IGFBP-4 physiologically. It is therefore likely that the pair of PAPP-A2 and IGFBP-5 play an analogous role in a number of the tissues mentioned above and/or elsewhere. Interestingly, incubating IGFBP-5 with smooth muscle cells conditioned medium resulted in cleavage between Ser-143 and Lys-144 (Imai et al., 1997, *J Clin Invest* 100, 2596-605), the so same cleavage site as found here with PAPP-A2. This immediately suggests PAPP-A2 as an obvious candidate IGFBP-5 proteinase for this tissue.

CITED REFERENCES

- [0337]** Altschul, S. F., Madden, T. L., Schaffer, A. A., Zhang, J., Zhang, Z., Miller, W., and Lipman, D. J. (1997). Gapped BLAST and PSI-BLAST: a now generation of protein database search programs. *Nucleic Acids Res* 25, 3389-402.
- [0338]** Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A., and Struhl, K. (1989). *Current Protocols in Molecular Biology* (New York City, N.Y.: John Wiley & Sons).
- [0339]** Barker, R. L., Gleich, G. J., and Pease, L. R. (1988). Acidic precursor revealed in human eosinophil granule major basic protein cDNA [published erratum appears in *J Exp Med* Sep. 1, 1989; 170(3):1057]. *J Exp Med* 106, 1493-8.
- [0340]** Bayes-Genis, A., Schwartz, R. S., Ashai, K., A., L. D., Overgaard, M. T., Christiansen, M., Oxvig, C., Holmes Jr, D. R., and Conover, C. A. (2000). Insulin-like growth factor binding protein-4 protease produced by arterial smooth muscle cells in vitro is increased in the coronary artery following angioplasty. *Arterioscler Thromb Vasc Biol*, in press.
- [0341]** Biagiotti, R., Cariafi, E., Brizz, L. Cappelli, G. and D'Agata, A. (1998). Maternal serum screening for trisomy 18 in the first trimester of pregnancy. *Prenat Diagn* 18, 907-13.
- [0342]** Bischof, P. (1979). Purification and characterization of pregnancy associated plasma protein A (PAPP-A). *Arch Gynecol* 227.315-26.
- [0343]** Bitter, G. A., Egan, K. M., Koski, R. A., Jones, M. O., Elliott, S. G., and Giffin, J. C. (1987). Expression and secretion vectors for yeast *Methods Enzymol* 153, 516-44.
- [0344]** Bode, W., Gomis-Ruth, F. X., and Stockler, W. (1993). Astacins, serralytins, snake venom and matrix metalloproteinases exhibit identical zinc-binding environments (HEXXHXXGXXH and Met-turn) and topologies and should be grouped into a common family, the 'metzincins'. *FEBS Lett* 331, 134-40.
- [0345]** Bonno, M., Oxvig, C., Kephart, G. M. Wagner, J. M. Kristensen, T., Sottrup-Jensen, L., and Gleich, G. J. (1994). Localization of pregnancy-associated plasma protein-A and colocalization of pregnancy-associated

- plasma protein-A messenger ribonucleic acid and eosinophil granule major basic protein messenger ribonucleic acid in placenta. *Lab Invest* 71, 560-6.
- [0346] Brambati, B., Macintosh, M. C., Teisner, B., Maguiness, S., Shrimanker, K., Lanzani, A., Bonacohi, I., Tului, L., Chard, T., and Grudzinskas, J. G. (1993). Low maternal serum levels of pregnancy associated plasma protein A (PAPP-A) in the first trimester in association with abnormal fetal karyotype. *Br J Obstet Gynaecol* 100, 324-6.
- [0347] Broglie, R., Coruzzi, G., Fraley, R. T., Rogers, S. G., Horsch, R. B., Niedermeyer, J. G., Fink, C. L., and Chua, N. H. (1984). Light-regulated expression of a pea ribulose-1,5-bisphosphate carboxylase small subunit gene in transformed plant cells. *Science* 224, 838-43.
- [0348] Busby, W. H., Jr., Nam, T. J., Morales, A., Smith, C., Jennings, M., and Clemmons, D. R. (2000). The Complement Component C1s is the Protease That Accounts for Cleavage of insulin-like Growth Factor Binding Protein-5 in Fibroblast Medium. *J Biol Chem*.
- [0349] Christiansen, M., Oxvig, C., Wagner, J. M., Qin, Q. P., Nguyen, T. H., Overgaard, M. T., Larsen, S. O., Sottrup-Jensen, L., Gleich, G. J., and Norgaard-Pedersen, B. (1999). The proform of eosinophil major basic protein: a new maternal serum marker for Down syndrome. *Prenat Diagn* 19, 905-10.
- [0350] Christiansen, M., Jaliashvili, I., Overgaard, M. T., Ensinger, C., Oxvig, C. (2000) Quantitation and characterization of pregnancy-associated complexes between angiotensinogen and the proform of eosinophil major basic protein in serum and amniotic fluid. *Clin. Chem.* 46, 1099-1105
- [0351] Clackson, T., Hoogenboom, H. R., Griffiths, A. D., and Winter, G. (1991). Making antibody fragments using phage display libraries. *Nature* 352, 624-8.
- [0352] Claussen, M., Zapf, J., and Braulke, T. (1994). Proteolysis of insulin-like growth factor binding protein-5 by pregnancy serum and amniotic fluid. *Endocrinology* 134, 1964-6.
- [0353] Conover, C. A., and Kiefer, M. C. (1993). Regulation and biological effect of endogenous insulin-like growth factor binding protein-5 in human osteoblastic cells. *J Clin Endocrinol Metab* 76, 1153-9.
- [0354] Conover, C. A., Kiefer, M. C., and Zapf, J. (1993). Posttranslational regulation of insulin-like growth factor binding protein-4 in normal and transformed human fibroblasts. Insulin-like growth factor dependence and biological studies. *J Clin Invest* 91, 1129-37.
- [0355] Conover, C. A., Oxvig, C., Overgaard, M. T., Christiansen, M., and Giudice, L. C. (1999). Evidence that the insulin-like growth factor binding protein-4 protease in human ovarian follicular fluid is pregnancy associated plasma protein-A [in Process Citation]. *J Clin Endocrinol Metab* 84, 4742-5.
- [0356] Crowther, J. R. (1995). ELISA. Theory and Practice, *Methods in Molecular Biology*. vol 42 (Totowa, N.J.: Humana Press).
- [0357] DuBridge, R. B., Tang, P., Haia, H. C., Leong, P. M., Miller, J. H., and Calos, M. P. (1987). Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. *Mol Cell Biol* 7, 379-87.
- [0358] Folkersen, J., Grudzinskas, J. G., Hindersson, P., Teisner, B. and Westergaard, J. G. (1981). Pregnancy-associated plasma protein A; circulating levels during normal pregnancy. *Am J Obstet Gynecol* 139, 910-4.
- [0359] Fowlkes, J. L. (1997). Insulinlike growth factor-binding protein proteolysis. An emerging paradigm in insulinlike growth factor physiology. *Trends Endocrinol Metab* 6, 299-306.
- [0360] Gmunder, H., and Kohli, J. (1989). Cauliflower mosaic virus promoters direct efficient expression of a bacterial G418 resistance gene in *Schizosaccharomyces pombe*. *Mol Gen Genet* 220, 95-101.
- [0361] Haddow, J. E., Palomaki, G. E., Knight, G. J., Williams, J., Miller, W. A., and Johnson, A. (1998), screening of maternal serum for fetal Down's syndrome in the first trimester. *N Engl J Med* 338, 955-61.
- [0362] Ho, S. N., Hunt, H. D., Horton, R. M., Pullen, J. K., and Pease, L. R. (1989). Site directed mutagenesis by overlap extension using the polymerase chain reaction [see comment]. *Gene* 77, 51-9.
- [0363] Hwa, V., Oh, Y., and Rosenfeld, R. G. (1999). The insulin-like growth factor-binding protein (IGFBP) superfamily. *Endocr Rev* 20, 761-87.
- [0364] Haaning, J., Oxvig, C., Overgaard, M. T., Ebbesen, P., Kritteneen, T., and Sottrup-Jensen, L. (1996). Complete cDNA sequence of the preproform of human pregnancy-associated plasma protein-A. Evidence for expression in the brain and induction by cAMP. *Eur J Biochem* 237, 159-63.
- [0365] Imai, Y., Busby, W. H., Jr., Smith, G. E., Clarke, J. B., Garmon, A. J., Horwitz, G. D., Rees, C., and Clemmons, D. R. (1997). Protease-resistant form of insulin-like growth factor-binding protein 5 is an inhibitor of insulin-like growth factor-I actions on porcine smooth muscle cells in culture. *J Clin Invest* 100, 2596-606.
- [0366] Kristensen, T., Oxvig, C., Sand, O., Moller, N. P., and Sottrup-Jensen, L. (1994). Amino acid sequence of human pregnancy-associated plasma protein-A derived from cloned cDNA. *Biochemistry* 33, 1592-8.
- [0367] Lawrence, J. B., Oxvig, C., Overgaard, M. T., Sottrup-Jensen, L., Gleich, G. J., Hays, L. G., Yates, J. R., 3rd, and Conover, C. A. (1999) The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A. *Proc Natl Acad Sci USA* 96, 3149-53.
- [0368] Lee, K O., Oh, Y., Giudice, L. C., Cohen, P., Peehl, D. M., and Rosenfeld, R. G. (1994). Identification of insulin-like growth factor-binding protein-3 (IGFBP-3) fragments and IGFBP-5 proteolytic activity in human seminal plasma: a comparison of normal and vasectomized patients. *J Clin Endocrinol Metab* 79, 1367-72.

- [0369] Lin, T. M., Galbert, S. P., Kiefer, D., Spellacy, W. N., and Gall, S. (1974). Characterization of four human pregnancy-associated plasma proteins. *Am J Obstet Gynecol* 118, 223-36.
- [0370] Logan, J., and Shenk, T. (1984). Adenovirus tripartite leader sequence enhances translation of mRNAs late after infection. *Proc Natl Acad Sci USA* 81, 3656-9.
- [0371] Mackett, M., Smith, G. L., and Moss, B. (1982). Vaccinia virus: a selectable eukaryotic cloning and expression vector. *Proc Natl Acad Sci USA* 79, 7415-9.
- [0372] Marks, J. D., Hoogenboom, H. R., Bonnert, T. P., McCafferty, J., Griffiths, A. D., and Winter, G. (1991). By-passing immunization. Human antibodies from V-gene libraries displayed on phage. *J Mol Biol* 222, 581-97.
- [0373] Matthews, D. J., and Wells, J. A. (1993). Substrate phage: selection of protease substrates by monovalent phage display. *Science* 260, 1113-7.
- [0374] McGrogan, M., Simonsen, C., Scott, R., Grifft, J., Ellis, N., Kennedy, J., Campanelli, D., Nathan, C., and Gabay, J. (1988). Isolation of a complementary DNA clone encoding a precursor to human eosinophil major basic protein. *J Exp Med* 168, 2295-308.
- [0375] Meldal, M. (1998). Intramolecular fluorescence-quenched substrate libraries. *Methods Mol Biol* 87, 65-74.
- [0376] Meldal, M. (1998). Introduction to combinatorial solid-phase assays for enzyme activity and inhibition. *Methods Mol Biol* 87, 51-7.
- [0377] Meldal, M. (1998). The solid-phase enzyme inhibitor library assay. *Methods Mol Biol* 87, 75-82.
- [0378] Nakayama, K. (1997). Furin: a mammalian subtilisin/Kex2p-like endoprotease involved in processing of a wide variety of precursor proteins, *Biochem J* 327, 625-35.
- [0379] Nielsen, H., Engelbrecht, J., Brunak, S., and von Heijne, G. (1997). Identification of prokaryotic and eukaryotic signal peptides and prediction of their cleavage sites. *Protein Eng* 10, 1-6.
- [0380] Overgaard, M. T., Haaning, J., Soldt, H. B., Olsen, I. M., Laursen, L., Christiansen, M., Gleich, G. J., Sottrup-Jensen, L., Conover, C. A., and Oxvig, C. (2000). Expression of Recombinant Human Pregnancy-Associated Plasma Protein-A and Identification of the Proform of Eosinophil Major Basic Protein as its Physiological Inhibitor. *J Biol Chem*.
- [0381] Overgaard, M. T., Oxvig, C., Christiansen, M., Lawrence, J. B., Conover, C. A., Gleich, G. J., Sottrup-Jensen, L., and Haaning, J. (1999). Messenger ribonucleic acid levels of pregnancy-associated plasma protein-A and the proform of eosinophil major basic protein: expression in human reproductive and nonreproductive tissues. *Biol Reprod* 61, 1083-9.
- [0382] Oxvig, C., Haaning, J., Hojrup, P., and Sottrup-Jensen, L. (1994). Location and nature of carbohydrate groups in proform of human major basic protein isolated from pregnancy serum. *Biochem Mol Biol Int* 33, 329-36.
- [0383] Oxvig, C., Haening, J., Kristensen, L., Wagner, J. M., Rubin, I., Stigbrand, T., Gleich, G. J., and Sottrup-Jensen, L. (1995). Identification of angiotensinogen and complement C3dg as novel proteins binding the proform of eosinophil major basic protein in human pregnancy serum and plasma. *J Biol Chem* 270, 13645-51.
- [0384] Oxvig, C., Sand, O., Kristensen, T., Gleich, G. J., and Sottrup-Jensen, L. (1993). Circulating human pregnancy-associated plasma protein-A is disulfide-bridged to the proform of eosinophil major basic protein. *J Biol Chem* 268 12243-6.
- [0385] Oxvig, C., Sand, O., Kristensen, T., Kristensen, L., and Sottrup-Jensen L. (1994). Isolation and characterization of circulating complex between human pregnancy-associated plasma protein-A and proform of eosinophil major basic protein. *Biochim Biophys Acta* 1201, 415-23.
- [0386] Pear, W. S., Nolan, G. P., Scott, M. L., and Baltimore, D. (1993). Production of high-titer helper-free retroviruses by transient transfection. *Proc Natl Acad Sci USA* 90, 8392-0.
- [0387] Peters, J. H., and Baumgarten, H. (1992). *Monoclonal Antibodies* (Offenbach, Germany, Springer-Verlag).
- [0388] Rajaram, S., Baylink, D. J., and Mohan, S. (1997). Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. *Endocr Rev* 18, 801-31.
- [0389] Resnick, C. E., Fielder, P. J., Rosenfeld, R. G., and Adashi, E. Y. (1998). Characterization and hormonal regulation of a rat ovarian insulin-like growth factor binding protein-5 endopeptidase: an FSH-inducible granulosa cell-derived metalloprotease. *Endocrinology* 139, 1249-57.
- [0390] Rosenfeld, S. A. (1999). Use of *Pichia pastoris* for expression of recombinant proteins. *Methods Enzymol* 206, 154-69.
- [0391] Ruther, U., and Muller-Hill, B. (1983). Easy identification of cDNA clones. *Embo J* 2, 1791-4.
- [0392] Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989). *Molecular Cloning. A Laboratory Manual* (Cold Spring Harbor, N.Y.: Cold Spring Harbor Laboratory Press).
- [0393] Scopes, R. K. (1987). *Protein Purification, Principles and Practice*. (Harrisonburg, Va.: Springer-Verlag).
- [0394] Sinosich, M. J. (1990). Molecular characterization of pregnancy-associated plasma protein-A by electrophoresis. *Electrophoresis* 71, 70-8.
- [0395] Smith, G. E., Summers, M. D., and Fraser, M. J. (1983). Production of human beta interferon in insect cells infected with a baculovirus expression vector. *Mol Cell Biol* 3, 2156-65.

- [0396] Sottrup-Jensen, L. (1993). Determination of halocystine in proteins as cysteine from reducing hydrolyzates. *Biochem Mol Biol Int* 30, 789-94.
- [0397] Sottrup-Jensen, L. (1995). A low-pH reverse-phase high-performance liquid chromatography system for analysis of the phenylthiohydantoins of S-carboxymethylcysteine and S-carboxyamidomethylcysteine. *Anal Biochem* 225, 187-8.
- [0398] Spencer, K., Ong, C., Skentou, H., A, W. L., and K, H. N. (2000). Screening for trisomy 13 by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation. *Prenat Diagn* 20, 411-6.
- [0399] Stocker, W., Grams, F., Baumann, U., Reinemer, P., Gomis-Ruth, F. X., McKay, D. B., and Bode, W. (1995). The metzincins-topological and sequential relations between the astacins, adamalysins, serralysins, and matrixins (collagenases) define a superfamily of zinc-peptidases. *Protein Sci* 4, 823-40.
- [0400] Thompson, J. D., Higgins, D. G., and Gibson, T. J. (1994). CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. *Nucleic Acids Res* 22, 4673-80.
- [0401] Thrailkill, K. M., Quarles, L. D., Nagase, H. Suzuki, K., Serra, D. M., and Fowikes, J. L. (1995). Characterization of insulin-like growth factor-binding protein 5-degrading proteases produced throughout murine osteoblast differentiation. *Endocrinology* 136, 3627-33.
- [0402] Wald, N. Stone, R., Cuckle, H. S., Grudzinskas, J. G., Barkai, G., Brambati, B., Teisner, B., and Fuhrmann, W. (1992). First trimester concentrations of pregnancy associated plasma protein A and placental protein 14 in Down's syndrome [see comments]. *Bmj* 306, 28.
- [0403] Wald, N. J., Watt, H. C., and Hackshaw, A. K. (1999). Integrated screening for Down's syndrome on the basis of tests performed during the first and second trimesters [see comments]. *N Engl J Med* 341, 461-7.
- [0404] Walsh, P. S., Erlich, H. A., and Higuchi, R. (1992). Preferential PCR amplification of alleles: mechanisms and solutions. *PCR Methods Appl* 1, 241-50.
- [0405] Westergaard, J. G., Chemnitz J., Teisner, B. Poulson. H. K, Ipsen, L., Beck, B., and Grudzinskas, J. G. (1983). Pregnancy-associated plasma protein A: a possible marker in the classification and prenatal diagnosis of Cornelia de Lange syndrome. *Prenat Diagn* 3, 225-32.

## SEQUENCE LISTING

```

<160> NUMBER OF SEQ ID NOS: 25

<210> SEQ ID NO 1
<211> LENGTH: 8527
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)..(5373)
<223> OTHER INFORMATION: prepro-PAPP-A2 coding sequence
<221> NAME/KEY: 3'UTR
<222> LOCATION: (5377)..(8527)
<223> OTHER INFORMATION:
<221> NAME/KEY: mat_peptide
<222> LOCATION: (700)..()
<223> OTHER INFORMATION:
<221> NAME/KEY: sig_peptide
<222> LOCATION: (1)..(66)
<223> OTHER INFORMATION:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1)..(66)
<223> OTHER INFORMATION: prepro part of PAPP-A2
<221> NAME/KEY: misc_feature
<222> LOCATION: (67)..(699)
<223> OTHER INFORMATION: pro part of PAPP-A2

<400> SEQUENCE: 1

atg atg tgc tta aag atc cta aga ata agc ctg gcg att ttg gct 45
Met Met Cys Leu Lys Ile Leu Arg Ile Ser Leu Ala Ile Leu Ala
-230 -225 -220

ggg tgg gca ctc tgt tct gcc aac tct gag ctg ggc tgg aca cgc 90
Gly Trp Ala Leu Cys Ser Ala Asn Ser Glu Leu Gly Trp Thr Arg
-215 -210 -205

```

-continued

aag aaa tcc ttg gtt gag agg gaa cac ctg aat cag gtg ctg ttg	135
Lys Lys Ser Leu Val Glu Arg Glu His Leu Asn Gln Val Leu Leu	
-200 -195 -190	
gaa gga gaa cgt tgt tgg ctg ggg gcc aag gtt cga aga ccc aga	180
Glu Gly Glu Arg Cys Trp Leu Gly Ala Lys Val Arg Arg Pro Arg	
-185 -180 -175	
gct tct cca cag cat cac ctc ttt gga gtc tac ccc agc agg gct	225
Ala Ser Pro Gln His His Leu Phe Gly Val Tyr Pro Ser Arg Ala	
-170 -165 -160	
ggg aac tac cta agg ccc tac ccc gtg ggg gag caa gaa atc cat	270
Gly Asn Tyr Leu Arg Pro Tyr Pro Val Gly Glu Gln Glu Ile His	
-155 -150 -145	
cat aca gga cgc agc aaa cca gac act gaa gga aat gct gtg agc	315
His Thr Gly Arg Ser Lys Pro Asp Thr Glu Gly Asn Ala Val Ser	
-140 -135 -130	
ctt gtt ccc cca gac ctg act gaa aat cca gca gga ctg agg ggt	360
Leu Val Pro Pro Asp Leu Thr Glu Asn Pro Ala Gly Leu Arg Gly	
-125 -120 -115	
gca gtt gaa gag ccg gct gcc cca tgg gta ggg gat agt cct att	405
Ala Val Glu Glu Pro Ala Ala Pro Trp Val Gly Asp Ser Pro Ile	
-110 -105 -100	
ggg caa tct gag ctg ctg gga gat gat gac gct tat ctc ggc aat caa	453
Gly Gln Ser Glu Leu Leu Gly Asp Asp Asp Ala Tyr Leu Gly Asn Gln	
-95 -90 -85	
aga tcc aag gag tct cta ggt gag gcc ggg att cag aaa ggc tca gcc	501
Arg Ser Lys Glu Ser Leu Gly Glu Ala Gly Ile Gln Lys Gly Ser Ala	
-80 -75 -70	
atg gct gcc act act acc acc gcc att ttc aca acc ctg aac gaa ccc	549
Met Ala Ala Thr Thr Thr Thr Ala Ile Phe Thr Thr Leu Asn Glu Pro	
-65 -60 -55	
aaa cca gag acc caa agg agg ggc tgg gcc aag tcc agg cag cgt cgc	597
Lys Pro Glu Thr Gln Arg Arg Gly Trp Ala Lys Ser Arg Gln Arg Arg	
-50 -45 -40 -35	
caa gtg tgg aag agg cgg gcg gaa gat ggg cag gga gac tcc ggt atc	645
Gln Val Trp Lys Arg Arg Ala Glu Asp Gly Gln Gly Asp Ser Gly Ile	
-30 -25 -20	
tct tca cat ttc caa cct tgg ccc aag cat tcc ctt aaa cac agg gtc	693
Ser Ser His Phe Gln Pro Trp Pro Lys His Ser Leu Lys His Arg Val	
-15 -10 -5	
aaa aag agt cca ccg gag gaa agc aac caa aat ggt gga gag ggc tcc	741
Lys Lys Ser Pro Pro Glu Glu Ser Asn Gln Asn Gly Gly Glu Gly Ser	
-1 1 5 10	
tac cga gaa gca gag acc ttt aac tcc caa gta gga ctg ccc atc tta	789
Tyr Arg Glu Ala Glu Thr Phe Asn Ser Gln Val Gly Leu Pro Ile Leu	
15 20 25 30	
tac ttc tct ggg agg cgg gag cgg ctg ctg ctg cgt cca gaa gtg ctg	837
Tyr Phe Ser Gly Arg Arg Glu Arg Leu Leu Leu Arg Pro Glu Val Leu	
35 40 45	
gct gag att ccc ccg gag gcg ttc aca gtg gaa gcc tgg gtt aaa ccg	885
Ala Glu Ile Pro Arg Glu Ala Phe Thr Val Glu Ala Trp Val Lys Pro	
50 55 60	
gag gga gga cag aac aac cca gcc atc atc gca ggt gtg ttt gat aac	933
Glu Gly Gly Gln Asn Asn Pro Ala Ile Ile Ala Gly Val Phe Asp Asn	
65 70 75	
tgc tcc cac act gtc agt gac aaa ggc tgg gcc ctg ggg atc cgc tca	981
Cys Ser His Thr Val Ser Asp Lys Gly Trp Ala Leu Gly Ile Arg Ser	
80 85 90	

-continued

ggg aag gac aag gga aag cgg gat gct cgc ttc ttc ttc tcc ctc tgc Gly Lys Asp Lys Gly Lys Arg Asp Ala Arg Phe Phe Ser Leu Cys 95 100 105 110	1029
acc gac cgc gtg aag aaa gcc acc atc ttg att agc cac agt cgc tac Thr Asp Arg Val Lys Lys Ala Thr Ile Leu Ile Ser His Ser Arg Tyr 115 120 125	1077
caa cca ggc aca tgg acc cat gtg gca gcc act tac gat gga cgg cac Gln Pro Gly Thr Trp Thr His Val Ala Ala Thr Tyr Asp Gly Arg His 130 135 140	1125
atg gcc ctg tat gtg gat ggc act cag gtg gct agc agt cta gac cag Met Ala Leu Tyr Val Asp Gly Thr Gln Val Ala Ser Ser Leu Asp Gln 145 150 155	1173
tct ggt ccc ctg aac agc ccc ttc atg gca tct tgc cgc tct ttg ctc Ser Gly Pro Leu Asn Ser Pro Phe Met Ala Ser Cys Arg Ser Leu Leu 160 165 170	1221
ctg ggg gga gac agc tct gag gat ggg cac tat ttc cgt gga cac ctg Leu Gly Gly Asp Ser Ser Glu Asp Gly His Tyr Phe Arg Gly His Leu 175 180 185 190	1269
ggc aca ctg gtt ttc tgg tcg acc gcc ctg cca caa agc cat ttt cag Gly Thr Leu Val Phe Trp Ser Thr Ala Leu Pro Gln Ser His Phe Gln 195 200 205	1317
cac agt tct cag cat tca agt ggg gag gag gaa gcg act gac ttg gtc His Ser Ser Gln His Ser Ser Gly Glu Glu Glu Ala Thr Asp Leu Val 210 215 220	1365
ctg aca gcg agc ttt gag cct gtg aac aca gag tgg gtt ccc ttt aga Leu Thr Ala Ser Phe Glu Pro Val Asn Thr Glu Trp Val Pro Phe Arg 225 230 235	1413
gat gag aag tac cca cga ctt gag gtt ctc cag ggc ttt gag cca gag Asp Glu Lys Tyr Pro Arg Leu Glu Val Leu Gln Gly Phe Glu Pro Glu 240 245 250	1461
cct gag att ctg tcg cct ttg cag ccc cca ctc tgt ggg caa aca gtc Pro Glu Ile Leu Ser Pro Leu Gln Pro Pro Leu Cys Gly Gln Thr Val 255 260 265 270	1509
tgt gac aat gtg gaa ttg atc tcc cag tac aat gga tac tgg ccc ctt Cys Asp Asn Val Glu Leu Ile Ser Gln Tyr Asn Gly Tyr Trp Pro Leu 275 280 285	1557
cgg gga gag aag gtg ata cgc tac cag gtg gtg aac atc tgt gat gat Arg Gly Glu Lys Val Ile Arg Tyr Gln Val Val Asn Ile Cys Asp Asp 290 295 300	1605
gag ggc cta aac ccc att gtg agt gag gag cag att cgt ctg cag cac Glu Gly Leu Asn Pro Ile Val Ser Glu Glu Gln Ile Arg Leu Gln His 305 310 315	1653
gag gca ctg aat gag gcc ttc agc cgc tac aac atc agc tgg cag ctg Glu Ala Leu Asn Glu Ala Phe Ser Arg Tyr Asn Ile Ser Trp Gln Leu 320 325 330	1701
agc gtc cac cag gtc cac aat tcc acc ctg cga cac cgg gtt gtg ctt Ser Val His Gln Val His Asn Ser Thr Leu Arg His Arg Val Val Leu 335 340 345 350	1749
gtg aac tgt gag ccc agc aag att ggc aat gac cat tgt gac ccc gag Val Asn Cys Glu Pro Ser Lys Ile Gly Asn Asp His Cys Asp Pro Glu 355 360 365	1797
tgt gag cac oca ctc aca ggc tat gat ggg ggt gac tgc cgc ctg cag Cys Glu His Pro Leu Thr Gly Tyr Asp Gly Gly Asp Cys Arg Leu Gln 370 375 380	1845
ggc cgc tgc tac tcc tgg aac cgc agg gat ggg ctc tgt cac gtg gag Gly Arg Cys Tyr Ser Trp Asn Arg Arg Asp Gly Leu Cys His Val Glu 385 390 395	1893

-continued

tgt aac aac atg ctg aac gac ttt gac gac gga gac tgc tgc gac ccc Cys Asn Asn Met Leu Asn Asp Phe Asp Asp Gly Asp Cys Cys Asp Pro 400 405 410	1941
cag gtg gct gat gtg cgc aag acc tgc ttt gac cct gac tca ccc aag Gln Val Ala Asp Val Arg Lys Thr Cys Phe Asp Pro Asp Ser Pro Lys 415 420 425 430	1989
agg gca tac atg agt gtg aag gag ctg aag gag gcc ctg cag ctg aac Arg Ala Tyr Met Ser Val Lys Glu Leu Lys Glu Ala Leu Gln Leu Asn 435 440 445	2037
agt act cac ttc ctc aac atc tac ttt gcc agc tca gtg cgg gaa gac Ser Thr His Phe Leu Asn Ile Tyr Phe Ala Ser Ser Val Arg Glu Asp 450 455 460	2085
ctt gca ggt gct gcc acc tgg cct tgg gac aag gac gct gtc act cac Leu Ala Gly Ala Ala Thr Trp Pro Trp Asp Lys Asp Ala Val Thr His 465 470 475	2133
ctg ggt ggc att gtc ctc agc cca gca tat tat ggg atg cct ggc cac Leu Gly Gly Ile Val Leu Ser Pro Ala Tyr Tyr Gly Met Pro Gly His 480 485 490	2181
acc gac acc atg atc cat gaa gtg gga cat gtt ctg gga ctc tac cat Thr Asp Thr Met Ile His Glu Val Gly His Val Leu Gly Leu Tyr His 495 500 505 510	2229
gtc ttt aaa gga gtc agt gaa aga gaa tcc tgc aat gac ccc tgc aag Val Phe Lys Gly Val Ser Glu Arg Glu Ser Cys Asn Asp Pro Cys Lys 515 520 525	2277
gag aca gtg cca tcc atg gaa acg gga gac ctc tgt gcc gac acc gcc Glu Thr Val Pro Ser Met Glu Thr Gly Asp Leu Cys Ala Asp Thr Ala 530 535 540	2325
ccc act ccc aag agt gag ctg tgc cgg gaa cca gag ccc act agt gac Pro Thr Pro Lys Ser Glu Leu Cys Arg Glu Pro Glu Pro Thr Ser Asp 545 550 555	2373
acc tgt ggc ttc act cgc ttc cca ggg gct ccg ttc acc aac tac atg Thr Cys Gly Phe Thr Arg Phe Pro Gly Ala Pro Phe Thr Asn Tyr Met 560 565 570	2421
agc tac acg gat gat aac tgc act gac aac ttc act cct aac caa gtg Ser Tyr Thr Asp Asp Asn Cys Thr Asp Asn Phe Thr Pro Asn Gln Val 575 580 585 590	2469
gcc cga atg cat tgc tat ttg gac cta gtc tat cag cag tgg act gaa Ala Arg Met His Cys Tyr Leu Asp Leu Val Tyr Gln Gln Trp Thr Glu 595 600 605	2517
agc aga aag ccc acc ccc atc ccc att cca cct atg gtc atc gga cag Ser Arg Lys Pro Thr Pro Ile Pro Ile Pro Pro Met Val Ile Gly Gln 610 615 620	2565
acc aac aag tcc ctc act atc cac tgg ctg cct cct att agt gga gtt Thr Asn Lys Ser Leu Thr Ile His Trp Leu Pro Pro Ile Ser Gly Val 625 630 635	2613
gta tat gac agg gcc tca ggc agc ttg tgt ggc gct tgc act gaa gat Val Tyr Asp Arg Ala Ser Gly Ser Leu Cys Gly Ala Cys Thr Glu Asp 640 645 650	2661
ggg acc ttt cgt cag tat gtg cac aca gct tcc tcc cgg cgg gtg tgt Gly Thr Phe Arg Gln Tyr Val His Thr Ala Ser Ser Arg Arg Val Cys 655 660 665 670	2709
gac tcc toa ggt tat tgg acc cca gag gag gct gtg ggg cct cct gat Asp Ser Ser Gly Tyr Trp Thr Pro Glu Ala Val Gly Pro Pro Asp 675 680 685	2757
gtg gat cag ccc tgc gag cca agc tta cag gcc tgg agc cct gag gtc Val Asp Gln Pro Cys Glu Pro Ser Leu Gln Ala Trp Ser Pro Glu Val 690 695 700	2805

-continued

cac ctg tac cac atg aac atg acg gtc ccc tgc ccc aca gaa ggc tgt	2853
His Leu Tyr His Met Asn Met Thr Val Pro Cys Pro Thr Glu Gly Cys	
705 710 715	
agc ttg gag ctg ctc ttc caa cac ccg gtc caa gcc gac acc ctc acc	2901
Ser Leu Glu Leu Leu Phe Gln His Pro Val Gln Ala Asp Thr Leu Thr	
720 725 730	
ctg tgg gtc act tcc ttc ttc atg gag tcc tcg cag gtc ctc ttt gac	2949
Leu Trp Val Thr Ser Phe Phe Met Glu Ser Ser Gln Val Leu Phe Asp	
735 740 745 750	
aca gag atc ttg ctg gaa aac aag gag tca gtg cac ctg ggc ccc tta	2997
Thr Glu Ile Leu Leu Glu Asn Lys Glu Ser Val His Leu Gly Pro Leu	
755 760 765	
gac act ttc tgt gac atc cca ctc acc atc aaa ctg cac gtg gat ggg	3045
Asp Thr Phe Cys Asp Ile Pro Leu Thr Ile Lys Leu His Val Asp Gly	
770 775 780	
aag gtg tcg ggg gtg aaa gtc tac acc ttt gat gag agg ata gag att	3093
Lys Val Ser Gly Val Lys Val Tyr Thr Phe Asp Glu Arg Ile Glu Ile	
785 790 795	
gat gca gca ctc ctg act tct cag ccc cac agt ccc ttg tgc tct ggc	3141
Asp Ala Ala Leu Leu Thr Ser Gln Pro His Ser Pro Leu Cys Ser Gly	
800 805 810	
tgc agg cct gtg agg tac cag gtt ctc cgc gat ccc cca ttt gcc agt	3189
Cys Arg Pro Val Arg Tyr Gln Val Leu Arg Asp Pro Pro Phe Ala Ser	
815 820 825 830	
ggt ttg ccc gtg gtg gtg aca cat tct cac agg aag ttc acg gac gtg	3237
Gly Leu Pro Val Val Val Thr His Ser His Arg Lys Phe Thr Asp Val	
835 840 845	
gag gtc aca cct gga cag atg tat cag tac caa gtt cta gct gaa gct	3285
Glu Val Thr Pro Gly Gln Met Tyr Gln Tyr Gln Val Leu Ala Glu Ala	
850 855 860	
gga gga gaa ctg gga gaa gct tcg cct cct ctg aac cac att cat gga	3333
Gly Gly Glu Leu Gly Glu Ala Ser Pro Pro Leu Asn His Ile His Gly	
865 870 875	
gct cct tat tgt gga gat ggg aag gtg tca gag aga ctg gga gaa gag	3381
Ala Pro Tyr Cys Gly Asp Gly Lys Val Ser Glu Arg Leu Gly Glu Glu	
880 885 890	
tgt gat gat gga gac ctt gtg agc gga gat ggc tgc tcc aag gtg tgt	3429
Cys Asp Asp Gly Asp Leu Val Ser Gly Asp Gly Cys Ser Lys Val Cys	
895 900 905 910	
gag ctg gag gaa ggt ttc aac tgt gta gga gag cca agc ctt tgc tac	3477
Glu Leu Glu Glu Gly Phe Asn Cys Val Gly Glu Pro Ser Leu Cys Tyr	
915 920 925	
atg tat gag gga gat ggc ata tgt gaa cct ttt gag aga aaa acc agc	3525
Met Tyr Glu Gly Asp Gly Ile Cys Glu Pro Phe Glu Arg Lys Thr Ser	
930 935 940	
att gta gac tgt ggc atc tac act ccc aaa gga tac ttg gat caa tgg	3573
Ile Val Asp Cys Gly Ile Tyr Thr Pro Lys Gly Tyr Leu Asp Gln Trp	
945 950 955	
gct acc cgg gct tac tcc tct cat gaa gac aag aag aag tgt cct gtt	3621
Ala Thr Arg Ala Tyr Ser Ser His Glu Asp Lys Lys Lys Cys Pro Val	
960 965 970	
tcc ttg gta act gga gaa cct cat tcc cta att tgc aca tca tac cat	3669
Ser Leu Val Thr Gly Glu Pro His Ser Leu Ile Cys Thr Ser Tyr His	
975 980 985 990	
cca gat tta ccc aac cac cgt ccc cta act ggc tgg ttt ccc tgt gtt	3717
Pro Asp Leu Pro Asn His Arg Pro Leu Thr Gly Trp Phe Pro Cys Val	
995 1000 1005	

-continued

gcc agt gaa aat gaa act cag gat gac agg agt gaa cag cca gaa	3762
Ala Ser Glu Asn Glu Thr Gln Asp Asp Arg Ser Glu Gln Pro Glu	
1010 1015 1020	
ggt agc ctg aag aaa gag gat gag gtt tgg ctc aaa gtg tgt ttc	3807
Gly Ser Leu Lys Lys Glu Asp Glu Val Trp Leu Lys Val Cys Phe	
1025 1030 1035	
aat aga cca gga gag gcc aga gca att ttt att ttt ttg aca act	3852
Asn Arg Pro Gly Glu Ala Arg Ala Ile Phe Ile Phe Leu Thr Thr	
1040 1045 1050	
gat gcc cta gtt ccc gga gag cat cag cag ccg aca gtg act ctc	3897
Asp Gly Leu Val Pro Gly Glu His Gln Gln Pro Thr Val Thr Leu	
1055 1060 1065	
tac ctg acc gat gtc cgt gga agc aac cac tct ctt gga acc tat	3942
Tyr Leu Thr Asp Val Arg Gly Ser Asn His Ser Leu Gly Thr Tyr	
1070 1075 1080	
gga ctg tca tgc cag cat aat cca ctg att atc aat gtg acc cat	3987
Gly Leu Ser Cys Gln His Asn Pro Leu Ile Ile Asn Val Thr His	
1085 1090 1095	
cac cag aat gtc ctt ttc cac cat acc acc tca gtg ctg ctg aat	4032
His Gln Asn Val Leu Phe His His Thr Thr Ser Val Leu Leu Asn	
1100 1105 1110	
ttc tca tcc cca cgg gtc ggc atc tca gct gtg gct cta agg aca	4077
Phe Ser Ser Pro Arg Val Gly Ile Ser Ala Val Ala Leu Arg Thr	
1115 1120 1125	
tcc tcc cgc att ggt ctt tcg gct ccc agt aac tgc atc tca gag	4122
Ser Ser Arg Ile Gly Leu Ser Ala Pro Ser Asn Cys Ile Ser Glu	
1130 1135 1140	
gac gag ggg cag aat cat cag gga cag agc tgt atc cat cgg ccc	4167
Asp Glu Gly Gln Asn His Gln Gly Gln Ser Cys Ile His Arg Pro	
1145 1150 1155	
tgt ggg aag cag gac agc tgt ccg tca ttg ctg ctt gat cat gct	4212
Cys Gly Lys Gln Asp Ser Cys Pro Ser Leu Leu Leu Asp His Ala	
1160 1165 1170	
gat gtg gtg aac tgt acc tct ata ggc cca ggt ctc atg aag tgt	4257
Asp Val Val Asn Cys Thr Ser Ile Gly Pro Gly Leu Met Lys Cys	
1175 1180 1185	
gct atc act tgt caa agg gga ttt gcc ctt cag gcc agc agt ggg	4302
Ala Ile Thr Cys Gln Arg Gly Phe Ala Leu Gln Ala Ser Ser Gly	
1190 1195 1200	
cag tac atc agg ccc atg cag aag gaa att ctg ctc aca tgt tct	4347
Gln Tyr Ile Arg Pro Met Gln Lys Glu Ile Leu Leu Thr Cys Ser	
1205 1210 1215	
tct ggg cac tgg gac cag aat gtg agc tgc ctt ccc gtg gac tgc	4392
Ser Gly His Trp Asp Gln Asn Val Ser Cys Leu Pro Val Asp Cys	
1220 1225 1230	
ggt gtt ccc gac ccg tct ttg gtg aac tat gca aac ttc tcc tgc	4437
Gly Val Pro Asp Pro Ser Leu Val Asn Tyr Ala Asn Phe Ser Cys	
1235 1240 1245	
tca gag gga acc aaa ttt ctg aaa cgc tgc tca atc tct tgt gtc	4482
Ser Glu Gly Thr Lys Phe Leu Lys Arg Cys Ser Ile Ser Cys Val	
1250 1255 1260	
cca cca gcc aag ctg caa gga ctg agc cca tgg ctg aca tgt ctt	4527
Pro Pro Ala Lys Leu Gln Gly Leu Ser Pro Trp Leu Thr Cys Leu	
1265 1270 1275	
gaa gat ggt ctc tgg tct ctc cct gaa gtc tac tgc aag ttg gag	4572
Glu Asp Gly Leu Trp Ser Leu Pro Glu Val Tyr Cys Lys Leu Glu	
1280 1285 1290	

-continued

tgt gat gct ccc cct att att ctg aat gcc aac ttg ctc ctg cct Cys Asp Ala Pro Pro Ile Ile Leu Asn Ala Asn Leu Leu Leu Pro 1295 1300 1305	4617
cac tgc ctc cag gac aac cac gac gtg ggc acc atc tgc aaa tat His Cys Leu Gln Asp Asn His Asp Val Gly Thr Ile Cys Lys Tyr 1310 1315 1320	4662
gaa tgc aaa cca ggg tac tat gtg gca gaa agt gca gag ggt aaa Glu Cys Lys Pro Gly Tyr Tyr Val Ala Glu Ser Ala Glu Gly Lys 1325 1330 1335	4707
gtc agg aac aag ctc ctg aag ata caa tgc ctg gaa ggt gga atc Val Arg Asn Lys Leu Leu Lys Ile Gln Cys Leu Glu Gly Gly Ile 1340 1345 1350	4752
tgg gag caa ggc agc tgc att cct gtg gtg tgt gag cca ccc cct Trp Glu Gln Gly Ser Cys Ile Pro Val Val Cys Glu Pro Pro Pro 1355 1360 1365	4797
cct gtg ttt gaa ggc atg tat gaa tgt acc aat ggc ttc agc ctg Pro Val Phe Glu Gly Met Tyr Glu Cys Thr Asn Gly Phe Ser Leu 1370 1375 1380	4842
gac agc cag tgt gtg ctc aac tgt aac cag gaa cgt gaa aag ctt Asp Ser Gln Cys Val Leu Asn Cys Asn Gln Glu Arg Glu Lys Leu 1385 1390 1395	4887
ccc atc ctc tgc act aaa gag ggc ctg tgg acc cag gag ttt aag Pro Ile Leu Cys Thr Lys Glu Gly Leu Trp Thr Gln Glu Phe Lys 1400 1405 1410	4932
ttg tgt gag aat ctg caa gga gaa tgc cca cca ccc ccc tca gag Leu Cys Glu Asn Leu Gln Gly Glu Cys Pro Pro Pro Pro Ser Glu 1415 1420 1425	4977
ctg aat tct gtg gag tac aaa tgt gaa caa gga tat ggg att ggt Leu Asn Ser Val Glu Tyr Lys Cys Glu Gln Gly Tyr Gly Ile Gly 1430 1435 1440	5022
gca gtg tgt tcc cca ttg tgt gta atc ccc ccc agt gac ccc gtg Ala Val Cys Ser Pro Leu Cys Val Ile Pro Pro Ser Asp Pro Val 1445 1450 1455	5067
atg cta cct gag aat atc act gct gac act ctg gag cac tgg atg Met Leu Pro Glu Asn Ile Thr Ala Asp Thr Leu Glu His Trp Met 1460 1465 1470	5112
gaa cct gtc aaa gtc cag agc att gtg tgc act ggc cgg cgt caa Glu Pro Val Lys Val Gln Ser Ile Val Cys Thr Gly Arg Arg Gln 1475 1480 1485	5157
tgg cac cca gac ccc gtc tta gtc cac tgc atc cag tca tgt gag Trp His Pro Asp Pro Val Leu Val His Cys Ile Gln Ser Cys Glu 1490 1495 1500	5202
ccc ttc caa gca gat ggt tgg tgt gac act atc aac aac cga gcc Pro Phe Gln Ala Asp Gly Trp Cys Asp Thr Ile Asn Asn Arg Ala 1505 1510 1515	5247
tac tgc cac tat gac ggg gga gac tgc tgc tct tcc aca ctc tcc Tyr Cys His Tyr Asp Gly Gly Asp Cys Cys Ser Ser Thr Leu Ser 1520 1525 1530	5292
tcc aag aag gtc att cca ttt gct gct gac tgt gac ctg gat gag Ser Lys Lys Val Ile Pro Phe Ala Ala Asp Cys Asp Leu Asp Glu 1535 1540 1545	5337
tgc acc tgc cgg gac ccc aag gca gaa gaa aat cag taactgtggg Cys Thr Cys Arg Asp Pro Lys Ala Glu Glu Asn Gln 1550 1555	5383
aacaagcccc tcctccact gcctcagagg cagtaagaaa gagaggccga cccaggagga	5443
aacaaagggt gaatgaagaa gaacaatcat gaaatggaag aaggaggaag agcatgaagg	5503

-continued

---

atcttataag	aaatgcaaga	ggatattgat	agggtggaac	tagttcatca	agtagcccaa	5563
gtaggagaga	atcatagca	aaagtttctt	taaagtggca	gttgattaac	atggaagggg	5623
aaatatgata	gatatataag	gaccctctct	cctcacttat	attctattaa	atcctatcct	5683
caactcttgc	cctgctctcc	gtcccaccc	ctgccaacta	ctcagtccca	cccaacttgt	5743
aaaccaatac	caaaatacta	gaggagaagt	tggcagggat	actgttaata	cccattttga	5803
atggattgcc	atctttcaga	gcttgtctgc	tctcaactgg	ctctttttct	ttttgtgtag	5863
tttcccttaa	ataatgaagt	tagttattaa	ttctttataa	gtatttaaac	ataattatat	5923
aaatatatta	tatatattat	attttttgct	gtttactaag	ctaaaaatta	ttcattgttc	5983
cacacatgct	gctgtgaagt	tcacattcaa	gatgaatgtt	gagactttga	ggacagaaag	6043
gcaacttatt	ttcccatctt	tctatggatg	cggattggca	ggttgaatgg	gaagtacaga	6103
aggagagaga	gtaattagat	ggaattctgg	atgctagcat	gtaaagctaa	tcactctttt	6163
ttttatgacc	tgggagctgg	gcccatttta	tgaccaagga	gatggggagt	tggaatggtg	6223
gtactaagag	gcataggaag	ttgagtgtga	ataccattgg	tgatgggtcc	aggagaacta	6283
gactatgggt	cttgaatata	tgtccacaaa	gaatatacta	acttttgtca	acttctcaga	6343
actccaact	ggagtcggtg	agacctagga	ttttctgcac	ttccacacat	gctgtttcca	6403
agtgtggctg	tcagccagct	aacaagtttg	tactatggcc	cattctctga	tcaccaggat	6463
tacaggaact	cacacactcc	tcatacttgg	cctgtagtcc	tacttcttgt	tagaagtctc	6523
caagtctggc	cagtcacatg	accaagtgtt	gatttttctg	gaggaaaaat	tttatggaaa	6583
tgatataggg	gaaaggtggg	aggagatgaa	agaacaggca	agagctgtca	gggttaaatac	6643
caggcccggg	catgagaatg	gaagtgatca	gggagactcg	gtccttgttc	caagtctcca	6703
aagaagacca	aagtgggtcc	cttgagcaat	gaagaatctg	agataaattc	tcttcaagta	6763
tcatgtacaa	aatctgtgag	ccagagattt	tgacttgagc	aagccatgga	aatgcatgga	6823
gcaaggggtga	cactctgtgg	ggagacagaa	gaatttcaac	tatttaatgt	ccattttgtt	6883
gtttttacco	tttcttatcc	aatagatgga	atgcacatga	aatgaccata	ttaagcctct	6943
ctctatttac	atcccaggct	cactgggatg	tgatctactg	cagttacatt	ttcttgtaac	7003
ggtttctgga	ttagacccta	gggaaagtga	gtaaggagcc	agtttctggt	taacattcta	7063
gttttactca	ttttaggaag	gctgtgagtg	aggcttgtct	cctttaaagt	ttcttctcca	7123
atggaaacca	agaacagaca	aaatttagag	ctcagctgtg	gtctcttctc	atcttctgct	7183
cttttgcttt	gaccacagtt	tttctactct	tcccatcaac	actagagcaa	tggtgtgca	7243
aataggaata	ggaaatacta	ccacaatgat	agaaatatta	tccacactat	cacgtaggga	7303
agaacaatat	cctgaaagag	aataaaacac	gaataaggtg	atgtaccacc	attaatctgt	7363
gggtttgtgg	aatgaggggt	gcaaagttat	tgggaaaagg	aaagagcaga	gttcacccat	7423
tcaaaaaaaaa	ccttttctct	actaatctct	agtgtaaaga	aaatgtagtt	cagataccat	7483
tcattgtctt	gggtcatgct	tagtgcccc	aagaagacaa	acatatttat	tcttgggatt	7543
ctgataggct	tcaatatgca	aaggacaatg	gaaaagttta	gacactctat	tttcaaaatt	7603
ttataaactt	gttttattgg	ggaaaatgtc	caaattgcta	gacacattct	aagttctgcc	7663
ttggagaato	ctactttgtc	tgagattgag	gcagaggaat	tgttatctctg	ggcattactc	7723
agctcaggaa	catggagcct	gtggttcatg	ccagtgtgtg	tcttcatgca	gtctctccac	7783

-continued

---

```

aagagcaaca gtaagaacat ttctgtttta aatttcattt taaaatattt tattatctgc 7843
aattcaccac tgctctggga aagcaaaagg aaagttctcg ttgtgtgtga agagcctctt 7903
aggctataag gcttcccagc catagtcagc tatagctatt cagagacagc aggttcttcc 7963
agtctttggt cctgggacct gatgttttga gcaactcagg tcaactgataa agtggaaagga 8023
ctaagacact gtggtcacag atcccagcaa catcaactca cactcaatcc atgtggtggt 8083
ccacattctg ctactcttat ccaccatgt ggtcattgag agcctttctc agagactctt 8143
ctgtgtgttt gattgtgccc aggtggccca gggctagctg gctctaacaa ctatgatgac 8203
agcctccaat cagaaaagca ggtaagggga cagggtgagg agaatgggca gatactgaca 8263
gaaattaaag taaagggatt gtgaaagtaa agagctcttc ctgattctca tcttctcttt 8323
tttctattac aaggcattga acttggcact tctgtattc ttgtgatca ctattgagtg 8383
cattagttaa cacccaaggg gatggcttga ttgggaatgt agtgaagga gctgatctac 8443
tgtattgtaa tgtaaaacag ctacagccag ttattttgta agattataag ttgttcatta 8503
aaaaatcagc acacaaaata tga 8527
    
```

```

<210> SEQ ID NO 2
<211> LENGTH: 1791
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1)..(66)
<223> OTHER INFORMATION: prepro part of PAPP-A2
<221> NAME/KEY: misc_feature
<222> LOCATION: (67)..(699)
<223> OTHER INFORMATION: pro part of PAPP-A2
    
```

<400> SEQUENCE: 2

```

Met Met Cys Leu Lys Ile Leu Arg Ile Ser Leu Ala Ile Leu Ala
-230 -225 -220
Gly Trp Ala Leu Cys Ser Ala Asn Ser Glu Leu Gly Trp Thr Arg
-215 -210 -205
Lys Lys Ser Leu Val Glu Arg Glu His Leu Asn Gln Val Leu Leu
-200 -195 -190
Glu Gly Glu Arg Cys Trp Leu Gly Ala Lys Val Arg Arg Pro Arg
-185 -180 -175
Ala Ser Pro Gln His His Leu Phe Gly Val Tyr Pro Ser Arg Ala
-170 -165 -160
Gly Asn Tyr Leu Arg Pro Tyr Pro Val Gly Glu Gln Glu Ile His
-155 -150 -145
His Thr Gly Arg Ser Lys Pro Asp Thr Glu Gly Asn Ala Val Ser
-140 -135 -130
Leu Val Pro Pro Asp Leu Thr Glu Asn Pro Ala Gly Leu Arg Gly
-125 -120 -115
Ala Val Glu Glu Pro Ala Ala Pro Trp Val Gly Asp Ser Pro Ile
-110 -105 -100
Gly Gln Ser Glu Leu Leu Gly Asp Asp Ala Tyr Leu Gly Asn Gln
-95 -90 -85
Arg Ser Lys Glu Ser Leu Gly Glu Ala Gly Ile Gln Lys Gly Ser Ala
-80 -75 -70
Met Ala Ala Thr Thr Thr Thr Ala Ile Phe Thr Thr Leu Asn Glu Pro
-65 -60 -55
    
```

-continued

---

Lys Pro Glu Thr Gln Arg Arg Gly Trp Ala Lys Ser Arg Gln Arg Arg  
 -50 -45 -40 -35  
 Gln Val Trp Lys Arg Arg Ala Glu Asp Gly Gln Gly Asp Ser Gly Ile  
 -30 -25 -20  
 Ser Ser His Phe Gln Pro Trp Pro Lys His Ser Leu Lys His Arg Val  
 -15 -10 -5  
 Lys Lys Ser Pro Pro Glu Glu Ser Asn Gln Asn Gly Gly Glu Gly Ser  
 -1 1 5 10  
 Tyr Arg Glu Ala Glu Thr Phe Asn Ser Gln Val Gly Leu Pro Ile Leu  
 15 20 25 30  
 Tyr Phe Ser Gly Arg Arg Glu Arg Leu Leu Leu Arg Pro Glu Val Leu  
 35 40 45  
 Ala Glu Ile Pro Arg Glu Ala Phe Thr Val Glu Ala Trp Val Lys Pro  
 50 55 60  
 Glu Gly Gly Gln Asn Asn Pro Ala Ile Ile Ala Gly Val Phe Asp Asn  
 65 70 75  
 Cys Ser His Thr Val Ser Asp Lys Gly Trp Ala Leu Gly Ile Arg Ser  
 80 85 90  
 Gly Lys Asp Lys Gly Lys Arg Asp Ala Arg Phe Phe Phe Ser Leu Cys  
 95 100 105 110  
 Thr Asp Arg Val Lys Lys Ala Thr Ile Leu Ile Ser His Ser Arg Tyr  
 115 120 125  
 Gln Pro Gly Thr Trp Thr His Val Ala Ala Thr Tyr Asp Gly Arg His  
 130 135 140  
 Met Ala Leu Tyr Val Asp Gly Thr Gln Val Ala Ser Ser Leu Asp Gln  
 145 150 155  
 Ser Gly Pro Leu Asn Ser Pro Phe Met Ala Ser Cys Arg Ser Leu Leu  
 160 165 170  
 Leu Gly Gly Asp Ser Ser Glu Asp Gly His Tyr Phe Arg Gly His Leu  
 175 180 185 190  
 Gly Thr Leu Val Phe Trp Ser Thr Ala Leu Pro Gln Ser His Phe Gln  
 195 200 205  
 His Ser Ser Gln His Ser Ser Gly Glu Glu Glu Ala Thr Asp Leu Val  
 210 215 220  
 Leu Thr Ala Ser Phe Glu Pro Val Asn Thr Glu Trp Val Pro Phe Arg  
 225 230 235  
 Asp Glu Lys Tyr Pro Arg Leu Glu Val Leu Gln Gly Phe Glu Pro Glu  
 240 245 250  
 Pro Glu Ile Leu Ser Pro Leu Gln Pro Pro Leu Cys Gly Gln Thr Val  
 255 260 265 270  
 Cys Asp Asn Val Glu Leu Ile Ser Gln Tyr Asn Gly Tyr Trp Pro Leu  
 275 280 285  
 Arg Gly Glu Lys Val Ile Arg Tyr Gln Val Val Asn Ile Cys Asp Asp  
 290 295 300  
 Glu Gly Leu Asn Pro Ile Val Ser Glu Glu Gln Ile Arg Leu Gln His  
 305 310 315  
 Glu Ala Leu Asn Glu Ala Phe Ser Arg Tyr Asn Ile Ser Trp Gln Leu  
 320 325 330  
 Ser Val His Gln Val His Asn Ser Thr Leu Arg His Arg Val Val Leu  
 335 340 345 350

-continued

---

Val	Asn	Cys	Glu	Pro	Ser	Lys	Ile	Gly	Asn	Asp	His	Cys	Asp	Pro	Glu
				355					360					365	
Cys	Glu	His	Pro	Leu	Thr	Gly	Tyr	Asp	Gly	Gly	Asp	Cys	Arg	Leu	Gln
			370					375					380		
Gly	Arg	Cys	Tyr	Ser	Trp	Asn	Arg	Arg	Asp	Gly	Leu	Cys	His	Val	Glu
		385					390					395			
Cys	Asn	Asn	Met	Leu	Asn	Asp	Phe	Asp	Asp	Gly	Asp	Cys	Cys	Asp	Pro
	400					405					410				
Gln	Val	Ala	Asp	Val	Arg	Lys	Thr	Cys	Phe	Asp	Pro	Asp	Ser	Pro	Lys
415					420					425					430
Arg	Ala	Tyr	Met	Ser	Val	Lys	Glu	Leu	Lys	Glu	Ala	Leu	Gln	Leu	Asn
			435						440					445	
Ser	Thr	His	Phe	Leu	Asn	Ile	Tyr	Phe	Ala	Ser	Ser	Val	Arg	Glu	Asp
			450					455						460	
Leu	Ala	Gly	Ala	Ala	Thr	Trp	Pro	Trp	Asp	Lys	Asp	Ala	Val	Thr	His
		465					470						475		
Leu	Gly	Ile	Val	Leu	Ser	Pro	Ala	Tyr	Tyr	Gly	Met	Pro	Gly	His	
	480				485					490					
Thr	Asp	Thr	Met	Ile	His	Glu	Val	Gly	His	Val	Leu	Gly	Leu	Tyr	His
495					500					505					510
Val	Phe	Lys	Gly	Val	Ser	Glu	Arg	Glu	Ser	Cys	Asn	Asp	Pro	Cys	Lys
				515					520					525	
Glu	Thr	Val	Pro	Ser	Met	Glu	Thr	Gly	Asp	Leu	Cys	Ala	Asp	Thr	Ala
			530						535					540	
Pro	Thr	Pro	Lys	Ser	Glu	Leu	Cys	Arg	Glu	Pro	Glu	Pro	Thr	Ser	Asp
		545					550						555		
Thr	Cys	Gly	Phe	Thr	Arg	Phe	Pro	Gly	Ala	Pro	Phe	Thr	Asn	Tyr	Met
	560					565						570			
Ser	Tyr	Thr	Asp	Asp	Asn	Cys	Thr	Asp	Asn	Phe	Thr	Pro	Asn	Gln	Val
575					580					585					590
Ala	Arg	Met	His	Cys	Tyr	Leu	Asp	Leu	Val	Tyr	Gln	Gln	Trp	Thr	Glu
				595					600					605	
Ser	Arg	Lys	Pro	Thr	Pro	Ile	Pro	Ile	Pro	Pro	Met	Val	Ile	Gly	Gln
			610					615					620		
Thr	Asn	Lys	Ser	Leu	Thr	Ile	His	Trp	Leu	Pro	Pro	Ile	Ser	Gly	Val
	625					630							635		
Val	Tyr	Asp	Arg	Ala	Ser	Gly	Ser	Leu	Cys	Gly	Ala	Cys	Thr	Glu	Asp
	640					645					650				
Gly	Thr	Phe	Arg	Gln	Tyr	Val	His	Thr	Ala	Ser	Ser	Arg	Arg	Val	Cys
655					660					665					670
Asp	Ser	Ser	Gly	Tyr	Trp	Thr	Pro	Glu	Glu	Ala	Val	Gly	Pro	Pro	Asp
				675					680					685	
Val	Asp	Gln	Pro	Cys	Glu	Pro	Ser	Leu	Gln	Ala	Trp	Ser	Pro	Glu	Val
			690						695					700	
His	Leu	Tyr	His	Met	Asn	Met	Thr	Val	Pro	Cys	Pro	Thr	Glu	Gly	Cys
		705					710						715		
Ser	Leu	Glu	Leu	Leu	Phe	Gln	His	Pro	Val	Gln	Ala	Asp	Thr	Leu	Thr
	720					725					730				
Leu	Trp	Val	Thr	Ser	Phe	Phe	Met	Glu	Ser	Ser	Gln	Val	Leu	Phe	Asp
735					740					745					750
Thr	Glu	Ile	Leu	Leu	Glu	Asn	Lys	Glu	Ser	Val	His	Leu	Gly	Pro	Leu

-continued

755				760				765							
Asp	Thr	Phe	Cys	Asp	Ile	Pro	Leu	Thr	Ile	Lys	Leu	His	Val	Asp	Gly
			770								775				780
Lys	Val	Ser	Gly	Val	Lys	Val	Tyr	Thr	Phe	Asp	Glu	Arg	Ile	Glu	Ile
			785				790								795
Asp	Ala	Ala	Leu	Leu	Thr	Ser	Gln	Pro	His	Ser	Pro	Leu	Cys	Ser	Gly
	800						805								810
Cys	Arg	Pro	Val	Arg	Tyr	Gln	Val	Leu	Arg	Asp	Pro	Pro	Phe	Ala	Ser
	815						820								830
Gly	Leu	Pro	Val	Val	Val	Thr	His	Ser	His	Arg	Lys	Phe	Thr	Asp	Val
															845
Glu	Val	Thr	Pro	Gly	Gln	Met	Tyr	Gln	Tyr	Gln	Val	Leu	Ala	Glu	Ala
															860
Gly	Gly	Glu	Leu	Gly	Glu	Ala	Ser	Pro	Pro	Leu	Asn	His	Ile	His	Gly
			865				870								875
Ala	Pro	Tyr	Cys	Gly	Asp	Gly	Lys	Val	Ser	Glu	Arg	Leu	Gly	Glu	Glu
							885								890
Cys	Asp	Asp	Gly	Asp	Leu	Val	Ser	Gly	Asp	Gly	Cys	Ser	Lys	Val	Cys
	895						900								910
Glu	Leu	Glu	Glu	Gly	Phe	Asn	Cys	Val	Gly	Glu	Pro	Ser	Leu	Cys	Tyr
															925
Met	Tyr	Glu	Gly	Asp	Gly	Ile	Cys	Glu	Pro	Phe	Glu	Arg	Lys	Thr	Ser
			930												940
Ile	Val	Asp	Cys	Gly	Ile	Tyr	Thr	Pro	Lys	Gly	Tyr	Leu	Asp	Gln	Trp
			945												955
Ala	Thr	Arg	Ala	Tyr	Ser	Ser	His	Glu	Asp	Lys	Lys	Lys	Cys	Pro	Val
							965								970
Ser	Leu	Val	Thr	Gly	Glu	Pro	His	Ser	Leu	Ile	Cys	Thr	Ser	Tyr	His
							980								990
Pro	Asp	Leu	Pro	Asn	His	Arg	Pro	Leu	Thr	Gly	Trp	Phe	Pro	Cys	Val
															1005
Ala	Ser	Glu	Asn	Glu	Thr	Gln	Asp	Asp	Arg	Ser	Glu	Gln	Pro	Glu	
			1010												1020
Gly	Ser	Leu	Lys	Lys	Glu	Asp	Glu	Val	Trp	Leu	Lys	Val	Cys	Phe	
			1025												1035
Asn	Arg	Pro	Gly	Glu	Ala	Arg	Ala	Ile	Phe	Ile	Phe	Leu	Thr	Thr	
			1040												1050
Asp	Gly	Leu	Val	Pro	Gly	Glu	His	Gln	Gln	Pro	Thr	Val	Thr	Leu	
			1055												1065
Tyr	Leu	Thr	Asp	Val	Arg	Gly	Ser	Asn	His	Ser	Leu	Gly	Thr	Tyr	
			1070												1080
Gly	Leu	Ser	Cys	Gln	His	Asn	Pro	Leu	Ile	Ile	Asn	Val	Thr	His	
			1085												1095
His	Gln	Asn	Val	Leu	Phe	His	His	Thr	Thr	Ser	Val	Leu	Leu	Asn	
			1100												1110
Phe	Ser	Ser	Pro	Arg	Val	Gly	Ile	Ser	Ala	Val	Ala	Leu	Arg	Thr	
			1115												1125
Ser	Ser	Arg	Ile	Gly	Leu	Ser	Ala	Pro	Ser	Asn	Cys	Ile	Ser	Glu	
			1130												1140
Asp	Glu	Gly	Gln	Asn	His	Gln	Gly	Gln	Ser	Cys	Ile	His	Arg	Pro	
			1145												1155

-continued

---

Cys	Gly	Lys	Gln	Asp	Ser	Cys	Pro	Ser	Leu	Leu	Leu	Asp	His	Ala
			1160					1165					1170	
Asp	Val	Val	Asn	Cys	Thr	Ser	Ile	Gly	Pro	Gly	Leu	Met	Lys	Cys
			1175					1180					1185	
Ala	Ile	Thr	Cys	Gln	Arg	Gly	Phe	Ala	Leu	Gln	Ala	Ser	Ser	Gly
			1190					1195					1200	
Gln	Tyr	Ile	Arg	Pro	Met	Gln	Lys	Glu	Ile	Leu	Leu	Thr	Cys	Ser
			1205					1210					1215	
Ser	Gly	His	Trp	Asp	Gln	Asn	Val	Ser	Cys	Leu	Pro	Val	Asp	Cys
			1220					1225					1230	
Gly	Val	Pro	Asp	Pro	Ser	Leu	Val	Asn	Tyr	Ala	Asn	Phe	Ser	Cys
			1235					1240					1245	
Ser	Glu	Gly	Thr	Lys	Phe	Leu	Lys	Arg	Cys	Ser	Ile	Ser	Cys	Val
			1250					1255					1260	
Pro	Pro	Ala	Lys	Leu	Gln	Gly	Leu	Ser	Pro	Trp	Leu	Thr	Cys	Leu
			1265					1270					1275	
Glu	Asp	Gly	Leu	Trp	Ser	Leu	Pro	Glu	Val	Tyr	Cys	Lys	Leu	Glu
			1280					1285					1290	
Cys	Asp	Ala	Pro	Pro	Ile	Ile	Leu	Asn	Ala	Asn	Leu	Leu	Leu	Pro
			1295					1300					1305	
His	Cys	Leu	Gln	Asp	Asn	His	Asp	Val	Gly	Thr	Ile	Cys	Lys	Tyr
			1310					1315					1320	
Glu	Cys	Lys	Pro	Gly	Tyr	Tyr	Val	Ala	Glu	Ser	Ala	Glu	Gly	Lys
			1325					1330					1335	
Val	Arg	Asn	Lys	Leu	Leu	Lys	Ile	Gln	Cys	Leu	Glu	Gly	Gly	Ile
			1340					1345					1350	
Trp	Glu	Gln	Gly	Ser	Cys	Ile	Pro	Val	Val	Cys	Glu	Pro	Pro	Pro
			1355					1360					1365	
Pro	Val	Phe	Glu	Gly	Met	Tyr	Glu	Cys	Thr	Asn	Gly	Phe	Ser	Leu
			1370					1375					1380	
Asp	Ser	Gln	Cys	Val	Leu	Asn	Cys	Asn	Gln	Glu	Arg	Glu	Lys	Leu
			1385					1390					1395	
Pro	Ile	Leu	Cys	Thr	Lys	Glu	Gly	Leu	Trp	Thr	Gln	Glu	Phe	Lys
			1400					1405					1410	
Leu	Cys	Glu	Asn	Leu	Gln	Gly	Glu	Cys	Pro	Pro	Pro	Pro	Ser	Glu
			1415					1420					1425	
Leu	Asn	Ser	Val	Glu	Tyr	Lys	Cys	Glu	Gln	Gly	Tyr	Gly	Ile	Gly
			1430					1435					1440	
Ala	Val	Cys	Ser	Pro	Leu	Cys	Val	Ile	Pro	Pro	Ser	Asp	Pro	Val
			1445					1450					1455	
Met	Leu	Pro	Glu	Asn	Ile	Thr	Ala	Asp	Thr	Leu	Glu	His	Trp	Met
			1460					1465					1470	
Glu	Pro	Val	Lys	Val	Gln	Ser	Ile	Val	Cys	Thr	Gly	Arg	Arg	Gln
			1475					1480					1485	
Trp	His	Pro	Asp	Pro	Val	Leu	Val	His	Cys	Ile	Gln	Ser	Cys	Glu
			1490					1495					1500	
Pro	Phe	Gln	Ala	Asp	Gly	Trp	Cys	Asp	Thr	Ile	Asn	Asn	Arg	Ala
			1505					1510					1515	
Tyr	Cys	His	Tyr	Asp	Gly	Gly	Asp	Cys	Cys	Ser	Ser	Thr	Leu	Ser
			1520					1525					1530	

-continued

Ser Lys Lys Val Ile Pro Phe Ala Ala Asp Cys Asp Leu Asp Glu  
 1535 1540 1545

Cys Thr Cys Arg Asp Pro Lys Ala Glu Glu Asn Gln  
 1550 1555

<210> SEQ ID NO 3  
 <211> LENGTH: 11  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: zinc binding motif  
 <221> NAME/KEY: misc\_feature  
 <222> LOCATION: (3)..(3)  
 <223> OTHER INFORMATION: Xaa is any amino acid  
 <221> NAME/KEY: misc\_feature  
 <222> LOCATION: (4)..(4)  
 <223> OTHER INFORMATION: Xaa is any amino acid  
 <221> NAME/KEY: misc\_feature  
 <222> LOCATION: (6)..(6)  
 <223> OTHER INFORMATION: Xaa is any amino acid  
 <221> NAME/KEY: misc\_feature  
 <222> LOCATION: (7)..(7)  
 <223> OTHER INFORMATION: Xaa is any amino acid  
 <221> NAME/KEY: misc\_feature  
 <222> LOCATION: (9)..(9)  
 <223> OTHER INFORMATION: Xaa is any amino acid  
 <221> NAME/KEY: misc\_feature  
 <222> LOCATION: (10)..(10)  
 <223> OTHER INFORMATION: Xaa is any amino acid  
 <400> SEQUENCE: 3

His Glu Xaa Xaa His Xaa Xaa Gly Xaa Xaa His  
 1 5 10

<210> SEQ ID NO 4  
 <211> LENGTH: 20  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: primer RT-N-mid  
 <400> SEQUENCE: 4

gctcacacac cacaggaatg 20

<210> SEQ ID NO 5  
 <211> LENGTH: 20  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: primer PR-mid5  
 <400> SEQUENCE: 5

gctcacacac cacaggaatg 20

<210> SEQ ID NO 6  
 <211> LENGTH: 22  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial Sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: primer PR-mid3  
 <400> SEQUENCE: 6

gcattgtatc ttcaggagct tg 22

<210> SEQ ID NO 7  
 <211> LENGTH: 23

-continued

---

<212> TYPE: DNA  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: primer PR-N5  
  
<400> SEQUENCE: 7  
  
gaagttgact tctggttctg tag 23

<210> SEQ ID NO 8  
<211> LENGTH: 21  
<212> TYPE: DNA  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: primer PR-N3  
  
<400> SEQUENCE: 8  
  
ccctgggaag cgagtgaagc c 21

<210> SEQ ID NO 9  
<211> LENGTH: 25  
<212> TYPE: DNA  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: primer RT-C  
  
<400> SEQUENCE: 9  
  
gcatttctta taagatcctt catgc 25

<210> SEQ ID NO 10  
<211> LENGTH: 22  
<212> TYPE: DNA  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: primer PR-C5  
  
<400> SEQUENCE: 10  
  
gacagctgtc cgtcattgct gc 22

<210> SEQ ID NO 11  
<211> LENGTH: 22  
<212> TYPE: DNA  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: primer PR-C3  
  
<400> SEQUENCE: 11  
  
cttactgcct ctgaggcagt gg 22

<210> SEQ ID NO 12  
<211> LENGTH: 22  
<212> TYPE: DNA  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: primer from AL031290, nt. 64900-64879  
  
<400> SEQUENCE: 12  
  
ggaaagagca gagttcaccc at 22

<210> SEQ ID NO 13  
<211> LENGTH: 21  
<212> TYPE: DNA  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: primer from AL031290, nt. 20499-20519

---

-continued

---

<400> SEQUENCE: 13  
ccgtcttagt ccaactgcatc c 21

<210> SEQ ID NO 14  
<211> LENGTH: 20  
<212> TYPE: DNA  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: primer from vector pcDNA3.1+, nt. 1040-1021

<400> SEQUENCE: 14  
ctagaaggca cagtcgaggc 20

<210> SEQ ID NO 15  
<211> LENGTH: 33  
<212> TYPE: DNA  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: primer from SEQ ID NO:1, nt. 2210-2178

<400> SEQUENCE: 15  
tgtcccactt gatggatcat ggtgtcgggtg tgg 33

<210> SEQ ID NO 16  
<211> LENGTH: 26  
<212> TYPE: DNA  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: primer from SEQ ID NO:1, nt. 2196-2221

<400> SEQUENCE: 16  
ccatcaagtg ggacatgttc tgggac 26

<210> SEQ ID NO 17  
<211> LENGTH: 32  
<212> TYPE: DNA  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: primer from SEQ ID NO:1, nt. 5373-5354

<400> SEQUENCE: 17  
gacgtaaagc ttctgatttt cttctgcctt gg 32

<210> SEQ ID NO 18  
<211> LENGTH: 4  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: synthetic linker in pPA2-mH

<400> SEQUENCE: 18  
Lys Leu Gly Pro  
1

<210> SEQ ID NO 19  
<211> LENGTH: 10  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: synthetic myc epitope in pPA2-mH

<400> SEQUENCE: 19

-continued

---

Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu  
1                    5                    10

<210> SEQ ID NO 20  
<211> LENGTH: 5  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: synthetic linker in pPA2-mH  
  
<400> SEQUENCE: 20

Asn Ser Ala Val Asp  
1                    5

<210> SEQ ID NO 21  
<211> LENGTH: 30  
<212> TYPE: DNA  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: primer containing XhoI site, for amplifying  
IGFBP-5 cDNA  
  
<400> SEQUENCE: 21

tccgctcgag atggtgttgc tcaccgcggt 30

<210> SEQ ID NO 22  
<211> LENGTH: 29  
<212> TYPE: DNA  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: primer containing HindIII site, for amplifying  
IGFBP-5 cDNA  
  
<400> SEQUENCE: 22

cgataagctt ctcaacgttg ctgctgtcg 29

<210> SEQ ID NO 23  
<211> LENGTH: 6  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: N-terminal sequence of degradation product of  
purified rIGFBP-5 digested with PAPP-A2  
  
<400> SEQUENCE: 23

Lys Phe Val Gly Gly Ala  
1                    5

<210> SEQ ID NO 24  
<211> LENGTH: 6  
<212> TYPE: PRT  
<213> ORGANISM: Artificial Sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: N-terminal sequence of degradation product of  
purified rIGFBP-5 digested with PAPP-A2  
<221> NAME/KEY: misc\_feature  
<222> LOCATION: (3)..(3)  
<223> OTHER INFORMATION: Xaa is unknown  
  
<400> SEQUENCE: 24

Leu Gly Xaa Phe Val His  
1                    5

<210> SEQ ID NO 25  
<211> LENGTH: 1627

-continued

---

```

<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 25

Met Arg Leu Trp Ser Trp Val Leu His Leu Gly Leu Leu Ser Ala Ala
1           5           10           15

Leu Gly Cys Gly Leu Ala Glu Arg Pro Arg Arg Ala Arg Arg Asp Pro
20           25           30

Arg Ala Gly Arg Pro Pro Arg Pro Ala Ala Gly Pro Ala Thr Cys Ala
35           40           45

Thr Arg Gly Pro Arg Pro Pro Arg Leu Ala Ala Ala Ala Ala Ala
50           55           60

Gly Arg Ala Trp Glu Ala Val Arg Val Pro Arg Arg Arg Gln Gln Arg
65           70           75           80

Glu Ala Arg Gly Ala Thr Glu Glu Pro Ser Pro Pro Ser Arg Ala Leu
85           90           95

Tyr Phe Ser Gly Arg Gly Glu Gln Leu Arg Val Leu Arg Ala Asp Leu
100          105          110

Glu Leu Pro Arg Asp Ala Phe Thr Leu Gln Val Trp Leu Arg Ala Glu
115          120          125

Gly Gly Gln Arg Ser Pro Ala Val Ile Thr Gly Leu Tyr Asp Lys Cys
130          135          140

Ser Tyr Ile Ser Arg Asp Arg Gly Trp Val Val Gly Ile His Thr Ile
145          150          155          160

Ser Asp Gln Asp Asn Lys Asp Pro Arg Tyr Phe Phe Ser Leu Lys Thr
165          170          175

Asp Arg Ala Arg Gln Val Thr Thr Ile Asn Ala His Arg Ser Tyr Leu
180          185          190

Pro Gly Gln Trp Val Tyr Leu Ala Ala Thr Tyr Asp Gly Gln Phe Met
195          200          205

Lys Leu Tyr Val Asn Gly Ala Gln Val Ala Thr Ser Gly Glu Gln Val
210          215          220

Gly Gly Ile Phe Ser Pro Leu Thr Gln Lys Cys Lys Val Leu Met Leu
225          230          235          240

Gly Gly Ser Ala Leu Asn His Asn Tyr Arg Gly Tyr Ile Glu His Phe
245          250          255

Ser Leu Trp Lys Val Ala Arg Thr Gln Arg Glu Ile Leu Ser Asp Met
260          265          270

Glu Thr His Gly Ala His Thr Ala Leu Pro Gln Leu Leu Leu Gln Glu
275          280          285

Asn Trp Asp Asn Val Lys His Ala Trp Ser Pro Met Lys Asp Gly Ser
290          295          300

Ser Pro Lys Val Glu Phe Ser Asn Ala His Gly Phe Leu Leu Asp Thr
305          310          315          320

Ser Leu Glu Pro Pro Leu Cys Gly Gln Thr Leu Cys Asp Asn Thr Glu
325          330          335

Val Ile Ala Ser Tyr Asn Gln Leu Ser Ser Phe Arg Gln Pro Lys Val
340          345          350

Val Arg Tyr Arg Val Val Asn Leu Tyr Glu Asp Asp His Lys Asn Pro
355          360          365

Thr Val Thr Arg Glu Gln Val Asp Phe Gln His His Gln Leu Ala Glu
370          375          380

```

-continued

---

Ala Phe Lys Gln Tyr Asn Ile Ser Trp Glu Leu Asp Val Leu Glu Val  
385 390 395 400

Ser Asn Ser Ser Leu Arg Arg Arg Leu Ile Leu Ala Asn Cys Asp Ile  
405 410 415

Ser Lys Ile Gly Asp Glu Asn Cys Asp Pro Glu Cys Asn His Thr Leu  
420 425 430

Thr Gly His Asp Gly Gly Asp Cys Arg His Leu Arg His Pro Ala Phe  
435 440 445

Val Lys Lys Gln His Asn Gly Val Cys Asp Met Asp Cys Asn Tyr Glu  
450 455 460

Arg Phe Asn Phe Asp Gly Gly Glu Cys Cys Asp Pro Glu Ile Thr Asn  
465 470 475 480

Val Thr Gln Thr Cys Phe Asp Pro Asp Ser Pro His Arg Ala Tyr Leu  
485 490 495

Asp Val Asn Glu Leu Lys Asn Ile Leu Lys Leu Asp Gly Ser Thr His  
500 505 510

Leu Asn Ile Phe Phe Ala Lys Ser Ser Glu Glu Glu Leu Ala Gly Val  
515 520 525

Ala Thr Trp Pro Trp Asp Lys Glu Ala Leu Met His Leu Gly Gly Ile  
530 535 540

Val Leu Asn Pro Ser Phe Tyr Gly Met Pro Gly His Thr His Thr Met  
545 550 555 560

Ile His Glu Ile Gly His Ser Leu Gly Leu Tyr His Val Phe Arg Gly  
565 570 575

Ile Ser Glu Ile Gln Ser Cys Ser Asp Pro Cys Met Glu Thr Glu Pro  
580 585 590

Ser Phe Glu Thr Gly Asp Leu Cys Asn Asp Thr Asn Pro Ala Pro Lys  
595 600 605

His Lys Ser Cys Gly Asp Pro Gly Pro Gly Asn Asp Thr Cys Gly Phe  
610 615 620

His Ser Phe Phe Asn Thr Pro Tyr Asn Asn Phe Met Ser Tyr Ala Asp  
625 630 635 640

Asp Asp Cys Thr Asp Ser Phe Thr Pro Asn Gln Val Ala Arg Met His  
645 650 655

Cys Tyr Leu Asp Leu Val Tyr Gln Gly Trp Gln Pro Ser Arg Lys Pro  
660 665 670

Ala Pro Val Ala Leu Ala Pro Gln Val Leu Gly His Thr Thr Asp Ser  
675 680 685

Val Thr Leu Glu Trp Phe Pro Pro Ile Asp Gly His Phe Phe Glu Arg  
690 695 700

Glu Leu Gly Ser Ala Cys His Leu Cys Leu Glu Gly Arg Ile Leu Val  
705 710 715 720

Gln Tyr Ala Ser Asn Ala Ser Ser Pro Met Pro Cys Ser Pro Ser Gly  
725 730 735

His Trp Ser Pro Arg Glu Ala Glu Gly His Pro Asp Val Glu Gln Pro  
740 745 750

Cys Lys Ser Ser Val Arg Thr Trp Ser Pro Asn Ser Ala Val Asn Pro  
755 760 765

His Thr Val Pro Pro Ala Cys Pro Glu Pro Gln Gly Cys Tyr Leu Glu  
770 775 780

-continued

---

Leu Glu Phe Leu Tyr Pro Leu Val Pro Glu Ser Leu Thr Ile Trp Val  
 785 790 795 800

Thr Phe Val Ser Thr Asp Trp Asp Ser Ser Gly Ala Val Asn Asp Ile  
 805 810 815

Lys Leu Leu Ala Val Ser Gly Lys Asn Ile Ser Leu Gly Pro Gln Asn  
 820 825 830

Val Phe Cys Asp Val Pro Leu Thr Ile Arg Leu Trp Asp Val Gly Glu  
 835 840 845

Glu Val Tyr Gly Ile Gln Ile Tyr Thr Leu Asp Glu His Leu Glu Ile  
 850 855 860

Asp Ala Ala Met Leu Thr Ser Thr Ala Asp Thr Pro Leu Cys Leu Gln  
 865 870 875 880

Cys Lys Pro Leu Lys Tyr Lys Val Val Arg Asp Pro Pro Leu Gln Met  
 885 890 895

Asp Val Ala Ser Ile Leu His Leu Asn Arg Lys Phe Val Asp Met Asp  
 900 905 910

Leu Asn Leu Gly Ser Val Tyr Gln Tyr Trp Val Ile Thr Ile Ser Gly  
 915 920 925

Thr Glu Glu Ser Glu Pro Ser Pro Ala Val Thr Tyr Ile His Gly Arg  
 930 935 940

Gly Tyr Cys Gly Asp Gly Ile Ile Gln Lys Asp Gln Gly Glu Gln Cys  
 945 950 955 960

Asp Asp Met Asn Lys Ile Asn Gly Asp Gly Cys Ser Leu Phe Cys Arg  
 965 970 975

Gln Glu Val Ser Phe Asn Cys Ile Asp Glu Pro Ser Arg Cys Tyr Phe  
 980 985 990

His Asp Gly Asp Gly Val Cys Glu Glu Phe Glu Gln Lys Thr Ser Ile  
 995 1000 1005

Lys Asp Cys Gly Val Tyr Thr Pro Gln Gly Phe Leu Asp Gln Trp  
 1010 1015 1020

Ala Ser Asn Ala Ser Val Ser His Gln Asp Gln Gln Cys Pro Gly  
 1025 1030 1035

Trp Val Ile Ile Gly Gln Pro Ala Ala Ser Gln Val Cys Arg Thr  
 1040 1045 1050

Lys Val Ile Asp Leu Ser Glu Gly Ile Ser Gln His Ala Trp Tyr  
 1055 1060 1065

Pro Cys Thr Ile Ser Tyr Pro Tyr Ser Gln Leu Ala Gln Thr Thr  
 1070 1075 1080

Phe Trp Leu Arg Ala Tyr Phe Ser Gln Pro Met Val Ala Ala Ala  
 1085 1090 1095

Val Ile Val His Leu Val Thr Asp Gly Thr Tyr Tyr Gly Asp Gln  
 1100 1105 1110

Lys Gln Glu Thr Ile Ser Val Gln Leu Leu Asp Thr Lys Asp Gln  
 1115 1120 1125

Ser His Asp Leu Gly Leu His Val Leu Ser Cys Arg Asn Asn Pro  
 1130 1135 1140

Leu Ile Ile Pro Val Val His Asp Leu Ser Gln Pro Phe Tyr His  
 1145 1150 1155

Ser Gln Ala Val Arg Val Ser Phe Ser Ser Pro Leu Val Ala Ile  
 1160 1165 1170

Ser Gly Val Ala Leu Arg Ser Phe Asp Asn Phe Asp Pro Val Thr

-continued

1175	1180	1185
Leu Ser Ser Cys Gln Arg Gly 1190	Glu Thr Tyr Ser 1195	Pro Ala Glu Gln 1200
Ser Cys Val His Phe Ala Cys 1205	Glu Lys Thr Asp 1210	Cys Pro Glu Leu 1215
Ala Val Glu Asn Ala Ser Leu 1220	Asn Cys Ser Ser 1225	Ser Asp Arg Tyr 1230
His Gly Ala Gln Cys Thr Val 1235	Ser Cys Arg Thr 1240	Gly Tyr Val Leu 1245
Gln Ile Arg Arg Asp Asp Glu 1250	Leu Ile Lys Ser 1255	Gln Thr Gly Pro 1260
Ser Val Thr Val Thr Cys Thr 1265	Glu Gly Lys Trp 1270	Asn Lys Gln Val 1275
Ala Cys Glu Pro Val Asp Cys 1280	Ser Ile Pro Asp 1285	His His Gln Val 1290
Tyr Ala Ala Ser Phe Ser Cys 1295	Pro Glu Gly Thr 1300	Thr Phe Gly Ser 1305
Gln Cys Ser Phe Gln Cys Arg 1310	His Pro Ala Gln 1315	Leu Lys Gly Asn 1320
Asn Ser Leu Leu Thr Cys Met 1325	Glu Asp Gly Leu 1330	Trp Ser Phe Pro 1335
Glu Ala Leu Cys Glu Leu Met 1340	Cys Leu Ala Pro 1345	Pro Pro Val Pro 1350
Asn Ala Asp Leu Gln Thr Ala 1355	Arg Cys Arg Glu 1360	Asn Lys His Lys 1365
Val Gly Ser Phe Cys Lys Tyr 1370	Lys Cys Lys Pro 1375	Gly Tyr His Val 1380
Pro Gly Ser Ser Arg Lys Ser 1385	Lys Lys Arg Ala 1390	Phe Lys Thr Gln 1395
Cys Thr Gln Asp Gly Ser Trp 1400	Gln Glu Gly Ala 1405	Cys Val Pro Val 1410
Thr Cys Asp Pro Pro Pro Pro 1415	Lys Phe His Gly 1420	Leu Tyr Gln Cys 1425
Thr Asn Gly Phe Gln Phe Asn 1430	Ser Glu Cys Arg 1435	Ile Lys Cys Glu 1440
Asp Ser Asp Ala Ser Gln Gly 1445	Leu Gly Ser Asn 1450	Val Ile His Cys 1455
Arg Lys Asp Gly Thr Trp Asn 1460	Gly Ser Phe His 1465	Val Cys Gln Glu 1470
Met Gln Gly Gln Cys Ser Val 1475	Pro Asn Glu Leu 1480	Asn Ser Asn Leu 1485
Lys Leu Gln Cys Pro Asp Gly 1490	Tyr Ala Ile Gly 1495	Ser Glu Cys Ala 1500
Thr Ser Cys Leu Asp His Asn 1505	Ser Glu Ser Ile 1510	Ile Leu Pro Met 1515
Asn Val Thr Val Arg Asp Ile 1520	Pro His Trp Leu 1525	Asn Pro Thr Arg 1530
Val Glu Arg Val Val Cys Thr 1535	Ala Gly Leu Lys 1540	Trp Tyr Pro His 1545
Pro Ala Leu Ile His Cys Val 1550	Lys Gly Cys Glu 1555	Pro Phe Met Gly 1560

-continued

---

Asp	Asn	Tyr	Cys	Asp	Ala	Ile	Asn	Asn	Arg	Ala	Phe	Cys	Asn	Tyr
1565						1570					1575			
Asp	Gly	Gly	Asp	Cys	Cys	Thr	Ser	Thr	Val	Lys	Thr	Lys	Lys	Val
1580						1585					1590			
Thr	Pro	Phe	Pro	Met	Ser	Cys	Asp	Leu	Gln	Gly	Asp	Cys	Ala	Cys
1595						1600					1605			
Arg	Asp	Pro	Gln	Ala	Gln	Glu	His	Ser	Arg	Lys	Asp	Leu	Arg	Gly
1610						1615					1620			
Tyr	Ser	His	Gly											
1625														

---

1. A purified polynucleotide selected from the group consisting of
  - i) 2 polynucleotide comprising nucleotides 1 to 5376 of SEQ ID NO:1 corresponding to the coding sequence of PAPP-A2, as deposited with DSMZ under accession number DSM 13783; and
  - ii) a polynucleotide encoding a polypeptide having the amino acid sequence as shown in SEQ ID NO:2; and
  - iii) a polynucleotide encoding a fragment of a polypeptide encoded by polynucleotides (i) or (ii), wherein said fragment
    - a) has a proteolytic activity specific for Insulin Like Growth Factor Binding Protein 5 (IGFBP-5), or a derivative thereof, or any other substrate; and/or
    - b) is recognised by an antibody, or a binding fragment thereof, which is capable of recognising a polypeptide having the amino acid sequence as shown in SEQ ID NO:2; and/or
    - c) competes with a polypeptide having the amino acid sequence as shown in SEQ ID NO:2 for binding to a cell surface receptor having an affinity for said polypeptide; and
  - iv) a polynucleotide, the complementary strand of which hybridizes, under stringent conditions, with a polynucleotide as defined in any of (i), (ii) and (iii), said polynucleotide encoding a polypeptide having the amino acid sequence as shown in SEQ ID NO:2, or a fragment thereof, wherein said fragment
    - a) has a proteolytic activity specific at least for Insulin Like Growth Factor Binding Protein 5 (IGFBP-5), and/or
    - b) is recognised by an antibody, or a binding fragment thereof, which is capable of recognising a polypeptide having the amino acid sequence as shown in SEQ ID NO:2; and/or
    - c) competes with a polypeptide having the amino acid sequence as shown in SEQ ID NO:2 for binding to a cell surface receptor having an affinity for said polypeptide; and
  - v) a polynucleotide comprising a nucleotide sequence which is degenerate to the nucleotide sequence of a polynucleotide as defined in any of (iii) and (iv), and the complementary strand of such a polynucleotide.
2. A purified polynucleotide according to claim 1 and comprising the coding sequence as shown in SEQ ID NO:1.
3. A polynucleotide according to claim 1 and encoding a polypeptide the amino acid sequence as shown in SEQ ID NO:2.
4. A polynucleotide according to claim 1 and encoding a fragment of the polypeptide having the amino acid sequence as shown in SEQ ID NO:2, wherein said fragment
  - a) has a proteolytic activity specific at least for Insulin Like Growth Factor Binding Protein 6 (IGFBP-5); and/or
  - b) is recognised by an antibody, or a binding fragment thereof, which is capable of recognising a polypeptide having the amino acid sequence as shown in SEQ ID NO:2; and/or
  - c) competes with a polypeptide having the amino acid sequence as shown in SEQ ID NO:2 for binding to a cell surface receptor having an affinity for said polypeptide
5. A polynucleotide according to claim 1, wherein the complementary strand of said polynucleotide hybridizes, under stringent conditions, with a polynucleotide according to any of claims 2 to 4.
6. A polynucleotide according to claim 1 and comprising a nucleotide sequence which is degenerate to the nucleotide sequence of a polynucleotide according to any of claims 3 and 4.
7. A polynucleotide according to claim 1, said polynucleotide comprising the complementary strand of a polynucleotide according to any of claims 2 to 6.
8. A polynucleotide according to any of the preceding claims operably linked to a further polynucleotide comprising nucleic acid residues 5377 to 8527 of SEQ ID NO:1, corresponding to a 3' untranslated region, or a fragment thereof, or SEQ ID NO:1.
9. A recombinant DNA molecule in the form of an expression vector comprising an expression signal operably linked to a polynucleotide according to any of claims 1 to 7.
10. A host organism transfected or transformed with the polynucleotide according to any of claims 1 to 8, or the vector according to claim 9.
11. Host organism according to claim 10, wherein said organism is a mammalian organism.

**12.** An isolated polypeptide comprising or essentially consisting of the amino acid sequence of SEQ ID NO:2, or a fragment thereof, wherein said fragment

- i) has a proteolytic activity specific at least for Insulin Like Growth Factor Binding Protein 5 (IGFBP-5); and/or
- ii) is recognised by an antibody, or a binding fragment thereof, which is capable of recognising a polypeptide having the amino acid sequence as shown in SEQ ID NO:2; and/or
- iii) competes with a polypeptide having the amino acid sequence as shown in SEQ ID NO:2 for binding to a cell surface receptor with an affinity for said polypeptide.

**13.** Polypeptide according to claim 12, wherein the fragment comprises or essentially consists of amino acid residues 234 to 1791 corresponding to the mature part of PAPP-A2, including any processing variant thereof.

**14.** Polypeptide according to claim 12, wherein the fragment comprises or essentially consists of amino acid residues 1 to 233 corresponding to the prepro part of PAPP-A2.

**15.** Polypeptide according to claim 12, wherein the fragment comprises or essentially consists of amino acid residues 23 to 233 corresponding to the pro part of PAPP-A2.

**16.** Polypeptide according to claim 12, wherein the fragment comprises or essentially consists of amino acid residues 1 to 22 corresponding to the signal peptide or leader sequence of PAPP-A2.

**17.** Polypeptide according to any of claims 14 to 16 operably linked to the mature part of PAPP-A2 corresponding to amino acid residues 234 to 1791 of SEQ ID NO:2.

**18.** Polypeptide according to any of claims 12 to 17, wherein said polypeptide is a recombinant polypeptide.

**19.** Polypeptide according to any of claims 12 to 18, wherein the polypeptide is free of human proteins, or other proteins natively associated with said polypeptide.

**20.** A composition comprising i) the polynucleotide according to any of claims 1 to 8, and/or ii) the vector according to claim 9, and/or iii) the host organism according to any of claims 10 and 11, and/or iv) the polypeptide according to any of claims 12 to 19, in combination with a physiologically acceptable carrier.

**21.** A pharmaceutical composition comprising i) the polynucleotide according to any of claims 1 to 8, and/or ii) the vector according to claim 9, and/or iii) the host organism according to any of claims 10 and 11, and/or iv) the polypeptide according to any of claims 12 to 19, in combination with a pharmaceutically acceptable carrier.

**22.** A method for producing an antibody with specificity for the polypeptide according to claim 12, said method comprising the steps of

- i) providing a host organism,
- ii) Immunizing the host organism with the polypeptide according to claim 10, and
- iii) obtaining said antibody.

**23.** An antibody having specific binding affinity for a polypeptide according to claim 12.

**24.** Antibody according to claim 23, wherein said antibody is selected from the group consisting of monoclonal antibodies and polyclonal antibodies.

**25.** Antibody according to claim 24, wherein said antibody is monoclonal.

**26.** A method for producing the polypeptide according to claim 18, said method comprising the steps of

- i) providing a suitable host organism,
- ii) transfecting or transforming the host organism provided in step i) with the polynucleotide according to any of claims 1 to 8, or the vector according to claim 9,
- iii) culturing the host organism obtained in step ii) under conditions suitable for expression of the polypeptide encoded by the polynucleotide or the vector; and optionally

iv) isolating from the host organism the polypeptide resulting from recombinant expression by the host organism.

**27.** The method of claim 25, wherein said host organism is a mammalian cell.

**28.** A method for inhibiting and/or reducing expression of PAPP-A2 in a cell by means of anti-sense technology, said method comprising the steps of

- i) providing the polynucleotide according to claim 7,
- ii) transfecting or transforming a cell capable of expressing PAPP-A2 with said polynucleotide provided in step i),
- iii) culturing the cell obtained in step ii) under conditions suitable for hybridization of the polynucleotide provided in step i) to a complementary polynucleotide in said cell involved in the expression of PAPP-A2, and
- iv) inhibiting and/or reducing the expression of PAPP-A2 in said cell.

**29.** Method of claim 28, wherein the antisense polynucleotide and the complementary polynucleotide are coexpressed from distinct polynucleotide molecules.

**30.** A method for detecting PAPP-A2, or measuring the level of PAPP-A2, in a biological sample obtained from an individual, said method comprising the steps of

- i) obtaining a biological sample from said individual,
- ii) detecting PAPP-A2 in said sample by detecting
  - a) a polypeptide according to claim 12; and/or
  - b) a polynucleotide in the form of mRNA originating from PAPP-A2 expression, and/or
  - c) PAPP-A2 specific protease activity, preferably by detecting cleavage of IGFBP-5, a derivative thereof, or any other suitable substrate for PAPP-A2.

**31.** Method of claim 30, said method comprising the further step of comparing the PAPP-A2 or the level of PAPP-A2 detected in step ii) with a predetermined value selected from the group consisting of

- i) a predetermined amount and/or concentration of PAPP-A2; and/or
- ii) a predetermined amount and/or concentration of PAPP-A2 mRNA, and/or
- iii) a predetermined PAPP-A2 specific protease activity.

**32.** Method of claim 31, wherein said predetermined value is indicative of a normal physiological condition of said individual.

**33.** The method of claim 30, wherein said biological sample is selected from the group consisting of blood, urine, pleural fluid, oral washings, tissue biopsies, and follicular fluid.

**34.** The method of claim 30, wherein said level of PAPP-A2 is measured as PAPP-A2 specific protease activity.

**35.** The method of claim 30, wherein said level of PAPP-A2 is measured as amount of PAPP-A2 protein.

**36.** The method of claim 30, wherein said level of PAPP-A2 is measured as amount of PAPP-A2 messenger RNA.

**37.** The method of claim 35, wherein said amount of PAPP-A2 protein is measured by immunochemical analysis.

**38.** The method of claim 37, wherein said amount of PAPP-A2 protein is detected by at least one monoclonal antibody.

**39.** The method of claim 30, wherein said PAPP-A2 protein is detected in a complex comprising at least one additional component preferably a polypeptide.

**40.** The method of claim 30, wherein said PAPP-2 is detected as a PAPP-A2 monomer.

**41.** The method of claim 30, wherein said PAPP-A2 is detected as a PAPP-A2 dimer.

**42.** A method of diagnosing a clinical condition in an individual, said method comprising the steps of

- i) performing the method of any of claims 30 to 41, and
- ii) diagnosing the clinical condition.

**43.** Method of claim 42, wherein said clinical condition is a fetal abnormality.

**44.** The method of claim 43, wherein said fetal abnormality is selected from the group consisting of Trisomy 21, Trisomy 18, Trisomy 13, and Open Spina Bifida.

**45.** The method according to claim 43, wherein said fetal abnormality is ectopic pregnancy, open spina bifida, neural tube defects, ventral wall defects, Edwards Syndrome, Patau Syndrome, Turner Syndrome, Monosomy X or Klinefelter's Syndrome.

**46.** The method of claim 43, wherein said clinical condition is an altered growth state selected from the group consisting of a growth promoting state and a growth inhibiting state.

**47.** The method of claim 46, wherein said clinical condition is selected from the group consisting of restenosis, atherosclerosis, wound healing, fibrosis, myocardial infarction, osteoporosis, rheumatoid arthritis, multiple myeloma, or cancer.

**48.** A method for detecting expression of a polynucleotide according to claim 1 in a biological sample, said method comprising the steps of:

- i) providing a biological sample putatively containing a polynucleotide according to claim 1, and
- ii) contacting the biological sample with a polynucleotide comprising a strand that is i) complementary to the polynucleotide according to claim 1 and ii) capable of hybridizing thereto, and
- iii) allowing hybridization to occur, and
- iv) detecting the hybridization complex obtained in step iii),

wherein the presence of the hybridization complex is indicative of the expression in the biological sample of the polynucleotide according to claim 1, or a fragment thereof.

**49.** A method for identifying an agent inhibiting the protease activity of PAPP-A2, said method comprising the steps of

- i) incubating a) the polypeptide according to claim 12 and b) a predetermined substrate for said polypeptide, and c) a putative inhibitory agent, and

ii) determining if proteolysis of said substrate is inhibited.

**50.** The method of claim 49, wherein said substrate comprises a polypeptide.

**51.** The method of claim 50, wherein said substrate comprises an internally quenched fluorescent peptide.

**52.** The method of claim 50, wherein said substrate comprises or essentially consists of IGFBP-5, or a fragment thereof.

**53.** An inhibitory agent obtainable according to any of the method of any of claims 49 to 52.

**54.** Use of the inhibitory agent according to claim 53 in the manufacture of a medicament for treating a clinical condition in an individual in need of such treatment.

**55.** A method for identifying an agent enhancing the protease activity of PAPP-A2, said method comprising the steps of

- i) incubating a) the polypeptide according to claim 12 and b) a predetermined substrate for said polypeptide, and c) a putative enhancer agent, and

ii) determining if proteolysis of said substrate is enhanced.

**56.** The method of claim 53, wherein said substrate comprises a polypeptide.

**57.** The method of claim 54, wherein said substrate comprises an internally quenched fluorescent peptide.

**58.** The method of claim 54, wherein said substrate comprises or essentially consists of IGFBP-5, or a fragment thereof.

**59.** An enhancing agent obtainable according to any of the method of any of claims 54 to 57.

**60.** Use of the enhancing agent according to claim 59 in the manufacture of a medicament for treating a clinical condition in an individual in need of such treatment.

**61.** A method of treatment by therapy of an individual, said method comprising the step of administering to said individual i) the pharmaceutical composition according to claim 21, and/or ii) the inhibitory agent according to claim 53, and/or the enhancing agent according to claim 59.

**62.** A method for purification of PAPP-A2 or complexes of PAPP-A2 with other proteins, said method comprising the steps of

- i) providing a polynucleotide or monoclonal antibody with specific binding affinity for a polypeptide according to claim 12,
- ii) purifying PAPP-A2 by means of affinity chromatography.

**63.** A method of diagnosing a clinical condition or diagnosing predisposition to said clinical condition in an individual comprising the steps of

- a) providing a body sample from said individual; and
- b) measuring the level of a complex selected from the group consisting of PAPP-A/proMBP, PAPP-A2/proMBP, PAPP-A/PAPP-A2, PAPP-A/PAPP-A2/

proMSP, proMBP/ANG and proMBP/ANG/C3dg in said body fluid sample; and

- e) diagnosing the clinical condition or diagnosing predisposition to the clinical condition, wherein the level of the complex above or below a predetermined value is indicative of the clinical condition or predisposition to the clinical condition.

**64.** A method of diagnosing a clinical condition or diagnosing predisposition to said clinical condition in a mammalian fetus comprising the steps of

- a) providing a body fluid sample from the mother of said fetus; and
- b) measuring the level of a complex selected from the group consisting of PAPP-A/proMBP, PAPP-A2/proMBP, PAPP-A/PAPP-A2, PAPP-A/PAPP-A2/proMBP, proMSP/ANG and proMBP/ANG/C3dg in said body fluid sample; and
- c) diagnosing the clinical condition or diagnosing predisposition to the clinical condition, wherein the level of

the complex above or below a predetermined value is indicative of the clinical condition or predisposition to the clinical condition.

**65.** The method according to any of claims **63** and **64**, wherein the clinical condition is selected from the group consisting of Down's syndrome, preeclampsia and acute coronary syndrome, including unstable angina and myocardial infarction.

**66.** The method according to any of claims **63** and **64**, wherein the complex is PAPP-A/proMBP and the clinical condition is selected from the group consisting of Down's syndrome and acute coronary syndrome, including unstable angina and myocardial infarction.

**67.** The method according to any of claims **63** and **64**, wherein the complex is proMBP/ANG and the clinical condition is Down's syndrome.

\* \* \* \* \*

专利名称(译)	妊娠相关血浆蛋白-A2 ( PAPP-A2 )		
公开(公告)号	<a href="#">US20030124529A1</a>	公开(公告)日	2003-07-03
申请号	US09/983025	申请日	2001-10-22
[标]申请(专利权)人(译)	COMO BIOTECH		
申请(专利权)人(译)	COMO BIOTECH APS		
当前申请(专利权)人(译)	COMO BIOTECH APS		
[标]发明人	OXVIG CLAUUS OVERGAARD MICHAEL TOFT		
发明人	OXVIG, CLAUUS OVERGAARD, MICHAEL TOFT		
IPC分类号	A01K67/027 A61K31/7088 A61K35/12 A61K38/00 A61K45/00 A61K48/00 A61P9/10 A61P19/02 A61P19/10 A61P29/00 A61P35/00 A61P43/00 C07K16/40 C12N1/15 C12N1/19 C12N1/21 C12N5/10 C12N9/64 C12N15/09 C12P21/08 C12Q1/02 C12Q1/37 C12Q1/68 G01N21/77 G01N21/78 G01N33/15 G01N33/50 G01N33/53 G01N33/566 G01N33/577 G01N33/68 C07H21/04 C12N9/00 C12P21/02 C12N5/06 C07K14/475		
CPC分类号	A61K38/00 C12N9/6489 C07K14/4715 C12Q1/6876 G01N33/689 C12Q1/37 A61P9/10 A61P19/02 A61P19/10 A61P29/00 A61P35/00 A61P43/00 C07K2319/21 C07K2319/41 G01N2333/96486 G01N2500/02		
优先权	200001571 2000-10-20 DK 60/241840 2000-10-20 US		
其他公开文献	US7083940		
外部链接	<a href="#">Espacenet</a> <a href="#">USPTO</a>		

摘要(译)

本发明提供了鉴定和编码与妊娠相关的血浆蛋白-A ( PAPP-A ) 具有同源性的新蛋白质的核苷酸和氨基酸序列。我们表示这种蛋白质PAPP-A2。编码PAPP-A2的cDNA来源于人胎盘。本发明还提供了编码PAPP-A2的核苷酸序列的反义分子,用于产生纯化的PAPP-A2的表达载体,能够特异性结合PAPP-A2的抗体,用于检测PAPP-A2的杂交探针或寡核苷酸。- 编码核苷酸序列,用于表达PAPP-A2的基因工程宿主细胞,使用该蛋白质产生能够与蛋白质特异性结合的抗体,用于筛选怀孕和非怀孕患者的病理学的方法,其基于检测PAPP-A2抗原在人体体液或PAPP-A2编码核酸分子中,使用该蛋白质筛选改变PAPP-A2蛋白酶活性的试剂,使用该蛋白质作为这些试剂的治疗靶标,并使用蛋白质作为相关病理状态的治疗剂。还描述了用于筛选怀孕和/或非怀孕患者中改变的局灶性增殖状态的方法,其包括检测PAPP-A2的水平。本发明还提供了PAPP-A2的天然底物,胰岛素样生长因子结合蛋白 ( IGFBP ) -5的鉴定。

Figure 1-

```

ATGATGCGCTAAGATCTTAGAATAGCCCTGCGATTTTCCTGCGCGTGCACCTCTTT      50
ATTCGACCTCTGACCTGCGCGACACACAGAAATCTCTGCTTGGAGAGGAGACCTG      100
AATGAGTCTGCTGAGAGGAGAACTCTGCTGGGGCCAGCTTCTGAGAGCCAGAA      150
GCTCTCTGAGAGGATCACTCTTGGAGTCTACCCGCGCGGGCTGGGACACTCAGGG      200
GCCATCCCTGGGGGAGCAAGAAATCTCTATACAGAGACCGCGAAGCAAGACTGAA      250
GGAATCTCTTGAAGCTTTTTCCTGAGACCTGAAATGAAATGACAGAGACTGAGGGGT      300
GCACTTGAAGAGCCGCTCCCTCCATGAGGATATCTCTATGGCACTCTGAGCTG      350
CTGGAGATATGACCTTATCTCTGATCAAAATCTGAGAGGCTCTGAGAGGCTG      400
GGATTTGAGAGGCTCAGCCATGCTGCTGACTATCCACCCGCTTCTCAGACCTG      450
GCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG      500
AACGAACTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTG      550
CTTGGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAG      600
GCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAG      650
GAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTG      700
GAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTG      750
GAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTG      800
GAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTG      850
GAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTG      900
GAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTG      950
GAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTG      1000
GAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTG      1050
GAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTG      1100
GAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTG      1150
GAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTG      1200
GAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTG      1250
GAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTG      1300
GAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTG      1350
GAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTG      1400
GAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTG      1450
GAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTG      1500
GAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTG      1550
GAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTG      1600
GAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTG      1650
GAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTG      1700
GAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTG      1750
GAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTG      1800
GAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTG      1850
GAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTG      1900
GAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTG      1950
GAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTGAGAGGCTG      2000
    
```